
<html lang="en"     class="pb-page"  data-request-id="b7492b63-1a8e-4129-8297-879cbd6169ef"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2021.64.issue-9;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.0c01545"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes" /></meta><meta name="dc.Creator" content="John R.  Cashman" /></meta><meta name="dc.Creator" content="Daniel  Ryan" /></meta><meta name="dc.Creator" content="Wesley L.  McKeithan" /></meta><meta name="dc.Creator" content="Karl  Okolotowicz" /></meta><meta name="dc.Creator" content="Jorge  Gomez-Galeno" /></meta><meta name="dc.Creator" content="Mark  Johnson" /></meta><meta name="dc.Creator" content="Kevin J.  Sampson" /></meta><meta name="dc.Creator" content="Robert S.  Kass" /></meta><meta name="dc.Creator" content="Arash  Pezhouman" /></meta><meta name="dc.Creator" content="Hrayr S.  Karagueuzian" /></meta><meta name="dc.Creator" content="Mark  Mercola" /></meta><meta name="dc.Description" content="Ventricular cardiac arrhythmia (VA) arises in acquired or congenital heart disease. Long QT syndrome type-3 (LQT3) is a congenital form of VA caused by cardiac sodium channel (INaL) SCN5A mutations..." /></meta><meta name="Description" content="Ventricular cardiac arrhythmia (VA) arises in acquired or congenital heart disease. Long QT syndrome type-3 (LQT3) is a congenital form of VA caused by cardiac sodium channel (INaL) SCN5A mutations..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 4, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01545" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01545" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01545" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01545" /></link>
        
    
    

<title>Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01545" /></meta><meta property="og:title" content="Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0019.jpeg" /></meta><meta property="og:description" content="Ventricular cardiac arrhythmia (VA) arises in acquired or congenital heart disease. Long QT syndrome type-3 (LQT3) is a congenital form of VA caused by cardiac sodium channel (INaL) SCN5A mutations that prolongs cardiac action potential (AP) and enhances INaL current. Mexiletine inhibits INaL and shortens the QT interval in LQT3 patients. Above therapeutic doses, mexiletine prolongs the cardiac AP. We explored structure–activity relationships (SAR) for AP shortening and prolongation using dynamic medicinal chemistry and AP kinetics in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Using patient-derived LQT3 and healthy hiPSC-CMs, we resolved distinct SAR for AP shortening and prolongation effects in mexiletine analogues and synthesized new analogues with enhanced potency and selectivity for INaL. This resulted in compounds with decreased AP prolongation effects, increased metabolic stability, increased INaL selectivity, and decreased avidity for the potassium channel. This study highlights using hiPSC-CMs to guide medicinal chemistry and “drug development in a dish”." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01545"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01545">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01545&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01545&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01545&amp;href=/doi/10.1021/acs.jmedchem.0c01545" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 5384-5403</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02036" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01549" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">John R. Cashman</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John R. Cashman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Human BioMolecular Research Institute, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#9bd1d8fae8f3f6faf5dbd3d9c9d2b5f4e9fc"><span class="__cf_email__" data-cfemail="5d171e3c2e35303c331d151f0f1473322f3a">[email protected]</span></a>. Phone: (858) 458-9305. Fax: (858) 458-9311.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+R.++Cashman">John R. Cashman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8628-9129" title="Orcid link">http://orcid.org/0000-0002-8628-9129</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Ryan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Ryan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Human BioMolecular Research Institute, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Ryan">Daniel Ryan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wesley L. McKeithan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wesley L. McKeithan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California 94305, United States</div><div class="loa-info-affiliations-info">Graduate School of Biomedical Sciences, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wesley+L.++McKeithan">Wesley L. McKeithan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karl Okolotowicz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karl Okolotowicz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Human BioMolecular Research Institute, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karl++Okolotowicz">Karl Okolotowicz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jorge Gomez-Galeno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jorge Gomez-Galeno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Human BioMolecular Research Institute, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jorge++Gomez-Galeno">Jorge Gomez-Galeno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Human BioMolecular Research Institute, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Johnson">Mark Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin J. Sampson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin J. Sampson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+J.++Sampson">Kevin J. Sampson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert S. Kass</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert S. Kass</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+S.++Kass">Robert S. Kass</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arash Pezhouman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arash Pezhouman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arash++Pezhouman">Arash Pezhouman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hrayr S. Karagueuzian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hrayr S. Karagueuzian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hrayr+S.++Karagueuzian">Hrayr S. Karagueuzian</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Mark Mercola</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Mercola</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cardiovascular Institute and Department of Medicine, Stanford University, Stanford, California 94305, United States</div><div class="loa-info-affiliations-info">Graduate School of Biomedical Sciences, Sanford Burnham Prebys Medical Discovery Institute, San Diego, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Mercola">Mark Mercola</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01545&amp;href=/doi/10.1021%2Facs.jmedchem.0c01545" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 5384–5403</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 4, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 September 2020</li><li><span class="item_label"><b>Published</b> online</span>4 May 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 May 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01545" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01545</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5384%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJohn%2BR.%2BCashman%252C%2BDaniel%2BRyan%252C%2BWesley%2BL.%2BMcKeithan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D9%26contentID%3Dacs.jmedchem.0c01545%26title%3DAntiarrhythmic%2BHit%2Bto%2BLead%2BRefinement%2Bin%2Ba%2BDish%2BUsing%2BPatient-Derived%2BiPSC%2BCardiomyocytes%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5403%26publicationDate%3DMay%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01545"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">497</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01545" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;R. Cashman&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Ryan&quot;},{&quot;first_name&quot;:&quot;Wesley&quot;,&quot;last_name&quot;:&quot;L. McKeithan&quot;},{&quot;first_name&quot;:&quot;Karl&quot;,&quot;last_name&quot;:&quot;Okolotowicz&quot;},{&quot;first_name&quot;:&quot;Jorge&quot;,&quot;last_name&quot;:&quot;Gomez-Galeno&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;J. Sampson&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;S. Kass&quot;},{&quot;first_name&quot;:&quot;Arash&quot;,&quot;last_name&quot;:&quot;Pezhouman&quot;},{&quot;first_name&quot;:&quot;Hrayr&quot;,&quot;last_name&quot;:&quot;S. Karagueuzian&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Mercola&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;5384-5403&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01545&quot;},&quot;abstract&quot;:&quot;Ventricular cardiac arrhythmia (VA) arises in acquired or congenital heart disease. Long QT syndrome type-3 (LQT3) is a congenital form of VA caused by cardiac sodium channel (INaL) SCN5A mutations that prolongs cardiac action potential (AP) and enhances INaL current. Mexiletine inhibits INaL and shortens the QT interval in LQT3 patients. Above therapeutic doses, mexiletine prolongs the cardiac AP. We explored structure–activity relationships (SAR) for AP shortening and prolongation using dynamic medicinal chemistry and AP kinetics in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Using patient-derived LQT3 and healthy hiPSC-CMs, we resolved distinct SAR for AP shortening and prolongation effects in mexiletine analogues and synthesized new analogues with enhanced potency and selectivity for INaL. This resulted in compounds with decreased AP prolongation effects, increased metabolic stability, increased INaL selectivity, and decreased avidity for the potassium channel. This study highl&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01545&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01545" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01545&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01545" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01545&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01545" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01545&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01545&amp;href=/doi/10.1021/acs.jmedchem.0c01545" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01545" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01545" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01545%26sid%3Dliteratum%253Aachs%26pmid%3D33942619%26genre%3Darticle%26aulast%3DCashman%26date%3D2021%26atitle%3DAntiarrhythmic%2BHit%2Bto%2BLead%2BRefinement%2Bin%2Ba%2BDish%2BUsing%2BPatient-Derived%2BiPSC%2BCardiomyocytes%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D9%26spage%3D5384%26epage%3D5403%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=291251" title="Sodium">Sodium</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/jmcmar.2021.64.issue-9/20210513/jmcmar.2021.64.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Ventricular cardiac arrhythmia (VA) arises in acquired or congenital heart disease. Long QT syndrome type-3 (LQT3) is a congenital form of VA caused by cardiac sodium channel (I<sub>NaL</sub>) SCN5A mutations that prolongs cardiac action potential (AP) and enhances I<sub>NaL</sub> current. Mexiletine inhibits I<sub>NaL</sub> and shortens the QT interval in LQT3 patients. Above therapeutic doses, mexiletine prolongs the cardiac AP. We explored structure–activity relationships (SAR) for AP shortening and prolongation using dynamic medicinal chemistry and AP kinetics in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Using patient-derived LQT3 and healthy hiPSC-CMs, we resolved distinct SAR for AP shortening and prolongation effects in mexiletine analogues and synthesized new analogues with enhanced potency and selectivity for I<sub>NaL</sub>. This resulted in compounds with decreased AP prolongation effects, increased metabolic stability, increased I<sub>NaL</sub> selectivity, and decreased avidity for the potassium channel. This study highlights using hiPSC-CMs to guide medicinal chemistry and “drug development in a dish”.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18580" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18580" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Approximately one million individuals are hospitalized every year for arrhythmias in the United States, making arrhythmias one of the top causes of healthcare expenditures with a direct cost of almost $50 billion annually for diagnosis, treatment, and rehabilitation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Another 300,000 individuals die of sudden arrhythmic death syndrome every year.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Arrhythmias are very common in older adults, but unfortunately, drugs used to treat arrhythmias have liabilities. In addition, numerous drugs have been withdrawn from the market because they induce QT prolongation (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) and a potentially fatal ventricular tachycardia (VT), torsade de pointes (TdP) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of cardiac cell membrane action potential (AP) and its relation with surface electrocardiogram.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of slow membrane depolarization on the QT interval on a surface electrocardiogram.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Cardiac sodium current (I<sub>NaP</sub>) occurs in less than a millisecond and underlies the rapid upstroke or phase 0 of the AP (action potential) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Thereafter, an activation gate and an inactivation gate on the sodium channel are both open. After several milliseconds, the current begins to decay, contributing to a notch in the AP called phase 1. At this point, some of the channels are inactivated (shown as “I” with the inactivation gate closed). There is no commonly accepted name for this phase of I<sub>Na</sub>, but here, it is labeled “early I<sub>Na</sub>” (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). After several milliseconds, I<sub>Na</sub> normally decays to <1% of I<sub>NaP</sub>, but a residual current flows as late I<sub>NaL</sub> and this depolarizing current along with calcium currents support phase 2 or the plateau of the AP. The mechanisms for I<sub>NaL</sub> at the sodium current level are multiple but can generally be thought of as incomplete inactivation. Eventually, activating potassium currents repolarize the membrane (phase 3 of the AP), and when the voltage decreases below the sodium channel threshold, the activation gate closes.</div><div class="NLM_p">Mexiletine is an orally available inhibitor of muscles and neuronal sodium channels and is a class 1B antiarrhythmic drug in the Vaughan–Williams classification scheme.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Mexiletine has been used to treat life-threatening ventricular arrhythmia and also long QT syndrome type 3 (LQT3).<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Cardiac AP is initiated by the opening of the cardiac sodium channel Na<sub>v</sub>1.5 (encoded by <i>SCN5A</i>) conducting the large peak sodium current (I<sub>NaP</sub>) responsible for the AP upstroke. In healthy individuals, the sodium channels inactivate with depolarization. However, LQT3 causal mutations in Na<sub>v</sub>1.5 impair channel inactivation and accelerate recovery from the inactivated state.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Increased I<sub>NaL</sub> opposes repolarization and prolongs the AP, thus prolonging the QT interval on the surface electrocardiogram.<a onclick="showRef(event, 'ref7 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref10">(7,10)</a> Mexiletine inhibits I<sub>NaL</sub> and consequently shortens the QT interval in LQT3 patients<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and decreases their risk of developing ventricular tachycardia and ventricular fibrillation.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> However, at concentrations slightly greater than its therapeutic plasma concentration and IC<sub>50</sub> for inhibition of I<sub>NaL</sub>, mexiletine also prolongs the cardiac AP and promotes potentially proarrhythmic events (including early after depolarizations (EADs)) <i>in vitro.</i><a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Observations of proarrhythmia have restricted mexiletine use although cardiologists generally predetermine a safe and efficacious dose. Mexiletine has liabilities. The FDA-approved label states that severe liver injury and blood dyscrasias (i.e., leukopenia or agranulocytosis) and other adverse reactions including reversible gastrointestinal and nervous system problems have been reported after mexiletine treatment. Mexiletine also has a relatively short half-life (i.e., <i>t</i><sub>1/2</sub> α-phase 3–12 min and β-phase 6–12 h<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>) that necessitates multiple doses per day. Greater doses of mexiletine produce side effects in the central nervous system.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Accordingly, mexiletine analogues were designed to replace metabolically labile groups with metabolically stable moieties to increase bioavailability, decrease the dose, and improve the therapeutic-to-toxicity ratio.</div><div class="NLM_p">Given that these latter properties are potentially proarrhythmic, it is important to determine if they are mediated by distinct determinants in the chemical structure of mexiletine as those responsible for the desirable inhibition of I<sub>NaL</sub> and whether structure modifications might decrease the AP prolonging effects, increase metabolic stability (and decrease the required dose), and increase selectivity for the sodium channel, thus decreasing avidity for the potassium channel and decrease toxicity.</div><div class="NLM_p">Herein, we report the application of human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to comprehensively evaluate proarrhythmic effects of mexiletine analogues and define chemical determinants responsible for antiarrhythmia. We used patient-derived hiPSC-CMs carrying a previously described LQT3 mutation in <i>SCN5A</i> (F1473C)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> to quantify the extent of AP shortening of mexiletine and analogues. LQT3 human CMs were used to determine the mexiletine analogue’s beneficial effects, quantified as the EC<sub>50</sub> for shortening the APD, a fold shortening of the APD, and a concentration that caused shortening of the action potential. These results were compared to the concentration of a test compound required for cessation of cell beating, an EC<sub>50</sub> for shortening the APD, and fold shortening of the APD in normal cardiomyocytes. Both normal and patient-derived LQT-3 hiPSC-CMs were previously characterized for the effects of benchmark reference drugs on AP kinetics and arrhythmia.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">To quantify the effect of chemical structural modification on the CM response, each test compound was tested in a dose–response study (i.e., 0–200 μM, nine concentrations, in triplicate) to identify the concentration of cessation of cell beating, determine the concentration at which EADs occurred, and quantify the EC<sub>50</sub> for prolonging the APD.</div><div class="NLM_p">Optical recordings of AP kinetics<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> were used as the primary assay, and results were confirmed by automated patch clamp recording<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> of exogenously expressed <i>SCN5A</i> variants as a secondary assay. Based on results for AP kinetics, inhibition of I<sub>NaL</sub> and I<sub>NaP</sub>, and blockade of the potassium current I<sub>Kr</sub> (i.e., hERG) that mediates the repolarizing potassium current, a SAR arose for the mexiletine analogues synthesized and tested. The results led to identification of significantly more potent and selective I<sub>NaL</sub> inhibitors with decreased proarrhythmic effects and much improved physicochemical properties. Compounds <b>30</b>, <b>33</b>, <b>39</b>, and <b>62</b> were shown to be effective antiarrhythmic compounds in hiPSC-CM models of LQT3-associated arrhythmia<named-content content-type="anchor" rid="sch1" type="simple"></named-content>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Regions of Mexiletine Modified to Lead to Greater Potency, Selectivity, and Less Toxicity. Region I (red) Is Alpha to the Amine, Region II (Green) Is the Phenoxy Moiety, and Region III (Blue) Contained N-Substituents</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36870" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36870" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Chemistry</h3><div class="NLM_p">Mexiletine and analogues were prepared using the synthetic routes described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Some synthetic procedures were adapted from literature reports.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> Mexiletine was divided into three hypothetical regions for theoretical molecular dissection as follows: Region I included substituents α to the amine, Region II included substituents associated with the phenoxy moiety, and Region III included <i>N</i>-substituents. In a typical synthesis, substituted phenols were combined with α-bromoketones in the presence of potassium carbonate to afford phenoxy alkyl ketones.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> α-Aryloxy ketones with variable substituents<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> were the precursors for one of the two synthetic routes. To prepare primary amines, a two-step protocol was employed that involved preparation of benzyl oximes and their subsequent reduction with borane to give the desired amines (<b>2–42</b>).</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Mexiletine Analogues and <i>N</i>-Substituted Mexiletine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) PhCH<sub>2</sub>ONH<sub>2</sub>-HCl, pyridine, ethanol, 21 °C. (b) BH<sub>3</sub>-THF, 65 °C, followed by treatment with HCl-ether. (c) <i>R</i>′-NH<sub>2</sub>, NaBH<sub>3</sub>CN, ethanol, 21 °C, followed by treatment with HCl-ether.</p></p></figure><div class="NLM_p">Secondary racemic amines were directly prepared by a one-step reductive amination procedure to give <i>N</i>-substituted products <b>43–50</b> and <b>55–63</b> as reported.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a><i>N</i>-Acylated analogues <b>51–54</b> were generated from the corresponding primary amines by treatment with either acetyl chloride or benzoyl chloride in the presence of triethylamine. Chiral analogues were generated by the method illustrated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> for (<i>R</i>)-<b>30</b> and (<i>R</i>)-<b>59</b>. Chiral <i>N</i>-acylated 4-phenyl 1,2,3-oxathiazolidine-2,2-dioxide derivatives were combined with substituted phenols under basic conditions.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> To convert to the primary amines, the <i>N</i>-acyl group used was a <i>t</i>-Boc substituent that was removed under acidic conditions. For the methoxyethyl-substituted amine <b>59</b>, an <i>N</i>-methoxy acetyl protecting group was reduced with lithium aluminum hydride and afforded the secondary amine (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Chiral Analogues (<i>R</i>)-<b>30</b> and (<i>R</i>)-<b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 2-Trifluoromethylphenol (for <b>(</b><i>R</i>)-<b>30</b>, R = <i>tert</i>-BuO−) or 2,3-dimethylphenol (for (<i>R</i>)-<b>59</b>, R = CH<sub>2</sub>OCH<sub>3</sub>), NaH, DMF, 21 °C, 16 h. (b) For (<i>R</i>)-<b>30</b>: HCl, methanol, 21 °C, 16 h. For (<i>R</i>)-<b>59</b>: LiAlH<sub>4</sub>, THF, 75 °C, 16 h.</p></p></figure><div class="NLM_p last">The hydrochloride salts of the amine products were used for biological testing and judged to be greater than 95% pure by <sup>1</sup>H NMR and HPLC.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Biological Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70722" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70722" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Effect of Mexiletine Analogues on Human Cardiomyocytes</h3><div class="NLM_p">Mexiletine, <b>1</b> was re-engineered by chemical synthesis to afford analogues with increased on-target potency (i.e., sodium channel) and decreased off-target (i.e., potassium channel) effects. The structure–activity relationship (SAR) for the effect of mexiletine analogues on normal and patient-derived hiPSC-CMs was systematically evaluated in CMs derived from an LQT3 patient (i.e., carrying the SCN5A F1473 mutation) and from an unrelated healthy donor. Thus, the effects of mexiletine analogues on CMs with channelopathies (i.e., disease in a dish) were compared to the effects of compounds on normal nonpathogenic CMs. To quantify the effect of modification of <b>1</b>, the molecule was conceptually divided into three exploratory regions (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>): (I) the region alpha to the primary amine moiety (red), (II) the phenoxy region (green), and (III) the <i>N</i>-substituted region (blue). Each compound was tested in a dose–response study (i.e., 0–200 μM, nine concentrations, in triplicate) in LQT3 hiPSC-CMs to determine a concentration of cessation of cell beating, an EC<sub>50</sub> for shortening the APD, a fold shortening of the APD, and a concentration that caused shortening of the AP. In normal cardiomyocytes, the concentration that caused cessation of cell beating, the concentration that caused proarrhythmic induction of EADs, and the EC<sub>50</sub> for shortening the APD were determined. These latter measures were indices of cell toxicity.</div><div class="NLM_p">Initially, a small group of approximately 20 compounds directed at structural modifications of the portion of <b>1</b> alpha to the primary amine (i.e., Region I) were synthesized and tested (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The results of these studies showed that an alpha aryl moiety showed greater fold shortening than aliphatic substituents. However, partial aryl characters (i.e., cyclopropyl compounds) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) were less effective at fold shortening than aryl compounds. Modifications of the phenoxy moiety (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) (i.e., Region II) resulted in compounds with potent APD shortening. <i>N</i>-Modification of selected compounds (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>, Region III) yielded additional derivatives with potent fold shortening and in some cases less toxicity to normal CMs.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effect of Alpha Substituents of Mexiletine on Cardiovascular Properties in Human iPSC-Derived Cardiomyocytes<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0009.gif" alt="" id="gr8" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0010.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Kinetic imaging cytometer assay results for alpha-substituted mexiletine derivatives.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Lowest dose that cessation of beating was observed.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">EC<sub>50</sub> for shortening the AP.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Ratio of AP untreated/AP treated.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Maximal dose that shortens the AP.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Dose that early after depolarization was observed.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">EC<sub>50</sub> for prolongation of the AP. The symbol “-” denotes that the indicated effect was not observed. EAD dose indicates the concentration at which the compound induced early after depolarizations.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effect of Phenoxy Substituents of Alpha Cyclopropane Mexiletine Analogues on Cardiovascular Properties in Human iPSC-Derived Cardiomyocytes<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0011.gif" alt="" id="gr10" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0012.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Kinetic imaging cytometer assay results for alpha cyclopropane mexiletine derivatives.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Lowest dose that cessation of beating was observed.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">EC<sub>50</sub> for shortening the AP.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Ratio of AP untreated/AP treated.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Maximal dose that shortens the AP.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">Dose that early after depolarization was observed.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">EC<sub>50</sub> for prolongation of the AP. The symbol “-” denotes that the indicated effect was not observed.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Effect of Phenoxy-Substituted Mexiletine Analogues on Cardiovascular Properties in Human iPSC-Derived Cardiomyocytes<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0013.gif" alt="" id="gr12" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Kinetic imaging cytometer assay results for phenoxy-substituted mexiletine derivatives.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Lowest dose that cessation of beating was observed.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">EC<sub>50</sub> for shortening the AP.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Ratio of AP untreated/AP treated.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Maximal dose that shortens the AP.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Dose that early after depolarization was observed.</p></div><div class="footnote" id="t3fn7"><sup><sup>g</sup></sup><p class="last">EC<sub>50</sub> for prolongation of the AP. The symbol “-” denotes that the indicated effect was not observed.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effect of Phenoxy Substituents of Alpha Phenyl Mexiletine Analogues on Cardiovascular Properties in Human iPSC-Derived Cardiomyocytes<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0015.gif" alt="" id="gr14" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0016.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Kinetic imaging cytometer assay results for phenyl mexiletine derivatives.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Lowest dose that cessation of beating was observed.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">EC<sub>50</sub> for shortening the AP.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Ratio of AP untreated/AP treated.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last">Maximal dose that shortens the AP.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">Dose that early after depolarization was observed.</p></div><div class="footnote" id="t4fn7"><sup><sup>g</sup></sup><p class="last">EC<sub>50</sub> for prolongation of the AP. The symbol “-” denotes that the indicated effect was not observed.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Effect of <i>N</i>-Substituted Mexiletine Analogues on Cardiovascular Properties in Human iPSC-Derived Cardiomyocytes<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0017.gif" alt="" id="gr16" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">LQT3 cells</th><th class="rowsep1 colsep0" colspan="3" align="center">Normal cells</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Number</th><th class="colsep0 rowsep0" align="center">R =</th><th class="colsep0 rowsep0" align="center">Cessation dose (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> shortening (μM)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">Fold shortening<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">Maximal shortening dose (μM)<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">Cessation dose (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">EAD dose (μM)<a class="ref internalNav" href="#t5fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">EC<sub>50</sub> prolongation (μM)<a class="ref internalNav" href="#t5fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">1.335</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">20.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">Methyl</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">1.112</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">Ethyl</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">21.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">1-Propyl</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">1.199</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">10.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">1-Butyl</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left"><0.8</td><td class="colsep0 rowsep0" align="left">1.180</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">2-Methoxyethyl</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">1.267</td><td class="colsep0 rowsep0" align="left">7.4</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">32.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">Phenyl</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">Benzyl</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">1.264</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">5.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">2-Phenylethyl</td><td class="colsep0 rowsep0" align="left">7.4</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">1.706</td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">Acetyl</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">Benzoyl</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">57.82</td><td class="colsep0 rowsep0" align="left">1.45</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="left">-</td><td class="colsep0 rowsep0" align="left">-</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Kinetic imaging cytometer assay results for <i>N-</i>modified mexiletine derivatives.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Lowest dose that cessation of beating was observed.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">EC<sub>50</sub> for shortening the AP.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Ratio of AP untreated/AP treated.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last">Maximal dose that shortens the AP.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last">Dose that early after depolarization was observed.</p></div><div class="footnote" id="t5fn7"><sup><sup>g</sup></sup><p class="last">EC<sub>50</sub> for prolongation of the AP. The symbol “-” denotes that the indicated effect was not observed.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Effect of <i>N</i>-Substituted Phenoxy-Substituted Phenyl Mexiletine Analogues on Cardiovascular Properties in Human iPSC-Derived Cardiomyocytes<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0018.gif" alt="" id="gr17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Kinetic imaging cytometer assay results for <i>N</i>-substituted phenyl mexiletine derivatives.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Lowest dose that cessation of beating was observed.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">EC<sub>50</sub> for shortening the AP.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Ratio of AP untreated/AP treated.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Maximal dose that shortens the AP.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Dose that early after depolarization was observed.</p></div><div class="footnote" id="t6fn7"><sup><sup>g</sup></sup><p class="last">EC<sub>50</sub> for prolongation of the AP. The symbol “-” denotes that the indicated effect was not observed.</p></div></div><div></div></div><div class="NLM_p last">LQT3 patient-derived hiPSC-CMs were resistant to the adverse effects of mexiletine, suggestive of the previously reported patient that tolerated a high dose.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Therefore, the detrimental effects on AP prolongation and EADs were most apparent in healthy normal donor hiPSC-CMs. Thus, the results from studies with normal CMs served as a control and an indicator of toxicity of compounds tested. In addition to measuring desired APD shortening in LQT3 cardiomyocytes and undesired APD prolongation and EADs in normal cardiomyocytes, on-target potency for inward sodium late currents (I<sub>NaL</sub>), selectivity for I<sub>NaL</sub> versus I<sub>NaP</sub>, and selectivity against potassium currents (I<sub>Kr</sub>) were obtained with whole cell automated planar patch clamp studies in which the SCN5A and hERG channels were expressed in CHO cells.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Region I. Analogues of Mexiletine</h3><div class="NLM_p">In LQT3 hiPSC-CMs, compared to mexiletine, <b>1</b>, <i>tert</i>-butyl, cyclopropyl, and cyclohexyl analogues (i.e., <b>2</b>, <b>3</b>, and <b>4</b>) were about 12–15% less potent at shortening the APD (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In contrast, aryl-substituted derivatives, 4-methyl phenyl, 4-CF<sub>3</sub> phenyl, and 4-methoxy phenyl (i.e., <b>6</b>, <b>7</b>, and <b>8</b>) were about 7–19% more potent than mexiletine at shortening the APD. The naphthyl derivative, compound <b>9</b>, was about as potent as mexiletine at shortening the APD. In contrast, in normal hiPSC-CMs, compounds <b>1–9</b> did not cause detectable shortening of the APD.</div><div class="NLM_p">Mexiletine did not cause cessation of cell beating in either LQT3 or normal hiPSC-CMs but induced EADs at 200 μM in normal cells in primary screening (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Cessation of beating is an indication of cardiotoxicity, and EADs are indicative of proarrhythmic activity for a compound. Compounds <b>2</b> and <b>3</b> induced EADs at 7.4 and 66 μM, respectively, in normal CMs. Of the alpha amine-substituted compounds examined, cessation of beating was observed (i.e., 66–133 μM range) but the cyclopropyl derivative (i.e., <b>3</b>) was less potent and less toxic.</div><div class="NLM_p">Generally, the potency for shortening the APD (i.e., EC<sub>50</sub> for shortening) did not exactly correspond to the potency of the concentration causing fold shortening of the APD in LQT3 cardiomyocytes (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) although compounds <b>2</b> (isopropyl), <b>4</b> (cyclohexyl), and <b>5</b> (phenyl) were similarly potent at both measures based on the lack of potency of cessation of beating. Based on the potency of shortening by cyclopropyl compound <b>3</b>, additional cyclopropyl derivatives were synthesized and tested (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">Like mexiletine or its individual enantiomers, the cyclopropyl-substituted compounds in this class (i.e., compounds <b>12</b>, <b>13</b>, <b>15</b>, and <b>16</b>) only caused cessation of cell beating at 200 μM or not at all in either LQT3 or normal CMs. Compound <b>14</b> caused cessation of cell beating at 66 μM and was not extensively examined further. However, compounds <b>12</b>, <b>13</b>, <b>15</b>, and <b>16</b> did induce EADs at 66 μM in normal CMs and were deemed to possess some potential for toxicity (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">In contrast to mexiletine or its stereoisomers, for this class of cyclopropyl mexiletine analogues, the potency for fold shortening the APD (i.e., EC<sub>50</sub> for shortening) corresponded to the potency of the concentration causing shortening of the APD in LQT3 CMs (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p last">However, based on the potency that these cyclopropyl analogues caused toxic EADs at relatively low concentrations (i.e., 66 μM), additional cyclopropyl derivatives were not synthesized and tested. Rather, exploration of the phenoxy portion of the molecule was investigated to determine substituents that would afford less toxicity (i.e., cessation of beating, APD prolongation, and EADs).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Region II. Effect of Phenoxy Substituents on Mexiletine and Phenyl Mexiletine Analogues</h3><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows the results of modifying the phenoxy portion of mexiletine to afford analogues. In LQT3 CMs, compared to mexiletine, <b>1</b>, <i>ortho</i> monosubstituted methyl-, ethyl-, or propyl-substituted compounds (i.e., <b>17</b>, <b>18</b>, and <b>19</b>) were less potent at shortening the APD based on fold shortening. In contrast, phenoxy-substituted derivatives, 2-CF<sub>3</sub>, 3-CH<sub>3</sub>, and 3-CF<sub>3</sub> (i.e., <b>20</b>, <b>22</b>, and <b>23</b>, respectively) were about 4–24% more potent than mexiletine at shortening the APD. The 3,5-disubstituted derivatives, compounds <b>24</b> and <b>25</b>, were slightly less potent than mexiletine at shortening the APD. In contrast, in normal CMs, compounds <b>17–26</b> did not cause detectable shortening of the APD and in some cases (i.e., compounds <b>19</b> and <b>24</b>) caused prolongation of the APD at relatively low concentrations.</div><div class="NLM_p">Except compound <b>25</b> (i.e., at 66 μM) and compounds <b>19</b>, <b>23</b>, and <b>24</b> (at elevated doses), compounds in this class did not cause cessation of cell beating in either LQT3 or normal CMs. Compound <b>22</b> induced EADs at 66 μM. However, it required high concentrations (133–200 μM) to induce EADs in normal CMs for compound <b>17</b>, <b>21</b>, or <b>26</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_p last">As observed for chemotypes described above, generally, the potency for shortening the APD (i.e., EC<sub>50</sub> for shortening) did not exactly correspond to the potency of the concentration causing fold shortening of the APD in LQT3 CMs (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). However, compound <b>19</b> was potent at both measures. Based on the increase in potency of shortening the APD by certain monosubstituted phenoxy derivatives of mexiletine, additional analogues combining beneficial properties of the phenoxy ring and aryl substituent alpha to the amine were synthesized and tested.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Effect of Phenoxy Substituents on Alpha Phenyl Mexiletine Analogues</h3><div class="NLM_p">Because certain phenoxy-substituted mexiletine compounds and certain alpha amino aryl mexiletine analogues showed potency at shortening the APD, synthesis and testing of compounds that combined those two moieties were undertaken. Compared to the alpha amino phenyl analogue of mexiletine, certain phenoxy-substituted alpha amino phenyl derivatives potently increased fold shortening of the APD (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In LQT3 CMs, compared to phenyl mexiletine, <b>5</b>, <i>ortho</i> monosubstituted methyl-, ethyl-, or propyl-substituted compounds (i.e., <b>27</b>, <b>28</b>, and <b>29</b>) were more potent at shortening the APD by 37, 69, and 13%, respectively. Compared to phenyl mexiletine, 2-CF<sub>3</sub>, 2-OCH<sub>3</sub>, and 2-<i>O</i>-methoxy-CF<sub>3</sub>, 2-<i>O</i>-CF<sub>3</sub> (i.e., <b>30</b>, <b>31</b>, and <b>32</b> and <b>33</b>, respectively) were 52, 26, 29, and 21% more potent at shortening the APD. The 3-substituted derivatives (i.e., compounds <b>34</b>–<b>38</b>) were slightly more potent than phenyl mexiletine at shortening the APD (i.e., 3−31%). Compared to phenyl mexiletine, compounds containing 4-substituted groups (i.e., <b>39</b> and <b>40</b>) increased shortening of the APD 2 and 17%, respectively. 1- and 2-Naphthyl derivatives of phenyl mexiletine increased shortening 12 and 25%, respectively, compared to phenyl mexiletine. In contrast, in normal CMs, compounds <b>5–42</b> did not cause detectable shortening of the APD and in some cases (i.e., compounds <b>5</b> and <b>31</b>) caused prolongation of the APD at relatively low concentrations.</div><div class="NLM_p">Except compounds <b>41</b> and <b>42</b>, phenoxy-substituted derivatives of phenyl mexiletine (i.e., <b>27</b>–<b>40</b>) caused cessation of cell beating in both LQT3 and normal CMs (albeit at elevated concentrations). Compound <b>31</b> induced EADs at a relatively low concentration (i.e., 7.4 μM) in normal CMs (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_p last">As a chemotype, generally, the phenoxy-substituted phenyl mexiletine analogues examined possessed great potency for shortening the APD (i.e., EC<sub>50</sub> for shortening) and most were in the 0.8 μM or lower range in LQT3 CMs (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Based on the increase in potency of shortening the APD by certain monosubstituted phenoxy derivatives of phenyl mexiletine, additional derivatives combining beneficial properties of the phenoxy ring substituents and the amine nitrogen were synthesized and tested.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Region III. <i>N</i>-Substituted Analogues of Mexiletine</h3><div class="NLM_p">The effect of <i>N</i>-substitution on the pharmacological properties of mexiletine was investigated. Compared to mexiletine, most <i>N</i>-substituted mexiletine derivatives examined decreased the shortening dose of the APD (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). In LQT3 CMs, compared to mexiletine, <b>1</b>, <i>N</i>-methyl-, <i>N</i>-propyl-, <i>N</i>-butyl-, <i>N</i>-ethyl methoxy-, and <i>N</i>-benzyl-substituted compounds (i.e., <b>43</b>, <b>44</b>, <b>45</b>, <b>46</b>, and <b>47</b>) were less potent at fold shortening the APD by 17, 10, 10, 5, and 5%, respectively. However, more lipophilic <i>N</i>-ethyl phenyl mexiletine (i.e., <b>50</b>) was 28% more potent at shortening the APD than mexiletine. Compared to mexiletine, the more polar <i>N</i>-acetyl phenyl-substituted compound <b>52</b> increased shortening of the APD 9%. In contrast, in normal CMs, compounds <b>45–52</b> did not cause detectable shortening of the APD and in some cases (i.e., compounds <b>43</b>, <b>45</b>, <b>46</b>, <b>49</b>, and <b>50</b>) caused prolongation of the APD at relatively low doses (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><div class="NLM_p">Except compound <b>52</b>, of the <i>N</i>-substituted derivatives of mexiletine tested (i.e., <b>45–51</b>), cessation of cell beating in normal CMs was observed only at elevated doses (i.e., 133–200 μM). However, in LQT3 CMs, lipophilic compounds <b>46</b> and <b>50</b> caused cessation of cell beating at relatively low doses (i.e., 66 and 7.4 μM, respectively) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Except compounds <b>43</b> and <b>50</b>, in normal CMs, compounds <b>44–49</b> either did not cause EADs or only caused EADs at elevated doses (i.e., 66 μM).</div><div class="NLM_p last">Generally, <i>N</i>-substituted mexiletines examined possessed significant potency for shortening the APD (i.e., EC<sub>50</sub> for shortening), and aside from compound <b>52</b>, most compounds that provided EC<sub>50</sub> values were below 2 μM in LQT3 CMs (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Based on the potency of shortening the APD by <i>N</i>-substituted derivatives of mexiletine, additional derivatives combining beneficial properties of the phenoxy ring and substituents on the amine nitrogen of phenyl mexiletine were synthesized and tested.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Region III. <i>N</i>-Substituted Analogues of Phenoxy-Substituted Phenyl Mexiletine</h3><div class="NLM_p">The effect of <i>N</i>-substitution on the pharmacological properties of phenyl mexiletine and analogues was investigated. Compared to phenyl mexiletine, most <i>N</i>-substituted-2,3-dimethyl phenoxy-substituted phenyl mexiletine compounds examined decreased fold shortening of the APD (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In LQT3 CMs, compared to phenyl mexiletine, (i.e., compound <b>5</b>), <i>N</i>-methyl, <i>N</i>-butyl, and <i>N</i>-ethyl methoxy-2,3-dimethyl phenoxy-substituted compounds (i.e., <b>55</b>, <b>58</b>, and <b>59</b>) were more potent at shortening the APD by 9, 18, and 22%, respectively. The more lipophilic <i>N</i>-ethyl methoxy 3,5-ditrifluoromethyl phenoxy-substituted phenyl mexiletine (i.e., <b>61</b>) was 28% more potent at shortening the APD than phenyl mexiletine. Compared to phenyl mexiletine, the somewhat more polar <i>N</i>-ethyl hydroxyl 3,5-dimethyl phenoxy-substituted phenyl mexiletine, compound <b>62</b>, increased shortening of the APD by 28%. In contrast, in normal CMs, compounds <b>53</b>–<b>63</b> did not cause detectable shortening of the APD nor did these compounds cause prolongation of the APD (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).</div><div class="NLM_p">Except compounds <b>62</b> and <b>63</b> of the <i>N</i>-substituted derivatives of phenyl mexiletine examined (i.e., <b>53–63</b>), cessation of cell beating in normal cardiomyocytes was observed only at elevated concentrations (i.e., 133–200 μM). However, in LQT3 CMs, somewhat polar compounds <b>62</b> and <b>63</b> and compound <b>56</b> caused cessation of cell beating at a relatively low concentration (i.e., 22 μM, respectively) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In normal CMs, compounds <b>53</b>–<b>63</b> did not cause EADs.</div><div class="NLM_p last">Generally, <i>N</i>-substituted phenyl mexiletine analogues examined possessed significant potency for shortening the APD (i.e., EC<sub>50</sub> for shortening), and aside from compound <b>58</b>, most compounds that provided EC<sub>50</sub> values were below 7 μM in LQT3 CMs (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The potency of shortening the APD by <i>N</i>-substituted derivatives of phenyl mexiletine was significant and showed that <i>N</i>-substituents on phenyl mexiletine were tolerated. In general, results indicated that <i>N-</i>alkylation decreased prolongation effects and did not induce EADs. Compared to phenyl mexiletine, the <i>N</i>-methoxyethyl derivative of a number of phenyl mexiletines displayed similar shortening to the parent compound and decreased prolongation effects (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Certain <i>N</i>-substituted phenyl mexiletine analogues examined possessed significant potency for shortening the APD (i.e., EC<sub>50</sub> for shortening). For example, compounds <b>53</b> and <b>54</b> afforded EC<sub>50</sub> values of 0.8 μM in LQT3 CMs (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compounds <b>58</b>, <b>59</b>, and <b>61</b> were less potent at shortening the APD (i.e., EC<sub>50</sub> for shortening: 20, 5.7, and 6.6 μM, respectively).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Automated Patch Clamp Studies of Mexiletine Analogues</h3><div class="NLM_p">Automated patch clamp experiments were done to determine IC<sub>50</sub>s for peak (I<sub>NaP</sub>) and late sodium current (I<sub>NaL</sub>) inhibition and potassium current (I<sub>Kr</sub>) inhibition for selected compounds. Mexiletine and analogues were applied over a concentration range from 0.1 to 100 μM, and inhibition relative to vehicle control was determined at a steady state (∼3 min) for each concentration. For I<sub>NaL</sub>, data were recorded and peak channel currents were measured in response to 100 ms voltage steps to −10 mV imposed from a holding potential of −100 mV at a rate of 0.1 Hz (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, panel A). Compounds were applied to the extracellular compartment in increasing concentrations from 0 (i.e., DMSO vehicle control) to 100 μM. The ratio of IC<sub>50</sub> values for inhibition of Na<sup>+</sup> channels was determined by normalizing measured current to control recordings for both I<sub>NaP</sub> and I<sub>NaL</sub> in the presence of a constant vehicle (DMSO, 0.1%). Tetradotoxin (TTX), 50 μM, was applied at the end of the experiments, so TTX currents could be subtracted from the rest of the traces to identify only sodium channels.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Traces of automated patch clamp studies. Panel (A) shows low-gain Na<sup>+</sup> channel signals where peak block was measured for a given concentration and high-gain (inset) traces for late current. Panel (B) shows dose–response relationships for the peak and late Na<sup>+</sup> current. Panels (C) and (D) show the analogous information for I<sub>Kr</sub> block with current traces in panel (C) and dose–response in panel (D). Recordings were analyzed at low (I<sub>NaP</sub>) and high (I<sub>NaL</sub>) gains for each compound concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For I<sub>Kr</sub> experiments, cells were held at −80 mV and activating pulses (500 ms) were applied at +40 mV followed by a return potential of −40 mV (0.1 Hz) whereupon deactivating tail currents were measured. Currents were recorded again over a concentration range of 0.1 to 100 μM and were normalized to control recordings (including 0.1% vehicle (DMSO)). The resulting peak tail current was then plotted versus test compound concentration to determine concentration–response relationships for test compounds and I<sub>Kr</sub> inhibition (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, panels C and D). The selective I<sub>Kr</sub> inhibitor E-4031, 5 μM, was used as a control inhibitor.</div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> shows automated patch clamp IC<sub>50</sub> values for I<sub>NaL</sub>, I<sub>NaP</sub>, and I<sub>Kr</sub> obtained for each of the 18 compounds examined with an <i>n</i> ≥ 4 for computed IC<sub>50</sub> values. Also included is a calculation for overall selectivity for inhibiting peak sodium current over late sodium current (i.e., I<sub>NaP</sub>/I<sub>NaL</sub>) or I<sub>Kr</sub> over late sodium current (i.e., I<sub>Kr</sub>/I<sub>NaL</sub>). Essentially, all compounds examined were selective for late sodium current over peak sodium current and hERG. Compared to mexiletine, there were compounds that were more selective and more potent late sodium current inhibitors. Consistent with a prior report,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> mexiletine was measured to have IC<sub>50</sub> values of 22.5 ± 4.4 and 182.8 ± 41.8 μM for late and peak Na currents, respectively, and 53.7 ± 8.0 μM for I<sub>Kr</sub>. Compared to mexiletine, replacement of the alpha methyl group with <i>tert</i>-butyl (i.e., <b>2</b>) or cylopropyl (i.e., <b>3</b>) had only modest changes in channel selectivity. Modification of the phenoxy ring of mexiletine (i.e., <b>15</b>, <b>16</b>, or <b>24</b>) also had modest changes on channel ratios. In contrast, alpha phenyl group modification (i.e., <b>30</b>, <b>33</b>, <b>39</b>, <b>40</b>, and <b>41</b>) afforded compounds with, in some cases, relatively great selectivity for I<sub>NaP</sub> (i.e., I<sub>Kr</sub>/I<sub>NaP</sub> ratios of 31–36-fold). The selectivity of <i>N</i>-methyl substituted mexiletine (i.e., <b>43</b>) was no different from that of mexiletine itself. However, <i>N</i>-substitution of alpha phenyl mexiletine analogues (i.e., <b>59</b>, <b>60</b>, and <b>63</b>) in some cases showed a significant I<sub>Kr</sub>/I<sub>NaP</sub> selectivity (i.e., 17–35-fold). Accordingly, based on the kinetic image cytometry results and the automated patch clamp IC<sub>50</sub> profiles of channel inhibition, certain compounds were advanced to further study. For selective late current block, we examined compounds in greater detail that were maximally selective over both I<sub>NaP</sub> and I<sub>Kr</sub> in electrophysiology experiments.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Effect of Mexiletine and Analogues on Automated Patch Clamp Dose–Response Data for Sodium and Potassium Channel-Transfected Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> I<sub>NaL</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> I<sub>NaP</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center" char="±">IC<sub>50</sub> I<sub>Kr</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center" char=".">Selectivity<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="char" char="±">22.5 ± 4.4<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">182.8 ± 41.8</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">53.7 ± 8.0</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="char" char="±">11.4 ± 3.7</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">91.4 ± 12.7</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">27.6 ± 12.5</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">2.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 0.4</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">130.4 ± 12.0</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char="±">30.1 ± 5.2</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">19.0 ± 4.6</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">128.6 ± 12.8</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">84.0 ± 7.5</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">4.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char="±">29.9 ± 5.4</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">128.2 ± 10.0</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">54.3 ± 11.1</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">1.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char="±">51.8 ± 5.9</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">161.6 ± 21.0</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">98.0 ± 4.8</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="char" char="±">10.0 ± 4.9</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">76.8 ± 9.0</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">45.8 ± 11.8</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="char" char="±">17.3 ± 10.5</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">153.7 ± 8.3</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">49.3 ± 8.4</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">2.84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="char" char="±">11.7 ± 0.8</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">20.6 ± 2.1</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 1.3</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char="±">0.643 ± 0.047</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">34.2 ± 6.7</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char="±">22.9 ± 4.7</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char=".">35.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char="±">1.04 ± 0.34</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">41.1 ± 8.4</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">37.5 ± 14.0</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">36.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char="±">0.20 ± 0.054</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">20.1 ± 4.1</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 0.8</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="char" char=".">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="char" char="±">1.03 ± 0.06</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char="±">20.0 ± 4.1</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="char" char="±">7.16 ± 1.2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">19.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char="±">1.03 ± 0.1</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">10.9 ± 0.7</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char="±">9.2 ± 1.3</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char=".">8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char="±">36.0 ± 3.2</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">124.1 ± 5.9</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char="±">44.1 ± 2.2</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="char" char="±">0.747 ± 0.063</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char="±">25.8 ± 6.6</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">27.6 ± 4.2</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char=".">34.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="char" char="±">0.753 ± 0.094</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char="±">38.0 ± 7.1</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char="±">5.1 ± 0.85</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char=".">6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="char" char="±">1.02 ± 0.02</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char="±">45.1 ± 9.2</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char="±">16.8 ± 2.4</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">16.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Selectivity is defined as IC<sub>50</sub> for the lesser of the ratios of I<sub>NaP</sub>/I<sub>NaL</sub> or I<sub>Kr</sub>/I<sub>NaL</sub>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Data presented as mean ± standard error, <i>n</i> = number of replicate determinations. Sodium channel SCN5A (F1473C mutant) was transfected into HEK cells and potassium channel was transfected into CHO cells.</p></div></div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Pharmaceutical Properties of Mexiletine and Analogues</h3><div class="NLM_p">The chemical and metabolic stabilities of certain mexiletine analogues were examined in advance of <i>in vivo</i> or <i>ex vivo</i> studies. Because one of the objectives was to develop a compound that possessed lower metabolic clearance than mexiletine, the effect of varying substituents of select compounds on metabolic stability was investigated (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Racemic compounds <b>27</b>, <b>30</b>, <b>36</b>, and <b>59</b> possessed metabolic stability (in human liver microsomes + NADPH of <i>T</i><sub>1/2</sub> > 60 min) and chemical stability (<i>T</i><sub>1/2</sub> > 30 days, pH 7.4, phosphate buffer, 37 °C) (data not shown) as judged by HPLC analysis. At pH 3, compounds <b>27</b> and <b>30</b> had <i>T</i><sub>1/2</sub> of >15 days and <b>33</b> and <b>59</b> had <i>T</i><sub>1/2</sub> of >30 days. (<i>R</i>)- and (<i>S</i>)-Enantiomers of <b>27</b>, <b>30</b>, and <b>36</b> were prepared and tested for stereoselective hepatic metabolism. Time-course studies (i.e., up to 1 h incubations at 37 °C in the presence of 0.5 mM NADPH) were conducted. In the presence of human liver S-9, the (<i>R</i>)-enantiomers of <b>27</b> and <b>36</b> appeared to be more metabolically labile than their corresponding (<i>S</i>)-enantiomers. Compared to (<i>R</i>)- and (<i>S</i>)-mexiletine and (<i>R</i>)- and (<i>S</i>)-<b>59</b> and -<b>30</b> and (<i>S</i>)-<b>27</b> and (<i>S</i>)-<b>36</b> that did not have detectable metabolism in the presence of S-9, compounds (<i>R</i>)-<b>27</b> and (<i>R</i>)-<b>36</b> had <i>T</i><sub>1/2</sub> values of 408 and 1015 min, respectively. In the presence of human liver microsomes, the (<i>R</i>)-enantiomers of <b>30</b> and <b>36</b> appeared to be more metabolically labile than their corresponding (<i>S</i>)-enantiomers. Both (<i>R</i>)- and (<i>S</i>)-mexiletine, -<b>27</b> and -<b>59</b>, did not have detectable metabolism in the presence of human liver microsomes. Highly purified human CYP3A4, 3A5, and 2D6 metabolized racemic mexiletine (46.2, 48.8, and 6.0 pmol/min/μg of protein, respectively). Highly purified CYP3A4, 3A5, and 2D6 metabolized racemic compound <b>30</b> (15.4, 42.6, and 43.6 pmol/min/μg of protein, respectively). Racemic compound <b>36</b> was detectably metabolized by highly purified CYP2D6 (6.9 pmol/min/μg of protein) but not CYP3A4 and CYP3A5. Metabolism of racemic <b>27</b> and <b>59</b> in the presence of highly purified CYP was not conducted.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Metabolic Stability of Mexiletine and Analogues with Human Liver Preparations</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center"><i>T</i><sub>1/2</sub> (min)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound number</th><th class="colsep0 rowsep0" align="center">Human liver S-9</th><th class="colsep0 rowsep0" align="center">Human liver microsomes</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)<i>-</i>mexiletine</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)<i>-</i>mexiletine</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<b>27</b></td><td class="colsep0 rowsep0" align="left">408 min</td><td class="colsep0 rowsep0" align="left">365 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>27</b></td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td><td class="colsep0 rowsep0" align="left">136 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<b>30</b></td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>30</b></td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<b>36</b></td><td class="colsep0 rowsep0" align="left">1015 min</td><td class="colsep0 rowsep0" align="left">406 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>36</b></td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<b>59</b></td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<b>59</b></td><td class="colsep0 rowsep0" align="left">1040 min</td><td class="colsep0 rowsep0" align="left">>95% after 1 h</td></tr></tbody></table></div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>In Vivo</i> Studies of Mexiletine and Analogues</h3><div class="NLM_p">Based on <i>in vitro</i> metabolism data, pharmacokinetics (PK) studies of mexiletine, racemic <b>30</b>, and its enantiomers were examined (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>). Animals were administered by intravenous (5 mg/kg) or oral (25 mg/kg) routes to obtain bioavailability (<i>F</i>) data. Compared to PK parameters of mexiletine, racemic <b>30</b>, (<i>R</i>)-<b>30</b>, and (<i>S</i>)-<b>30</b> afforded superior oral administration PK properties. This included acceptable half-lives, greater peak onset (<i>C</i><sub>max</sub>), and greater bioavailability (<i>F</i>). Compared to mexiletine (<i>F</i> = 37%), (<i>R</i>)-<b>30</b> (100%) possessed superior oral PK properties. Bioavailability values for (<i>S</i>)-<b>30</b> and rac-<b>30</b> were 42 and 38%, respectively.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Effect of Mexiletine and Analogues on Pharmacokinetic Parameters in Rats<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">Route of administration</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (mg/mL)</th><th class="colsep0 rowsep0" align="center" char="±">AUC (h × ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mexiletine</td><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char="±">289 ± 39</td><td class="colsep0 rowsep0" align="char" char="±">447 ± 47</td><td class="colsep0 rowsep0" align="char" char=".">10.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char="±">167 ± 41</td><td class="colsep0 rowsep0" align="char" char="±">839 ± 456</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> = 37%</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(Rac)-<b>30</b></td><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char="±">250 ± 16</td><td class="colsep0 rowsep0" align="char" char="±">544 ± 27</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char="±">226 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">1008 ± 227</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> = 38%</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<b><i>R</i></b>)<b>-30</b></td><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" align="char" char=".">0.18</td><td class="colsep0 rowsep0" align="char" char="±">249 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">280 ± 59</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char="±">258 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">1556 ± 19</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> = 100%</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">(<b><i>S</i></b>)<b>-30</b></td><td class="colsep0 rowsep0" align="left">i.v.</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char="±">219 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">407 ± 34</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char="±">226 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">1008 ± 227</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> = 42%</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Two-four male rats for each route of administration.</p></div></div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Behavioral Studies of Mexiletine and Analogues in Mice</h3><div class="NLM_p">Previously, it was reported that mexiletine has an LD<sub>50</sub> of 115 mg/kg in mice.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In our hands, significant behavioral effects (i.e., seizures and deaths) were observed for mexiletine at 100 and 200 mg/kg (i.p.). In contrast, we observed that synthetic phenyl mexiletine analogues examined possessed LD<sub>50</sub> > 200 mg/kg (i.p.) in mice. Administration of 200 mg/kg (i.p.) of (<i>R</i>)- or (<i>S</i>)-enantiomers of <b>27</b>, <b>30</b>, <b>36</b>, or <b>59</b> did not show any lethality. Thus, the LD<sub>50</sub> was >200 mg/kg for the phenyl mexiletine compounds examined.</div><div class="NLM_p">Among the adverse reactions in rodents<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and human patients<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> administered (<i>R</i>)-mexiletine are nausea and seizures. We examined the behavioral properties of enantiomerically pure <b>27</b>, <b>30</b>, <b>36</b>, or <b>59</b> and compared them to (<i>R</i>)- or (<i>S</i>)-mexiletine at 100 mg/kg (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). The phenyl mexiletine enantiomers (i.e., enantiomers of <b>27</b>, <b>30</b>, <b>36</b>, or <b>59</b>) were relatively well-tolerated <i>in vivo</i> (100 mg/kg, i.p.). For (<i>R</i>)-mexiletine, administration of 100 mg/kg produced immobilization, seizures, and death. (<i>S</i>)-Mexiletine (100 mg/kg) produced lethargy and immobilization, but severe seizures were not observed. In contrast, mice treated with enantiomer (<i>R</i>)-<b>30</b>, <b>36</b>, or <b>59</b> (100 mg/kg) showed no apparent behavioral effects although (<i>R</i>)-<b>27</b> showed some immobilization effects. Lethargy and other central nervous system effects were observed for (<i>S</i>)-<b>27</b>, <b>30</b>, <b>36</b>, or <b>59</b> at 100 mg/kg. Thus, behavioral effects for phenyl mexiletines <b>30</b>, <b>36</b>, or <b>59</b> were stereoselective (i.e., behavioral toxicity was (<i>S</i>)- > (<i>R</i>)-enantiomer). In conclusion, compared to mexiletine, it was apparent that (<i>R</i>)-enantiomers of compounds <b>30</b>, <b>36</b>, and <b>59</b> examined showed considerably less toxicity (i.e., seizures and death) than that observed for mexiletine enantiomers.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Effect of Mexiletine and Analogues on Behavior in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">Behavioral effect ((<i>R</i>)-enantiomer)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Behavioral effect ((<i>S</i>)-enantiomer)<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Mexiletine</td><td class="colsep0 rowsep0" align="left">1 seizure, 1 death, 2 immobilized</td><td class="colsep0 rowsep0" align="left">4/4 immobilized</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">4/4 immobilized</td><td class="colsep0 rowsep0" align="left">3/4 immobilized</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">No detectable effect</td><td class="colsep0 rowsep0" align="left">2/4 slightly lethargic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">No detectable effect</td><td class="colsep0 rowsep0" align="left">2/4 lethargic</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">No detectable effect</td><td class="colsep0 rowsep0" align="left">2/4 shaking</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Four mice were administered 100 mg/kg compound, i.p. Behavioral effects were monitored for 30 min. Lethality was measured after 24 h.</p></div></div></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>Ex Vivo</i> Studies of (<i>R</i>)-<b>30</b> with Rat Heart Preparations</h3><div class="NLM_p">As an adjunct to LQT3 <i>in vitro</i> studies, we conducted <i>ex vivo</i> studies of (<i>R</i>)-<b>30</b> in aged rats. In this model, conduction velocity (CV), action potential duration (APD), and responsiveness to drugs were measured in perfused <i>ex-vivo</i> rat heart preparations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). <i>Ex vivo</i> heart preparations can be used to study the effect of compounds to decrease arrhythmias because CV and APD are preserved in buffer-perfused rat hearts for up to 2 days. We chose a rat heart model to test the effects of (<i>R</i>)-<b>30</b><i>ex vivo</i> because (<i>R</i>)-<b>30</b> is potent and stereoselective, not extensively metabolized, has good bioavailability and solubility (8–10 mg/mL water), and no apparent toxicity up to 200 mg/kg (i.p.). In this perfused <i>ex-vivo</i> rat heart model, the continuous presence (perfusion) of H<sub>2</sub>O<sub>2</sub> (0.1 mM) produced EADs and ectopic ventricular beats 6 min after exposure that degenerated to ventricular tachycardia (VT) and ventricular fibrillation (VF) after 12 min (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). Left untreated, these perfused hearts generally die within 45 min. Using this preparation, complete resolution of all forms of arrhythmias to normal sinus rhythm was observed 30–40 min after administration of compound (<i>R</i>)-<b>30</b> (10 μM) in the continuous presence of H<sub>2</sub>O<sub>2</sub> (0.1 mM) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c). This shows that administration of (<i>R</i>)-<b>30</b> to a heart suffering from severe arrhythmias potently reverses VT and VF and corrects EADs in a very short time. This may be clinically relevant. The effect of (<i>R</i>)-<b>30</b> is similar to or more potent than the effect of ranolazine (10 μM) in the same <i>ex vivo</i> model<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> or GS-967 or roscovitine in related <i>ex vivo</i> models.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The conclusion is that (<i>R</i>)-<b>30</b> is more efficacious than the currently used standard of care.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Initiation of early after depolarizations-mediated ectopic ventricular beats and ventricular fibrillation in an isolated perfused aged rat heart exposed to hydrogen peroxide. (B) Representative example of administration of compound (<i>R</i>)-<b>30</b> (10 μM) after 20 min to an aged rat heart perfused with H<sub>2</sub>O<sub>2</sub> (0.1 mM). Note that compound (<i>R</i>)-<b>30</b> suppressed ventricular fibrillation (VF) by conversion to monomorphic ventricular tachycardia (VT) and then to sinus rhythm. (C) In the aged rat heart (treated as in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) with continued perfusion of H<sub>2</sub>O<sub>2</sub> (0.1 mM) and treatment with compound (<i>R</i>)-<b>30</b> (10 μM) after 40 min, the heart continued to show sustained sinus rhythm. Complete resolution of all forms of arrhythmias to normal sinus rhythm 30–40 min after perfusion of compound (<i>R</i>)-<b>30</b> (10 μM) was observed in an isolated perfused aged heart in the presence of hydrogen peroxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Patient-derived iPSC CMs combined with dynamic medicinal chemistry were used to re-engineer mexiletine. Replacement of metabolically labile mexiletine substituents with more metabolically resilient groups (e.g., −CF<sub>3</sub> for −CH<sub>3</sub>) improved the pharmaceutical and pharmacological properties of the molecule. The combination of drug design in a dish and disease in a dish approaches was shown to be useful to identify more potent, selective, less toxic analogues of mexiletine that may hold clinical relevance. In addition, compounds such as relatively long-lived (<i>R</i>)-<b>30</b> possessing later <i>T</i><sub>max</sub> and greater oral <i>C</i><sub>max</sub> and AUC with good <i>ex vivo</i> efficacy showed that major shortcomings of mexiletine (the need for multiple and repeated administration and toxicity) have potentially been overcome.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General</h3><div class="NLM_p last">Reagents, starting materials, and solvents were purchased in the highest purity available from commercial suppliers and used as received. Mexiletine, (<i>R</i>)-mexiletine, and (<i>S</i>)-mexiletine were purchased from Toronto Research (Toronto, CA). Hydrochloride salts were prepared by dissolution of the appropriate compound in a minimum amount of dichloromethane and addition of excess 2 M HCl in ether. The solvent was evaporated, and hydrochlorides were used directly for evaluation. Phosphate-buffered saline (PBS) and SYBR Green used in cell proliferation assays were purchased from Life Technologies (Carlsbad, CA). Fluorescence was determined using a Tecan SPECTRAFluor Plus plate reader (Tecan, San Jose, CA). Luminescence was recorded on a Wallac Victor plate reader (PerkinElmer Inc., Waltham, MA).</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Chemistry Experimental Section</h3><div class="NLM_p">Experiments were carried out under an inert atmosphere when oxygen- or moisture-sensitive reagents or intermediates were employed. Commercial solvents and reagents were used without further purification. Microwave reactions were conducted using a Biotage Initiator microwave synthesizer (Biotage, Uppsala, Sweden). Reaction products were purified, when necessary, using an Isco Combiflash <i>R</i><sub>f</sub> flash chromatography system (Teledyne-Isco, Lincoln, NE) with the solvent systems indicated. Nuclear magnetic resonance (NMR) data were recorded on a Varian Mercury 300 MHz spectrometer (Agilent, Santa Clara, CA) unless specified or in a Bruker 500 MHz instrument at NuMega Resonance Laboratories (San Diego, CA) in the indicated solvents. Chemical shifts for nuclear magnetic resonance (NMR) data were expressed in parts per million (ppm, δ) referenced to residual peaks from deuterated solvents. Mass spectrometry (MS) data were reported from liquid chromatography–mass spectrometry (LCMS) instrumentation. Electrospray ionization (ESI) mass spectral data were obtained using an Agilent 1100 LC/MS (Agilent, Santa Clara, CA). Final test compounds were pure based on LCMS analysis using UV–vis detection at 275 and 220 nM. Mexiletine and analogue compound purities were determined by high-performance liquid chromatography (HPLC), and all final test compounds were of >95% purity. Final compounds were assessed for purity by HPLC via the following conditions: column: Waters Atlantis dC18 4.6 × 50, 5 um; mobile phase A: 0.05% TFA in water (v/v); mobile phase B: 0.05% TFA in acetonitrile (v/v); gradient: 95.0% water/5.0% acetonitrile linear to 5% water/95% acetonitrile in 4.0 min, hold at 5% water/95% acetonitrile to 5.0 min; flow: 2 mL/min. Samples analyzed for ESI-TOF high-accuracy mass spectroscopy were sent for analysis at the mass spectroscopy service at The Scripps Research Institute, San Diego, CA.</div><div class="NLM_p last">Chiral compounds were analyzed using a Hitachi-7100 HPLC system equipped with a Phenomenex Lux 5 μm Cellulose-1 150 × 4.6 mm column. Detection was achieved with a Hitachi-7400 UV detector with monitoring at 220 nm. Compounds were eluted with a mixture of 70:20:5 hexanes/isopropanol/acetonitrile containing 0.02% perchloric acid with a flow rate of 0.5 mL/min.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Syntheses of Amines via Reduction of <i>O</i>-Benzyloximes</h3><div id="sec6_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(2,6-Dimethylphenoxy)-3,3-dimethylbutan-2-amine (<b>2</b>)</h4><div id="sec6_3_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step 1: 1-(2,6-Dimethylphenoxy)-3,3-dimethylbutan-2-one</h5><div class="NLM_p last">To a mixture of 1-bromo-3,3-dimethylbutan-2-one (0.75 mL, 5.6 mmol) and 2,6-dimethylphenol (1.02 g, 8.3 mmol) in DMF (5 mL) was added 1.1 g (8.3 mmol) of potassium carbonate. After stirring at 21 °C for 16 h water was added and extracted with diethyl ether. The organic phase was washed (water, 2 M sodium hydroxide, brine), dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using an ethyl acetate/hexane gradient. The target ketone was obtained (0.49 g) in 40% yield. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.00–7.02 (m, 2H), 6.93–6.96 (m, 1H), 4.64 (s, 2H), 2.26 (s, 6H), 1.22 (s, 9H). MS: 221.0 (MH <sup>+</sup>).</div></div><div id="sec6_3_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 2: (<i>E</i>/<i>Z</i>)-1-(2,6-Dimethylphenoxy)-3,3-dimethylbutan-2-one <i>O</i>-Benzyl Oxime</h5><div class="NLM_p last">To a flask containing 400 mg (1.8 mmol) of 1-(2,6-dimethylphenoxy)-3,3-dimethylbutan-2-one in 8 mL of ethanol were added <i>O</i>-benzylhydroxylamine hydrochloride (879 mg, 5.5 mmol) and pyridine (0.882 mL, 10.9 mmol) and stirred at 21 °C for 16 h, diluted with water, and extracted with diethyl ether. The organic phase was washed (water, brine), dried over sodium sulfate, and concentrated. Chromatography on silica gel using a gradient of ethyl acetate in hexane was conducted to yield 365 mg (62%) of the product as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.31 (s, 9H), 2.26 (s, 6H), 4.59 (s, 2H), 5.08 (s, 2H), 6.87–6.92 (m, 1H), 6.96–6.98 (m, 2H), 7.28–7.31 (m, 5H). MS: 326.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> Step 3: 1-(2,6-Dimethylphenoxy)-3,3-dimethylbutan-2-amine (<b>2</b>)</h5><div class="NLM_p">To a flask containing 100 mg (0.31 mmol) of the above <i>O</i>-benzyl oxime in 1 mL of THF was added 1.2 mL (1.2 mmol) of a 1 M solution of borane in THF and heated at 50 °C for 16 h. The mixture was allowed to cool to room temperature and carefully stopped by addition of 6 M aqueous HCl. After about 10 min, the mixture was taken to pH > 10 by addition of an excess of 6 M aqueous sodium hydroxide and extracted with ethyl acetate. The organic phase was washed (water, brine), dried (sodium sulfate), and concentrated. Chromatographic purification using 5% methanol in dichloromethane afforded the target product. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 1.03 (s, 9H), 2.31 (s, 6H), 3.12–3.16 (m, 1H), 3.75–3.87 (m, 2H), 6.89–6.94 (m, 1H), 6.96–7.02 (m, 2H) MS: 222.0 (MH<sup>+</sup>).</div><div class="NLM_p last">The following compounds were prepared using similar sequences with the appropriate starting materials:</div></div></div><div id="sec6_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-Cyclopropyl-2-(2,6-dimethylphenoxy)ethanamine (<b>3</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.03–6.90 (m, 3H), 3.90–3.77 (AB of ABX, <i>J</i><sub>AB</sub> = 9.0 Hz, 2H), 2.41 (m, 1H, overlapping with neighboring peak), 2.32 (s, 6H), 0.96 (m, 1H), 0.57 (m, 2H), 0.32 (m, 2H) ppm. MS: 206.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.17 (10% methanol in dichloromethane, silica gel).</div></div><div id="sec6_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-Cyclohexyl-2-(2,6-dimethylphenoxy)ethan-1-amine (<b>4</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, methanol-<i>d</i><sub>4</sub>) δ 1.15–1.39 (m, 5H), 1.63–2.05 (m, 6H), 2.30 (s, 6H), 3.41 (td, <i>J</i> = 3.7, 7.2 Hz, 1H), 3.66 (s, 1H), 3.86–4.05 (m, 1H), 6.87–7.07 (m, 2H). MS: 248.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 2-(2,6-Dimethylphenoxy)-1-phenylethanamine (<b>5</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.43–7.46 (m, 2H), 7.27–7.37 (m, 3H), 6.97–6.99 (m, 2H), 6.87–6.92 (m, 1H), 4.46 (dd, <i>J</i> = 4.7 and 8.0 Hz, 1H), 3.79–3.89 (m, 2H), 2.25 (s, 6H). MS: 242.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-(2,6-Dimethylphenoxy)-1-<i>p</i>-tolylethanamine (<b>6</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.29 (s, 6H), 2.36 (s, 3H), 3.78–3.87 (m, 2H), 4.43 (dd, <i>J</i> = 4.1 and 8.0 Hz, 1H), 6.88–6.93 (m, 1H), 6.98–7.01 (m, 2H), 7.17 (d, <i>J</i> = 8.0 Hz, 2H), 7.33 (d, <i>J</i> = 8.0 Hz, 2H). MS: 256.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-(2,6-Dimethylphenoxy)-1-(4-(trifluoromethyl)phenyl)ethanamine (<b>7</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 2.23 (s, 6H), 3.78–3.88 (m, 2H), 4.51 (dd, <i>J</i> = 4.4 and 4.4 Hz, 1H), 6.88–6.93 (m, 1H), 6.97–7.00 (m, 2H), 7.56–7.72 (m, 4H). MS: 309.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-(2,6-Dimethylphenoxy)-l-(4-methoxyphenyl)ethanamine (<b>8</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.36 (s, <i>J</i> = 8.8 Hz, 2H), 6.97–6.99 (m, 2H), 6.85–6.92 (m, 3H), 4.39–4.43 (m, 1H), 3.80 (s, 3H), 3.79–3.82 (m, 2H), 2.26 (s, 6H). MS: 272.1 (MH<sup>+</sup>).</div></div><div id="sec6_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-(2,6-Dimethylphenoxy)-1-(naphthalen-2-yl)ethan-1-amine (<b>9</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.95 (s, 3H), 8.15 (s, 1H), 7.97 (m, 3H), 7.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.57 (dd, <i>J</i> = 5.7, 3.8 Hz, 2H), 7.01–6.87 (m, 3H), 4.90 (s, 1H), 4.38–4.00 (m, 2H), 2.10 (s, 6H). MS: 292.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.52 (5% methanol in dichloromethane on silica).</div></div><div id="sec6_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-Cyclopropyl-2-(2,6-dimethylphenoxy)ethan-1-amine (<b>12</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.03–6.90 (m, 3H,), 3.90–3.77 (AB of ABX, <i>J</i><sub>AB</sub> = 9.0 Hz, 2H), 2.41 (m, 1H, overlapping with neighboring peak), 2.32 (s, 6H), 0.96 (m, 1H), 0.57 (m, 2H), 0.32 (m, 2H). MS: 206.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 1-Cyclopropyl-2-(2,4-dimethylphenoxy)ethan-1-amine (<b>13</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) 6.90–7.00 (m, 2H), 6.77–6.86 (m, 1H), 4.06–4.28 (m, 2H), 2.84 (ddd, <i>J</i> = 3.4, 6.3, 10.0 Hz, 1H), 2.24 (broad s, 6H), 1.11 (m, 1H), 0.78 (ddd, <i>J</i> = 2.0, 3.8, 8.0 Hz, 2H), 0.45–0.63 (m, 2H). MS: 206.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-Cyclopropyl-2-(3,4-dimethylphenoxy)ethan-1-amine (<b>14</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) 7.03 (d, <i>J</i> = 8.2 Hz, 1H), 6.80 (d, <i>J</i> = 2.8 Hz, 1H), 6.72 (dd, <i>J</i> = 2.7, 8.2 Hz, 1H), 4.23 (dd, <i>J</i> = 3.5, 10.3 Hz, 1H), 4.09 (dd, <i>J</i> = 7.0, 10.3 Hz, 1H), 2.79 (ddd, <i>J</i> = 3.5, 7.0, 10.4 Hz, 1H), 2.2.4 (s, 3H), 2.20 (s, 3H), 1.07–1.24 (m, 1H), 0.70–0.82 (m, 2H), 0.54 (qd, <i>J</i> = 4.9, 10.2 Hz, 2H). MS: 206.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-Cyclopropyl-2-(3,5-dimethylphenoxy)-<i>N</i>-(2-methoxyethyl)ethan-1-amine (<b>15</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) 6.58 (s, 1H), 6.54 (s, 2H), 4.05–4.16 (m, 1H), 4.05–4.16 (m, 1H), 3.44–3.63 (m, 2H), 3.37 (s, 3H), 2.95–3.16 (m, 1H), 2.73–2.95 (m, 1H), 2.10–2.22 (m, 1H), 0.45–0.61 (m, 1H), 0.32–0.47 (m, 2H), 0.14–0.32 (m, 2H). MS: 264.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1-Cyclopropyl-2-(3,5-dimethylphenoxy)ethan-1-amine (<b>16</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 8.67 (br. s., 3H), 6.68 (s, 2H), 6.58 (s, 1H), 3.85–4.39 (m, 2H), 2.26 (s, 6H), 2.16–2.39 (m, 1H), 1.82–2.10 (m, 1H), 0.93–1.30 (m, 2H), 0.52 (m, 2H). MS: 206.2 (MH<sup>+</sup>).</div></div><div id="sec6_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-(2-Methylphenoxy)propan-2-amine (<b>17</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.16 (m, 2H), 6.87 (td, <i>J</i> = 7.5, 1.1 Hz, 1H), 6.82 (m, 1H), 3.93–3.70 (AB of ABX, <i>J</i><sub>AB</sub> = 8.8 Hz, 2H), 3.41 (m, 1H), 2.27 (s, 3H), 1.23 (d, <i>J</i> = 6.6 Hz, 1H). MS: 166.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.20 (15% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-(2-Ethylphenoxy)propan-2-amine (<b>18</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.16 (m, 2H), 6.92 (td, <i>J</i> = 7.4, 1.1 Hz, 1H), 6.82 (dd, <i>J</i> = 8.8, 0.9 Hz, 1H), 3.92–3.71 (AB of ABX, <i>J</i><sub>AB</sub> = 9.0 Hz, 2H), 3.41 (m, 1H,), 2.69 (q, <i>J</i> = 7.5 Hz, 2H), 1.24 (t, <i>J</i> = 7.5 Hz, 3H), 1.23 (d, <i>J</i> = 6.6 Hz, 1H). MS: 180.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.22 (15% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(2-Propylphenoxy)propan-2-amine (<b>19</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.15 (m, 2H), 6.89 (td, <i>J</i> = 7.4, 1.4 Hz, 1H), 6.82 (m, 1H), 3.92–3.70 (AB of ABX, <i>J</i><sub>AB</sub> = 8.8 Hz, 2H), 3.41 (m, 1H), 2.64 (t, <i>J</i> = 7.5 Hz, 2H), 1.64 (m, 2H), 1.23 (d, <i>J</i> = 6.6 Hz, 1H), 0.98 (t, <i>J</i> = 7.1 Hz, 3H). MS: 194.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.24 (15% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(2-(Trifluoromethyl)phenoxy)propan-2-amine (<b>20</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.57 (dd, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.48 (m, 1H), 7.00 (m, 2H), 4.03–3.76 (AB of ABX, <i>J</i><sub>AB</sub> = 8.5 Hz, 2H), 3.44 (m, 1H), 1.23 (d, <i>J</i> = 6.6 Hz, 1H) ppm. MS: 220.0 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.16 (15% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 1-(2-Methoxyphenoxy)propan-2-amine (<b>21</b>)</h4><div class="NLM_p last">1H NMR (300 MHz, CDCl<sub>3</sub>): 6.96–6.88 (m, 4H), 3.98–3.70 (AB of ABX, <i>J</i><sub>AB</sub> = 9.4 Hz, 2H), 3.88 (s, 3H), 3.41 (m, 1H), 1.20 (d, <i>J</i> = 6.6 Hz, 1H). MS: 183.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.29 (15% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-(<i>m</i>-Tolyloxy)propan-2-amine (<b>22</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 7.11–7.23 (m, 1H), 6.69–6.90 (m, 3H), 4.09–4.23 (m, 1H), 3.91–4.04 (m, 1H), 3.66–3.76 (m, 1H), 2.32 (s, 3H), 1.41 (d, = 7.1 Hz, 3H). MS: 166.1 (MH<sup>+</sup>).</div></div><div id="sec6_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-(3-(Trifluoromethyl)phenoxy)propan-2-amine (<b>23</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 6.90–6.95 (m, 1H), 7.15–7.30 (m, 3H), 4.31 (d, <i>J</i> = 3.3 Hz, 1H), 4.23 (d, <i>J</i> = 6.6 Hz, 1H), 2.77–2.98 (m, 1H), 2.28 (s, 6H), 1.12–1.27 (m, 1H), 0.80–0.93 (m, 1H), 0.71–0.81 (m, 1H), 0.56–0.70 (m, 1H), 0.43–0.52 (m, 1H). MS: 220.1 (MH<sup>+</sup>).</div></div><div id="sec6_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-(3,5-Dimethylphenoxy)propan-2-amine (<b>24</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 6.67 (none, 1H), 6.65 (s, 2H), 4.31 (d, <i>J</i> = 3.29 Hz, 1H), 4.23 (d, <i>J</i> = 6.57 Hz, 1H), 2.77–2.98 (m, 1H), 2.28 (s, 6H), 1.12–1.27 (m, 1H), 0.80–0.93 (m, 1H), 0.71–0.81 (m, 1H), 0.56–0.70 (m, 1H), 0.43–0.52 (m, 1H). MS: 180.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1-(3,5-Bis(trifluoromethyl)phenoxy)propan-2-amine (<b>25</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 7.63–7.44 (m, 1H), 7.04–7.26 (m, 1H), 6.72–6.92 (m, 1H), 4.65–4.80 (m, 1H), 4.32–4.41 (m, 1H), 4.25–4.33 (m, 1H), 2.32 (s, 3H). MS: 288.1 (MH<sup>+</sup>).</div></div><div id="sec6_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 2-(2,4-Dimethylphenoxy)-1-phenylethan-1-amine (<b>26</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 7.41–7.69 (m, 5H), 6.90–7.01 (m, 2H), 6.77–6.84 (m, 1H), 4.75–4.82 (m, 1H), 4.26–4.34 (m, 2H), 2.23 (s, 3H), 2.22 (s, 2H). MS: 242.1 (MH<sup>+</sup>).</div></div><div id="sec6_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-Phenyl-2-(<i>o</i>-tolyloxy)ethanamine (<b>27</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.44–7.47 (m, 1H), 7.29–7.37 (m, 4H), 7.08–7.13 (m, 2H), 6.83–6.88 (m, 1H), 6.75–6.78 (m, 1H), 4.45–4.49 (m, 1H), 4.13 (dd, <i>J</i> = 4.1 and 9.1 Hz, 1H), 3.98–4.05 (m, 1H), 2.88 (bs, 2H), 2.24 (s, 3H). MS: 228.0 (MH<sup>+</sup>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): 157.14, 135.27, 130.99, 130.55, 128.88, 128.23, 123.04, 115.62, 71.35, 55.81, 28.86. Calcd <i>m</i>/<i>z</i> for [C<sub>15</sub>H<sub>17</sub>NO + H]<sup>+</sup>: 228.1383. Observed: 228.1387. MS: 228.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-(2-Ethylphenoxy)-1-phenylethan-1-amine (<b>28</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.44–7.47 (m, 1H), 7.29–7.38 (m, 4H), 7.08–7.15 (m, 2H), 6.86–6.91 (m, 1H), 6.77–6.80 (m, 1H), 4.45–4.49 (m, 1H), 4.12 (dd, <i>J</i> = 4.1 and 9.1 Hz, 1H), 3.99–4.05 (m, 1H), 2.65 (q, <i>J</i> = 7.4 Hz, 2H), 2.52 (bs, 2H), 1.18 (t, <i>J</i> = 7.4 Hz, 3H). MS: 242.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1-Phenyl-2-(2-propylphenoxy)ethanamine (<b>29</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.44–7.47 (m, 1H), 7.29–7.38 (m, 4H), 7.08–7.14 (m, 2H), 6.84–6.90 (m, 1H), 6.77–6.80 (m, 1H), 4.44–4.48 (m, 1H), 4.11 (dd, <i>J</i> = 4.4 and 9.1 Hz, 1H), 3.98–4.04 (m, 1H), 2.56–2.61 (m, 2H), 2.36 (bs, 2H), 1.57 (sextet, <i>J</i> = 7.4 Hz, 2H), 0.95 (t, <i>J</i> = 7.4 Hz, 3H). MS: 256.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-Phenyl-2-(2-(trifluoromethyl)phenoxy)ethanamine (<b>30</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.54–7.58 (m, 1H), 7.44–7.49 (m, 2H), 7.29–7.42 (m, 4H), 6.98–7.03 (m, 1H), 6.91–6.94 (m, 1H), 4.48–4.58 (m, 1H), 4.19–4.27 (m, 1H), 4.02–4.11 (m, 1H), 2.38 (bs, 2H). MS: 282.0 (MH<sup>+</sup>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): 157.50, 135.56, 132.08, 130.88, 130.54, 128.75, 128.25, 122.97, 113.09, 70.40, 56.11. Calcd <i>m</i>/<i>z</i> for [C<sub>15</sub>H<sub>14</sub>F<sub>3</sub>NO + H]<sup>+</sup>: 282.1100. Observed: 282.1089.</div></div><div id="sec6_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 2-(2-Methoxyphenoxy)-1-phenylethanamine (<b>31</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.47–7.50 (m, 1H), 7.30–7.39 (m, 4H), 6.86–6.98 (m, 4H), 4.48–4.52 (m, 1H), 4.15–4.20 (m, 1H), 4.05–4.11 (m, 1H), 3.79 (m, 3H), 2.68 (bs, 2H).). MS: 244.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-Phenyl-2-(2-(trifluoromethoxy)phenoxy)ethan-1-amine (<b>32</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.44–7.58 (m, 2H), 7.31–7.43 (m, 3H), 7.14–7.30 (m, 2H), 6.84–7.03 (m, 2H), 4.51 (dd, <i>J</i> = 3.58, 8.53 Hz, 1H), 4.15 (dd, <i>J</i> = 3.58, 8.80 Hz, 1H), 3.91–4.07 (m, 1H) for the free base amine. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) d 7.41–7.63 (m, 5H), 7.26–7.39 (m, 2H), 7.17–7.25 (m, 1H), 7.00–7.13 (m, 1H), 4.80 (dd, <i>J</i> = 4.95, 7.15 Hz, 1H), 4.34–4.53 (m, 2H) for the hydrochloride salt. MS: 298.0 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.5 (5% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1-Phenyl-2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethan-1-amine (<b>33</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.25–7.59 (m, 5H), 6.81–7.13 (m, 4H), 4.48 (d, <i>J</i> = 4.40 Hz, 1H), 4.29 (qd, <i>J</i> = 2.06, 8.39 Hz, 2H), 4.20 (td, <i>J</i> = 3.44, 4.75 Hz, 1H), 3.99–4.14 (m, 1H) for the amine free base. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.57 (br. s., 3H), 7.63–7.53 (m, 2H), 7.39–7.52 (m, 2H), 7.06–7.24 (m, 3H), 6.91–7.06 (m, 2H), 4.76 (m, 1H), 4.53–4.70 (m, 2H), 4.23–4.36 (m, 2H) for the hydrochloride. MS: 311.0 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> for the free base = 0.5 (5% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-Phenyl-2-(<i>m</i>-tolyloxy)ethan-1-amine (<b>34</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ 7.63–7.44 (m, 1H), 7.04–7.26 (m, 1H), 6.72–6.92 (m, 1H), 4.65–4.80 (m, 1H), 4.32–4.41 (m, 1H), 4.25–4.33 (m, 1H), 2.32 (s, 3H). MS: 228.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-Phenyl-2-(3-(trifluoromethyl)phenoxy)ethan-1-amine (<b>35</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.27–7.49 (m, 8H), 4.48 (dd, <i>J</i> = 3.8, 8.6 Hz, 1H), 4.15 (dd, <i>J</i> = 3.8, 8.7 Hz, 1H), 4.02 (t, <i>J</i> = 8.7 Hz, 1H). MS: 282.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 2-(3,5-Dimethylphenoxy)-1-phenylethanamine Hydrochloride (<b>36</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): δ 7.56–7.46 (m, 5H), 6.64 (s, 3H), 4.74 (dd, <i>J</i> = 8.3, 4.4 Hz, 1H), 4.35–4.24 (AB of ABX, <i>J</i><sub>AB</sub> = 10.5 Hz, 2H), 2.27 (s, 6H). MS: 242.0 (MH<sup>+</sup>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): 159.47, 140.71, 135.41, 130.86, 130.54, 128.75, 124.65, 113.61, 69.94, 56.07, 21.07. MS: 242.0 (MH<sup>+</sup>). Calcd <i>m</i>/<i>z</i> for [C<sub>16</sub>H<sub>19</sub>NO + H]<sup>+</sup>: 242.1540. Observed: 242.1542.</div></div><div id="sec6_3_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 2-(3,5-Bis(trifluoromethyl)phenoxy)-1-phenylethan-1-amine (<b>37</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.27–7.49 (m, 8H), 4.48 (dd, <i>J</i> = 3.8, 8.6 Hz, 1H), 4.15 (dd, <i>J</i> = 3.8, 8.7 Hz, 1H), 4.02 (t, <i>J</i> = 8.7 Hz, 1H). MS: 350.0 (MH<sup>+</sup>).</div></div><div id="sec6_3_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 2-(2,3-Dimethylphenoxy)-1-phenylethanamine (<b>38</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.50–7.47 (m, 2H), 7.42–7.28 (m, 3H), 7.03 (t, <i>J</i> = 7.7 Hz, 1H), 6.79 (d, <i>J</i> = 7.5 Hz, 1H), 6.68 (d, <i>J</i> = 8.0 Hz, 1H), 4.47 (dd, <i>J</i> = 7.7, 3.8 Hz, 1H), 4.13–3.95 (AB of ABX, <i>J</i><sub>AB</sub> = 9.1 Hz, 2H), 2.39 (broad s, 2H), 2.30. MS: 242.1 (MH<sup>+</sup>).</div></div><div id="sec6_3_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 2-(2,4-Dimethylphenoxy)-1-phenylethan-1-amine (<b>39</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): 7.42–7.60 (m, 5H), 6.94 (m, 2H), 6.80 (d, <i>J</i> = 8.1 Hz, 1H), 4.79 (dd, <i>J</i> = 4.9, 7.1 Hz, 1H), 4.22–4.36 (m, 2H), 2.23 (s, 3H), 2.24 (s, 3H). MS: 242.3 (MH<sup>+</sup>).</div></div><div id="sec6_3_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 2-(3,4-Dimethylphenoxy)-1-phenylethan-1-amine (<b>40</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): 7.42–7.58 (m, 5H), 7.03 (d, <i>J</i> = 8.2 Hz, 1H), 6.82 (d, <i>J</i> = 2.7 Hz, 1H), 6.73 (dd, <i>J</i> = 2.8, 8.2 Hz, 1H), 4.73 (dd, <i>J</i> = 4.2, 8.4 Hz, 1H), 4.18–4.37 (m, 2H), 2.24 (s, 3H), 2.19 (s, 3H). MS: 242.1 (MH<sup>+</sup>).</div></div><div id="sec6_3_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 2-(Naphthalen-2-yloxy)-1-phenylethan-1-amine (<b>41</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD): 8.81–8.35 (m, 3H), 7.82 (dd, <i>J</i> = 16.8, 10.6 Hz, 3H), 7.63 (d, <i>J</i> = 6.5 Hz, 4H), 7.56–7.09 (m, 5H), 4.81 (s, 1H), 4.40 (s, 2H). MS: 264.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.45 (5% methanol in dichloromethane on silica gel).</div></div><div id="sec6_3_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 2-(Naphthalen-1-yloxy)-1-phenylethan-1-amine (<b>42</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): 8.8 (s, 3H), 8.44 (d, <i>J</i> = 9.6 Hz, 1H), 7.96–7.76 (m, 1H), 7.49 (m, 9H), 6.99 (d, <i>J</i> = 7.5 Hz, 1H), 4.9 (m, 1H), 4.46 (d, <i>J</i> = 5.7 Hz, 2H). MS: 264.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.50 (5% methanol in dichloromethane on silica gel).</div></div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Synthesis of <i>N</i>-Alkylated Analogues via Reductive Amination</h3><div id="sec6_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-methylpropan-2-amine (<b>43</b>)</h4><div id="sec6_4_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Step 1: 1-(2,6-Dimethylphenoxy)propan-2-one</h5><div class="NLM_p last">To a solution of α-bromoacetone (3.17 g, 16.66 mmol) in 30 mL of DMF were added 3.10 g (25.4 mmol) of 2,6-dimethylphenol and 3.40 g (24.6 mmol) of potassium carbonate. The mixture was stirred at 21 °C for 20 h and then at 55 °C for an additional 2 h. The reaction mixture was poured on water and extracted with ether. The organic phase was washed (2 M sodium hydroxide, brine), dried over sodium sulfate, and concentrated under reduced pressure. Chromatography on silica gel using a gradient of ethyl acetate in hexanes afforded 1.01 g (34% yield) of the target ketone. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.04–6.94 (m, 3H), 4.37 (s, 2H), 2.38 (s, 3H,), 2.30 (s, 6H)<i>. R</i><sub>f</sub> = 0.31 (10% diethyl ether in hexanes on silica gel).</div></div><div id="sec6_4_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> Step 2. 1-(2,6-Dimethylphenoxy)-<i>N</i>-methylpropan-2-amine (<b>43</b>)</h5><div class="NLM_p">Sodium cyanoborohydride (38 mg, 0.602 mmol) was added to a solution of methylamine hydrochloride (76.3 mg, 1.13 mmol) and 1-(2,6-dimethylphenoxy)propan-2-one (54.5 mg, 0.31 mmol) in ethanol (2.7 mL) at 21 °C. The reaction was heated at 90 °C in a microwave reactor for 1 h and stopped by dropwise addition of 10% (w/w) Na<sub>2</sub>CO<sub>3(aq)</sub> until pH 9; then Celite was added, and the mixture was concentrated to dryness. Product-infused Celite was loaded onto a silica gel column and eluted using a gradient of methanol in dichloromethane to provide the title compound (22.6 mg, 38% yield) as a pale yellow oil that solidified over time. <sup>1</sup>H NMR (CDCl<sub>3</sub>): 7.02–6.93 (m, 3H), 6.43 (broad s, 1H), 3.93 (m, 2H), 3.58 (m, 1H), 2.86 (s, 3H), 2.30 (s, 6H), 1.52 (d, <i>J</i> = 6.6 Hz, 3H) ppm<i>. R</i><sub>f</sub> = 0.23 (10% methanol in dichloromethane on silica gel).</div><div class="NLM_p last">The following compounds were synthesized by the same sequence as <b>43</b>:</div></div></div><div id="sec6_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-ethylpropan-2-amine (<b>44</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.02–6.92 (m, 3H), 6.23 (broad s, 1H), 4.03–3.96 (AB of ABX, <i>J</i><sub>AB</sub> = 10.1 Hz, 2H), 3.61 (m, 1H), 3.24 (m, 2H), 2.30 (s, 6H), 1.51 (d, <i>J</i> = 6.9 Hz, 3H), 1.45 (t, <i>J</i> = 6.4 Hz, 3H). MS: 208.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.19 (10% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-propylpropan-2-amine (<b>45</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.03–6.90 (m, 3H), 3.70 (m, 2H), 3.17 (m, 1H), 2.82–2.62 (m, 2H), 2.50 (broad s, 1H), 2.31 (s, 6H), 1.62 (m, 2H), 1.28 (d, <i>J</i> = 6.6 Hz, 3H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H). MS: 222.3 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.24 (10% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-butylpropan-2-amine (<b>46</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.02–6.91 (m, 3H), 4.21 (broad s, 1H), 3.83–3.73 (AB of ABX, <i>J</i><sub>AB</sub> = 9.6 Hz, 2H), 3.27 (m, 1H), 2.95–2.76 (m, 2H), 2.30 (s, 6H), 1.65 (m, 2H), 1.43 (m, 2H,), 1.28 (d, <i>J</i> = 6.6 Hz, 3H), 0.98 (t, <i>J</i> = 7.2 Hz, 3H). MS: 236.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.31 (10% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-butylpropan-2-amine (<b>47</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.02–6.89 (m, 3H), 3.76–3.67 (m, 2H), 3.59 (app t, <i>J</i> = 4.9 Hz, 2H), 3.40 (s, 3H), 3.22–3.12 (m, 2H), 3.01–2.85 (m, 2H), 2.54 (broad s, 1H), 2.31 (s, 6H,), 1.22 (d, <i>J</i> = 6.6 Hz, 3H). MS: 238.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.36 (10% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-phenylpropan-2-amine (<b>48</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.20 (t, <i>J</i> = 7.7 Hz, 2H), 7.00 (m, 2H), 6.92 (m, 1H), 6.75–6.69 (m, 3H), 4.13 (broad s, 1H), 3.89 (m, 1H), 3.85–3.80 (m, 2H), 2.27 (s, 6H), 1.47 (d, <i>J</i> = 6.6 Hz, 3H). MS: 256.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.34 (20% ethyl acetate in hexane on silica gel).</div></div><div id="sec6_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-benzylpropan-2-amine (<b>49</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.40–7.3 (m, 4H), 7.27 (m, 1H, overlapping with the solvent signal), 7.01 (m, 2H), 6.93 (m, 1H), 4.00–3.87 (AB quartet, <i>J</i> = 13.1 Hz, 2H), 3.77–3.69 (m, 2H), 3.20 (m, 1H), 2.29 (s, 6H), 1.22 (d, <i>J</i> = 6.0 Hz, 3H). MS: 270.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.24 (5% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 1-(2,6-Dimethylphenoxy)-<i>N</i>-(2-phenylethyl)propan-2-amine (<b>50</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.31 (m, 2H), 7.26 (m, 2H, overlapping with the solvent signal), 7.22 (t, <i>J</i> = 7.1 Hz, 1H), 7.01 (m, 2H), 6.92 (m, 1H), 3.67 (m, 2H), 3.15 (m, 1H), 3.06 (m, 1H), 2.96–2.83 (m, 2H), 2.25 (s, 6H), 1.18 (d, <i>J</i> = 6.1 Hz, 3H). MS: 284.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.25 (5% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 2-(2,3-Dimethylphenoxy)-<i>N</i>-methyl-1-phenylethanamine (<b>55</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.48–7.46 (m, 2H), 7.42–7.3 (m, 3H), 7.01 (t, <i>J</i> = 7.7 Hz, 1H), 6.78 (d, <i>J</i> = 7.4 Hz, 1H), 6.68 (d, <i>J</i> = 8.3 Hz, 1H), 4.02 (m, 3H), 2.42 (s, 3H), 2.29 (s, 3H), 2.18 (s, 3H). MS: 256.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.33 (5% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 2-(2,3-Dimethylphenoxy)-<i>N</i>-ethyl-1-phenylethanamine (<b>56</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.49–7.46 (m, 2H), 7.41–7.29 (m, 3H), 7.01 (t, <i>J</i> = 8.0 Hz, 1H), 6.78 (d, <i>J</i> = 7.4 Hz, 1H), 6.68 (d, <i>J</i> = 8.3 Hz, 1H), 4.20 (app dd, <i>J</i> = 8.0, 4.7 Hz, 1H), 4.12–4.03 (m, 2H), 2.64 (q, <i>J</i> = 7.2 Hz, 2H), 2.29 (s, 3H), 2.17 (s, 3H), 1.17 (t, <i>J</i> = 7.1 Hz, 3H). MS: 270.3 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.18 (4% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 2-(2,3-Dimethylphenoxy)-<i>N</i>-propyl-1-phenylethanamine (<b>57</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.50–7.46 (m, 2H), 7.42–7.29 (m, 3H), 7.03 (t, <i>J</i> = 7.7 Hz, 1H), 6.79 (d, <i>J</i> = 7.1 Hz, 1H), 6.68 (d, <i>J</i> = 8.0 Hz, 1H), 4.18 (app dd, <i>J</i> = 8.5, 4.1 Hz, 1H), 4.10–3.99 (m, 2H), 2.56 (t, <i>J</i> = 7.1 Hz, 2H), 2.30 (s, 3H), 2.19 (s, 3H), 1.58 (m, 2H), 0.96 (t, <i>J</i> = 7.7 Hz, 3H). MS: 284.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.23 (2% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 2-(2,3-Dimethylphenoxy)-<i>N</i>-butyl-1-phenylethanamine (<b>58</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.49–7.46 (m, 2H), 7.41–7.29 (m, 3H), 7.02 (t, <i>J</i> = 8.0 Hz, 1H), 6.79 (d, <i>J</i> = 7.4 Hz, 1H), 6.67 (d, <i>J</i> = 8.0 Hz, 1H), 4.17 (app dd, <i>J</i> = 8.2, 3.9 Hz, 1H), 4.10–3.99 (m, 2H), 2.59 (t, <i>J</i> = 6.9 Hz, 2H), 2.30 (s, 3H), 2.19 (s, 3H), 1.54 (m, 2H), 1.40 (m, 2H), 0.94 (t, <i>J</i> = 7.4 Hz, 3H). MS: 298.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.25 (2% methanol in dichloromethane on silica gel).</div></div><div id="sec6_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 2-(2,3-Dimethylphenoxy)-<i>N</i>-methoxy-ethyl-1-phenylethanamine (<b>59</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.25 (s, 1H), 6.96–7.05 (m, 2H), 6.92 (dd, <i>J</i> = 6.2, 8.4 Hz, 1H), 4.14–4.31 (m, 1H), 3.58–3.79 (m, 2H), 2.29 (s, 6H), 1.27 (d, <i>J</i> = 6.5 Hz, 7H). MS: 300.1 (MH<sup>+</sup>). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): 157.22, 139.42, 133.80, 131.31, 130.69, 129.87, 124.84, 111.27, 69.93, 68.14, 63.04, 59.41, 49.32, 20.23. MS: 300.1 (MH<sup>+</sup>). Calcd <i>m</i>/<i>z</i> for [C<sub>19</sub>H<sub>25</sub>NO<sub>2</sub> + H<sup>+</sup>]: 300.1958. Observed: 300.1952.</div></div><div id="sec6_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 2-(3,5-Dimethylphenoxy)-<i>N</i>-(2-methoxyethyl)-1-phenylethan-1-amine (<b>60</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 7.22–7.47 (m, 5H), 6.49–6.61 (m, 3H), 3.96–4.13 (m, 2H), 3.33–3.56 (m, 2H), 3.35 (s, 3H), 2.53–2.76 (m, 1H), 2.24 (d, <i>J</i> = 0.7 Hz, 6H). MS: 300.1 (MH<sup>+</sup>).</div></div><div id="sec6_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 2-(3,5-Bis(trifluoromethyl)phenoxy)-<i>N</i>-(2-methoxyethyl)-1-phenylethan-1-amine (<b>61</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.32–7.50 (m, 6H), 7.27 (d, <i>J</i> = 10.2 Hz, 2H), 4.08–4.21 (m, 4H), 3.50 (m, 1H), 3.38 (s, 3H), 2.62–2.85 (m, 2H). MS: 407.2 (MH<sup>+</sup>).</div></div><div id="sec6_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 2-((2-(3,5-Dimethylphenoxy)-1-phenylethyl)amino)ethan-1-ol (<b>62</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 2.28 (s, 6H), 2.61–2.87 (m, 2H), 3.52–3.74 (m, 2H), 3.94–4.10 (m, 2H), 4.10–4.19 (m, 1H), 6.50–6.64 (m, 2H), 7.22–7.46 (m, 6H). MS: 286.2 (MH<sup>+</sup>).</div></div><div id="sec6_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 2-((2-(3,5-Bis(trifluoromethyl)phenoxy)-1-phenylethyl)amino)ethan-1-ol (<b>63</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.37–7.61 (m, 6H), 7.33 (d, <i>J</i> = 10.2 Hz, 2H), 4.08–4.21 (m, 4H), 3.50 (m, 1H), 2.62–2.85 (m, 2H). MS: 394.0 (MH<sup>+</sup>).</div></div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Synthesis of Amide Analogues</h3><div id="sec6_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>N</i>-(1-(2,6-Dimethylphenoxy)propan-2-yl)acetamide (<b>51</b>)</h4><div class="NLM_p last">To 15 mg (0.06 mmol) of mexiletine hydrochloride and triethylamine (0.020 mL, 0.14 mmol) in dichloromethane (1 mL), acetyl chloride (0.006 mL, 0.08 mmol) was added. The mixture was stirred at 21 °C for 15 h, concentrated to dryness, and purified by flash chromatography (silica gel, ethyl acetate/hexane gradient) to afford 10.2 mg (65%) of <b>51</b>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 6.86–7.08 (m, 3H), 5.93 (s, 1H), 4.28–4.44 (m, 1H), 3.66–3.86 (m, 2H), 2.26 (s, 6H), 2.04 (s, 3H), 1.41 (d, <i>J</i> = 6.8 Hz, 3H). MS: 222.2 (MH<sup>+</sup>).</div></div><div id="sec6_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> <i>N</i>-(1-(2,6-Dimethylphenoxy)propan-2-yl)benzamide (<b>52</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.73–7.92 (m, 2H), 7.38–7.57 (m, 3H), 6.87–7.05 (m, 3H), 6.64 (d, <i>J</i> = 8.4 Hz, 1H), 4.57 (m, 1H), 3.95 (dd, <i>J</i> = 3.8, 9.1 Hz, 1H), 3.90 (s, 2H), 3.78–4.00 (m, 2H), 2.28 (s, 6H), 1.54 (d, <i>J</i> = 6.8 Hz, 3H). MS: 284.2 (MH<sup>+</sup>).</div></div><div id="sec6_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>N</i>-(2-(2,6-Dimethylphenoxy)-1-phenylethyl)acetamide (<b>53</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.29–7.43 (m, 4H), 6.87–6.98 (m, 3H), 6.39–6.43 (m, 1H), 5.33–5.39 (m, 1H), 3.98–4.10 (m, 2H), 2.11 (s, 6H). MS: 284.1 (MH<sup>+</sup>).</div></div><div id="sec6_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>N</i>-(2-(2,6-Dimethylphenoxy)-1-phenylethyl)benzamide (<b>54</b>)</h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 7.84–7.88 (1H), 7.44–7.53 (m, 4H), 7.30–7.41 (m, 4H), 7.15–7.18 (m, 1H), 6.88–6.98 (m, 4H), 6.39–6.43 (m, 1H), 5.52–5.58 (m, 1H), 4.21 (dd, <i>J</i> = 4.4 and 9.4 Hz, 1H), 4.11 (dd, <i>J</i> = 3.9 and 9.4 Hz, 1H), 2.13 (s, 6H). MS: 346.0 (MH<sup>+</sup>).</div></div><div id="sec6_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (<i>R</i>)-1-Phenyl-2-(2-(trifluoromethyl)phenoxy)ethanamine (<i>R</i>)-<b>30</b></h4><div id="sec6_5_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> Step 1: (<i>R</i>)-<i>tert</i>-Butyl 1-Phenyl-2-(2-(trifluoromethyl)phenoxy)ethylcarbamate</h5><div class="NLM_p last">To sodium hydride (78 mg of 60% suspension in oil, 0.76 mmol) in DMF (5 mL) was added 299 mg of 2-trifluoromethylphenol (1.8 mmol). After ca. 5 min, 499 mg (1.7 mmol) (4<i>R</i>)-1,2,3-oxathiazolidine-3-carboxylic acid, 4-phenyl 1,1-dimethylethyl ester-2,2-dioxide<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> in DMF (1 mL) was added. The mixture was stirred at 21 °C for 16 h and diluted with water. The product was extracted with ethyl acetate. The organic phase was washed (1 M aqueous sodium hydroxide, water, and brine), dried (magnesium sulfate), and concentrated under reduced pressure. Purification of the residue afforded 587 mg (92% yield) of a colorless oil that was used without further characterization<i>. R</i><sub>f</sub> = 0.7 (30% ethyl acetate in hexanes on silica gel).</div></div><div id="sec6_5_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> Step 2</h5><div class="NLM_p">To a solution of the precursor from Step 1 above (587 mg, 1.5 mmol) in methanol (10 mL) at 21 °C was added a solution of hydrogen chloride in ether (2 M, 2 mL, 4.0 mmol). After stirring for 16 h, the solvent and excess hydrogen chloride were removed under a stream of nitrogen and the solid obtained was vacuum dried at room temperature to afford 350 mg (72%) of (<i>R</i>)-<b>30</b>. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (br. s., 3H), 7.51–8.05 (m, 4H), 7.37–7.51 (m, 2H), 7.32 (d, <i>J</i> = 8.53 Hz, 1H), 7.14 (t, <i>J</i> = 7.56 Hz, 1H), 4.72 (t, <i>J</i> = 6.05 Hz, 1H), 4.32–4.59 (m, 2H). MS: 282.0 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> = −19.9° (<i>c</i> = 0.23; methanol). Chiral HPLC retention time: 10.22 min<i>. R</i><sub>f</sub> = 0.3 (5% methanol in dichloromethane on silica gel, weak UV activity, stains with ninhydrin) for the free base.</div><div class="NLM_p last">The following compounds were synthesized using the same sequence as (<i>R</i>)-<b>30</b> with appropriate modifications:</div></div></div><div id="sec6_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> (<i>S</i>)-1-Phenyl-2-(2-(trifluoromethyl)phenoxy)ethanamine (<i>S</i>)-<b>30</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.60 (br. s., 3H), 7.59 (dd, <i>J</i> = 7.84, 15.54 Hz, 4H), 7.36–7.51 (m, 3H), 7.32 (d, <i>J</i> = 8.53 Hz, 1H), 7.14 (t, <i>J</i> = 7.84 Hz, 1H), 4.73 (t, <i>J</i> = 6.05 Hz, 1H), 4.34–4.59 (m, 2H). MS: 282.0 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> +20.2° (<i>c</i> = 0.24; methanol). Chiral HPLC retention time: 10.96 min<i>. R</i><sub>f</sub> = 0.3 (5% methanol in dichloromethane on silica gel, for the free base).</div></div><div id="sec6_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> (<i>R</i>)-1-Phenyl-2-(2-methylphenoxy)ethanamine (<i>R</i>)-<b>27</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 7.55–7.63 (m, 2H), 7.43–7.55 (m, 3H), 7.09–7.20 (m, 2H), 6.84–6.99 (m, 2H), 4.30–4.40 (m, 2H), 2.26 (s, 3H). MS: 228.0 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> −25.4° (<i>c</i> = 0.22; methanol) Chiral HPLC retention time: 7.42 min.</div></div><div id="sec6_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (<i>S</i>)-1-Phenyl-2-(2-methylphenoxy)ethanamine (<i>S</i>)-<b>27</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 7.54–7.61 (m, 2H), 7.42–7.54 (m, 3H), 7.06–7.19 (m, 2H), 6.82–6.99 (m, 2H), 4.28–4.43 (m, 2H), 2.26 (s, 3H). MS: 228.0 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> +26.0° (<i>c</i> = 0.19; methanol). Chiral HPLC retention time: 8.34 min.</div></div><div id="sec6_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> (<i>R</i>)-2-(3,5-Dimethylphenoxy)-1-phenylethanamine (<i>R</i>)-<b>36</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 7.66–7.41 (m, 5H), 6.65 (s, 3H), 4.74 (dd, <i>J</i> = 8.4, 4.1 Hz, 1H), 4.35–4.25 (m, 2H), 2.27 (s, 6H). MS: 242.0 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> −26.7° (<i>c</i> = 0.19, CD<sub>3</sub>OD). Chiral HPLC retention time: 12.66 min. <i>R</i><sub>f</sub> = 0.42 (1:20 methanol/dichloromethane on silica gel).</div></div><div id="sec6_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> (<i>S</i>)-2-(3,5-Dimethylphenoxy)-1-phenylethanamine (<i>S</i>)-<b>36</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) 7.93–7.15 (m, 5H), 6.65 (s, 3H), 4.74 (dd, <i>J</i> = 8.4, 4.1 Hz, 1H), 4.36–4.24 (m, 2H), 2.27 (s, 6H). MS: 242.0 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> +28.2° (<i>c</i> = 0.1875, methanol). Chiral HPLC retention time: 9.71 min<i>. R</i><sub>f</sub> = 0.42 (1:20 methanol/dichloromethane).</div></div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Synthesis of (<i>R</i>)-<b>59</b></h3><div id="sec6_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Step 1: (<i>R</i>)-<i>N</i>-(2-Hydroxy-1-phenylethyl)-2-methoxyacetamide</h4><div class="NLM_p last">Methoxyacetic acid (1.595 mL, 20.8 mmol) and EDCI (4.12 g 21.5 mmol) were added to a solution of (<i>R</i>)-phenylglycinol (3.17 g, 23.1 mmol) in dichloromethane (150 mL). The mixture was vigorously shaken to break the aggregates formed and then stirred at 21 °C for 5 h. After cooling to −20 °C and filtering through a Celite pad, the filtrate was concentrated under reduced pressure and purified by chromatography on silica gel using a methanol/dichloromethane gradient to give 750 mg of the <i>N</i>-(2-hydroxy-1-phenylethyl)-2-methoxyacetamide as an off-white solid that was used without characterization.</div></div><div id="sec6_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Step 2: (4<i>R</i>)-1,2,3-Oxathiazolidine-3-methoxyacetamido-4-phenyl-2,2-dioxide</h4><div class="NLM_p last">A solution of imidazole (1.75 g, 25.6 mmol) and triethylamine (2.14 mL, 15.4 mmol) in dichloromethane (30 mL) was cooled to −60 °C. Thionyl chloride (0.56 mL, 7.69 mmol) was added dropwise. Temperature was kept at −60 to −50 °C. (<i>R</i>)-<i>N</i>-(2-Hydroxy-1-phenylethyl)-2-methoxyacetamide (1.34 g, 6.4 mmol) in dichloromethane (100 mL) was added dropwise over a period of 1 h. The mixture was stirred at −60 °C for an additional 3 h and then allowed to reach ambient temperature. After 20 min at 21 °C, water was added and the organic phase was separated. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was dissolved in 3:1 acetonitrile/water (100 mL) and cooled in an ice–water bath (4–5 °C). Sodium periodate (2.92 g, 13.6 mmol) was added followed by RuCl<sub>3</sub>(H<sub>2</sub>O)<sub>3</sub> (5 mg, 0.02 mmol). The mixture was stirred for 30 min and allowed to reach ambient temperature. More water was added to bring the acetonitrile/water ratio to 1:1. After stirring for an additional hour, the mixture was extracted with ether. The organic phase was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel using an ethyl acetate/hexane gradient to afford (4<i>R</i>)-1,2,3-oxathiazolidine-3-methoxyacetamido-4-phenyl-2,2-dioxide as a white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.48–7.33 (m, 5H), 5.61 (dd, <i>J</i> = 7.1, 6.0 Hz, 1H), 5.02–4.86 (m, 1H), 4.53 (dd, <i>J</i> = 9.4, 5.9 Hz, 1H), 4.32 (dd, <i>J</i> = 33.6, 15.7 Hz, 2H), 3.42 (s, 3H). MS: 272.1 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.43 (40% hexanes/EtOAc on silica gel).</div></div><div id="sec6_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Step 3: (<i>R</i>)-<i>N</i>-(2-(2,3-Dimethylphenoxy)-1-phenylethyl)-2-methoxyacetamide</h4><div class="NLM_p last">2,3-Dimethyl phenol (396 mg, 3.2 mmol) in DMF (10 mL) was treated with NaH, 60% dispersion in mineral oil (141 mg, 3.5 mmol), and stirred for 20 min. (<i>R</i>)<i>-</i>Cyclic sulfamidate (obtained in Step 2 above) (800 mg, 2.9 mmol) was added. The mixture was stirred for 4 h and partitioned between brine and ethyl acetate. The organic phase was washed with additional brine and dried over sodium sulfate. The solvent was removed <i>in vacuo</i>, and the crude product was purified on silica gel using an ethyl acetate/hexane gradient to afford 479 mg of (<i>R</i>)-<i>N</i>-(2-(2,3-dimethylphenoxy)-1-phenylethyl)-2-methoxyacetamide as a clear oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.22–7.49 (m, 5H), 7.04 (t, <i>J</i> = 7.98 Hz, 1H), 6.80 (d, <i>J</i> = 7.70 Hz, 1H), 6.68 (d, <i>J</i> = 8.25 Hz, 1H), 5.39–5.59 (m, 1H), 4.18–4.39 (m, 2H), 3.97 (s, 2H), 3.39–3.51 (m, 3H), 2.28 (s, 3H), 2.10–2.18 (m, 3H). MS: 314.2 (MH<sup>+</sup>)<i>. R</i><sub>f</sub> = 0.7 (19:1 dichloromethane/methanol on silica gel).</div></div><div id="sec6_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Step 4: (<i>R</i>)-2-(2,3-Dimethylphenoxy)-<i>N</i>-(2-methoxyethyl)-1-phenylethanamine (<i>R</i>)-<b>59</b></h4><div class="NLM_p">To 479 mg (1.5 mmol) of (<i>R</i>)-<i>N</i>-(2-(2,3-dimethylphenoxy)-1-phenylethyl)-2-methoxyacetamide in 15 mL of anhydrous THF was added 1.0 M LiAlH<sub>4</sub> in THF (6.0 mL). The mixture was heated at 80 ° C for 24 h, cooled in an ice/water bath, and diluted with anhydrous THF. The excess reagent was neutralized by dropwise addition of H<sub>2</sub>O (240 μL), dropwise addition of 3.5 M NaOH (240 μL), and further addition of H<sub>2</sub>O (720 μL). After stirring for 10 min, magnesium sulfate was added; the mixture was allowed to reach ambient temperature and filtered through Celite. The filtrate was concentrated <i>in vacuo</i> and purified by chromatography on silica gel using a methanol/dichloromethane gradient. The amine was transferred to a vial using an appropriate amount of 0.5 M HCl in methanol. After thoroughly drying the product <i>in vacuo</i>, the desired HCl salt was obtained as a white powder. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.61 (dd, <i>J</i> = 7.7, 1.9 Hz, 2H), 7.58–7.45 (m, 3H), 7.04 (t, <i>J</i> = 7.9 Hz, 1H), 6.82 (t, <i>J</i> = 7.9 Hz, 2H), 4.88–4.83 (m, 1H), 4.48 (dd, <i>J</i> = 10.6, 7.1 Hz, 1H), 4.43–4.33 (m, 1H), 3.40 (s, 3H), 2.33–2.18 (m, 3H), 2.17 (s, 3H). MS: 300.1 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> −25.1° (<i>c</i> = 0.278, methanol). Chiral HPLC retention time: 13.37 min<i>. R</i><sub>f</sub> = 0.45 (5% dichloromethane in methanol on silica gel).</div><div class="NLM_p last">(<i>S</i>)-<b>59</b> was prepared by the same route as (<i>R</i>)-<b>59</b> except that (<i>S</i>)-phenylglycinol was used as the starting material.</div></div><div id="sec6_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> (<i>S</i>)-2-(2,3-Dimethylphenoxy)-<i>N</i>-(2-methoxyethyl)-1-phenylethanamine (<i>S</i>)-<b>59</b></h4><div class="NLM_p last"><sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 7.61 (dd, <i>J</i> = 7.7, 1.8 Hz, 2H), 7.57–7.48 (m, 3H), 7.04 (t, <i>J</i> = 7.9 Hz, 1H), 6.82 (t, <i>J</i> = 7.3 Hz, 2H), 4.49 (dd, <i>J</i> = 10.6, 7.1 Hz, 1H), 4.39 (dd, <i>J</i> = 10.6, 4.7 Hz, 1H), 3.77–3.57 (m, 1H), 3.40 (s, 3H), 2.26 (s, 3H), 2.15 (s, 3H). MS: 300.1 (MH<sup>+</sup>). [α]<sub class="stack">589</sub><sup class="stack">20</sup> +24.4° (<i>c</i> = 0.281, methanol). Chiral HPLC retention time: 14.17 min<i>. R</i><sub>f</sub> = 0.45 (5% dichloromethane: methanol on silica gel).</div></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i116">Biology Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Cell Culture and Cell Differentiation to hiPSC-CMs</h3><div class="NLM_p">MyCell (LQTS3) and iCell (healthy individual) cardiomyocytes (Cellular Dynamics International, Madison, Wisconsin) were prepared as described previously.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Media were exchanged every other day by removing 50 μL of media and adding 50 μL of fresh iCCMM for 14 days prior to imaging. Human iPSCs were dissociated using 0.5 mM EDTA (ThermoFisher Scientific) in PBS without CaCl<sub>2</sub> or MgCl<sub>2</sub> (Corning) for 7 min at room temperature. Dissociated hiPSCs were plated at a density of 3 × 10<sup>5</sup> cells per well in a Matrigel coated 12-well plate in mTeSR1 media (StemCell Technologies) supplemented with 2 μM thiazovivin (Selleck Chemicals). After 24 h, the media were replaced with mTESR1 without thiazovivin and were replenished daily for 3–5 days until the cells reached ≥90% confluence to begin differentiation. Cardiomyocytes were differentiated by methods previously described.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a></div><div class="NLM_p last">At day 25, cells were dissociated and plated onto Matrigel coated 384-well tissue culture plates (Greiner Bio-One) at a density of 20,000 cells/well. Experiments were conducted day 28 post-differentiation.</div></div><div id="sec7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> Preparation of VF2.1.Cl Loading Solution and Automated Image Acquisition</h3><div class="NLM_p last">A VF2.1.Cl dye used was synthesized as described previously (Fluovolt, ThermoFisher).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> One microliter of 2 mM VF2.1.Cl in DMSO was mixed with 1 μL of 10% Pluronic F127 (diluted in 1.7 mL water) by agitating and centrifuging three times. Separately, Hoechst 33258 was diluted into Tyrode’s solution (136 mM NaCl, 5 mM KCl, 2 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM glucose, 10 mM HEPES, pH 7.4) to a concentration of 4 μg/mL. One milliliter of Hoechst/Tyrode’s solution was added to a 1.7 mL VF2.1.Cl/Pluronic F127 mixture and mixed for 10 s. Each test compound was diluted in Tyrode’s solution to a 2× concentrated stock and added to a well and incubated at 37 °C and 5% CO<sub>2</sub> for 5 min before image acquisition. Time series images were acquired automatically using a IC200 KIC instrument (Vala Sciences, San Diego, CA) at an acquisition frequency of 100 Hz for a duration of 6.5 s or 33 Hz for 20 s, with an excitation wavelength of 485/20 nm and emission filter of 525/30 nm using a 0.75 NA 20× Nikon Apo VC objective. A single image of the Hoechst/Tyrode solution was acquired after the time series. Optimized dye loading and imaging conditions were replicated using a different high content imager, the ImageXpress Micro XLS platform (Molecular Devices), and hiPSC-CMs produced by a novel differentiation protocol.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div></div><div id="sec7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> Image Analysis, Physiological Parameter Calculations, and Data Analysis</h3><div class="NLM_p last">Image analysis and physiological parameter calculations were conducted using Cyteseer (Vala Sciences) as previously described.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Briefly, an image output by a Cyteseer scanner was loaded into Cyteseer and a cardiac time series algorithm was executed on image files. Data were analyzed using Microsoft Excel 2013, and dose–response curves were calculated using GraphPad Prism 7 software (Prism, San Diego, CA).</div></div><div id="sec7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> Meta-Analysis of Experimental Data</h3><div class="NLM_p last">An R-script (R version 3.3.1) was developed in-house that read CSV files generated by Cyteseer and amalgamated all the physiological parameters of interest into a single file. Using this dataset, meta-analysis of experimental data was conducted and showed intra- and intervariability in studies examining thawing cells in different ways (i.e., APD<sub>75</sub>) and the relationship between APD<sub>75</sub> and beat rate. Because of the nonlinear relationship of APD<sub>75</sub> and beat rate, statistical significance was determined using a sliding window (center value ±3) to mirror experimental ranges. A Mann–Whitney test was applied to the data (using the Bonferroni criterion) for multiple testing.</div></div><div id="sec7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> Automated Patch Clamp Studies</h3><div class="NLM_p">Whole cell planar patch clamp recordings were used to study the effects of test compounds in transfected cells using ion channel currents including: I<sub>NaP</sub>, I<sub>NaL</sub>, and I<sub>Kr</sub> channels.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> For each compound studied, at least six increasing concentrations were included to obtain a dose–response relationship. For Na<sup>+</sup> channel experiments, a stable HEK cell line expressing a long QT mutant, F1473C,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> was used. For I<sub>Kr</sub>, a commercially available CHO stable cell line, hERG Duo (Bsys, Basel, Switzerland), was used. Cells were grown to ∼75% confluence, dissociated with trypsin–EDTA (Gibco, Waltham, MA), and resuspended in extracellular recording solutions at a density of ∼1 million cells/mL. Cells in solution were added to the Patchliner system (Nanion, Munich, DE) for voltage clamp recordings. The following solutions were used: internal solution for K<sup>+</sup> channel experiments: 50 mM KCl, 10 mM NaCl, 60 mM K-fluoride, 20 mM EGTA, and 10 mM HEPES/KOH, pH 7.2; internal solution for Na<sup>+</sup> channel experiments: 50 mM CsCl, 10 mM NaCl, 60 mM Cs-fluoride, 20 mM EGTA, 10 mM HEPES/CsOH, pH 7.2; external solutions for K<sup>+</sup> and Na<sup>+</sup> channel experiments; 140 mM NaCl, 4 mM KCl, 1 mM MgCl<sub>2</sub>, 5 mM <span class="smallcaps smallerCapital">d</span>-glucose monohydrate, and 10 mM HEPES/NaOH H 7.4. Test compounds (and controls) were prepared in extracellular solution with 0.01% DMSO. All reagents, unless otherwise noted, were obtained from Sigma-Aldrich (St. Louis, MO). Specific channel blockers tetrodotoxin (Calbiochem, San Diego, CA) and E-4031 were prepared in extracellular solution.</div><div id="sec7_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Data Analysis</h4><div class="NLM_p last">Normalized blocking ratio data, for each of I<sub>Kr</sub>, I<sub>NaP</sub>, and I<sub>NaL</sub>, were fitted by a four parameter logistic fit. Patch clamp data were acquired with PatchMaster (HEKA, Lambrecht, DE) and PatchLiner Data acquisition (Nanion, Munich, DE) and analyzed with Origin 7.0 (OriginLab, Northampton, MA, USA), IgorPro (WaveMetrics, Portland, OR, USA), and MATLAB (Mathworks, Natick, MA, USA). Data were shown as mean ± SEM. Statistical data analyses were assessed with Student’s <i>t</i>-test; differences at <i>P</i> < 0.05 were considered as statistically significant.</div></div><div id="sec7_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> Data Analysis</h4><div class="NLM_p last">Offline data analysis, curve fitting, and statistical evaluations were conducted with OriginPro 2016 (OriginLab, Northampton, MA) software. Dose–response curves for test compound inhibition were determined by measuring “peak” and “late” sodium current components on the same current trace. “Peak” values for the each response were defined automatically by the “negative peak searching” algorithm in OriginPro, whereas “late” component values were defined as an average of 20 ms of the current response after the current amplitude reached the steady-state level. Values for each test compound concentration were normalized to control currents recorded during the control solution applications. Dose–response data for each sodium current response component were fitted using a Marquardt–Levenberg iteration algorithm with a standard Hill equation. Data were presented as mean ± s.d.</div></div></div><div id="sec7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Chemical Stability of Mexiletine Analogues at Various Temperatures and pHs</h3><div class="NLM_p last">A typical chemical stability incubation contained 100 μM of the test compound prepared in 50 mM PBS buffer (pH 3.0 or 7.4,) with 1% ethanol. Test compounds were incubated at 37 °C. An aliquot from each incubation was taken at various times and injected onto an RP-HPLC. Samples were run on a Hitachi D-7000 HPLC system (Hitachi High Tech) using an L-7100 analytical pump, L-7400 UV–vis variable wavelength detector, and L-7600 automatic sample injector. A Gemini C18 column (250 × 4.6 mm, 5 μm particle size; Phenomenex) with a C18 guard column (Phenomenex) was used for chromatographic separation of mexiletine analogues. The mobile phase used was an isocratic system using 75% water (0.05% TFA) and 25% acetonitrile (0.05% TFA) with a flow rate of 1.25 mL/min and monitored at 275 nM. The disappearance of the analyte was monitored over time. A plot of the area under the curve for the normalized analyte versus time afforded the half-life values and k<sub>app</sub>.</div></div><div id="sec7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> Metabolic Stability Studies in the Presence of Human Liver Microsomes and S-9</h3><div class="NLM_p last">Human liver S-9, human liver microsomes, highly purified cytochrome P-450 (CYP) 3A4, 3A5, and 2D6, and NADPH-generating system were obtained from BD Biosciences (Waltham, MA). A typical incubation contained human liver microsomes or S-9 (0.4–0.5 and 1 mg of protein, respectively), 50 mM potassium phosphate buffer (pH 7.4), 50 μM test compound, an NADPH-generating system consisting of 0.5 mM NADP<sup>+</sup>, 0.5 mM glucose-6-phosphate, 5 U/mL glucose-6-phosphate dehydrogenase, 1 mg/mL diethylenetriaminepentaacetic acid (DETAPAC), and 3 mM MgCl<sub>2</sub> in a final incubation volume of 0.25 mL. Incubations were run for 0, 7, 15, 30, and 60 min with constant shaking at 37 °C in a water bath and were terminated by addition of 0.75 mL of cold acetonitrile. After centrifugation at 3000 rpm for 5 min, the organic fraction was collected and solvent was removed with a stream of argon. The residue was reconstituted in 125 μL of MeOH and 125 μL of H<sub>2</sub>O, mixed thoroughly, centrifuged at 13,000 rpm for 5 min, and analyzed by high-performance liquid chromatography. Samples were run on a Hitachi D-7000 HPLC system (Hitachi High Tech) as described above with a Gemini C18 column (250 × 4.6 mm, 5 μm particle size; Phenomenex) with a C18 guard column (Phenomenex). The mobile phase used was an isocratic system using 75% water (0.05% TFA) and 25% acetonitrile (0.05% TFA) with a flow rate of 1.25 mL/min and monitored at 275 nM. The disappearance of the analyte was monitored over time. A plot of the area under the curve for normalized analyte versus time afforded the half-life values and k<sub>app</sub>.</div></div><div id="sec7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> <i>In Vivo</i> Effects of Mexiletine and Analogues</h3><div class="NLM_p">Animal work followed the Guide for Care and Use of Animals as adopted by NIH. Formal approval was obtained from the IACUC of HBRI and UCLA. Animals used in the research studies were handled, housed, and killed in accordance with the current IACUC protocol and all applicable local, state, and federal regulations and guidelines.</div><div class="NLM_p last">Adult male Balb/C mice or Sprague Dawley rats (from Charles River, San Diego, CA) were housed in groups of four and maintained in a temperature-controlled environment on a 12 h:12 h light cycle (0600H on–1800H off) upon arrival to the laboratory. Animals were given free access to food and water during a 1 week habituation period to the laboratory. For PK studies, mexiletine and test compounds (in 0.9% saline) were administered to individually housed, starved jugular-cannulated Sprague Dawley rats (5 mg/kg i.v. or 25 mg/kg oral). At 10 time points over 25 h, blood was withdrawn, cooled, and centrifuged. Serum was combined with an internal standard (compound <b>44</b>), extracted with aqueous NaCl, Na<sub>2</sub>CO<sub>3</sub>, and ethyl acetate, separated, evaporated to dryness, taken up in methanol, and injected into the Agilent LCMS described above. Peak areas were quantified, and pharmacokinetic parameters were determined with a WinNonlin-Pro program (Pharsight, Inc., Princeton, NJ). For behavioral studies, test compounds or mexiletine were dissolved in DMSO (7%), PEG400 (57%) isotonic saline (40%), and administered i.p. to separate groups in a volume of 0.1 mL/mouse.</div></div><div id="sec7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> <i>Ex Vivo</i> Studies</h3><div class="NLM_p last">For <i>ex-vivo</i> studies, the effect of (<i>R</i>)-<b>30</b> on isolated heart tissue isolated from aged Sprague Dawley rats was examined. Vulnerability to EAD formation was investigated by examining the arrhythmogenic effects of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) perfusion in isolated Langendorff rat hearts. Oxidative stress was shown to readily induce EADs at the isolated myocyte level in aged hearts from 24–26 month old rats. H<sub>2</sub>O<sub>2</sub> exposure consistently promoted EADs and triggered activity in >90% of the aged fibrotic hearts that lead to VT/VF.</div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i128">Authorship Contributions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">J.R.C., K.O., D.R., R.S.K., H.S.K., and M.M. participated in the research design. J.R.C., D.R., J.G.-G., K.O., M.J., W.L.M., A.P., and K.S. conducted experiments. D.R., J.G.-G., K.O., and M.J. contributed new reagents or analytical tools. J.R.C., W.M., K.J.S., R.S.K., H.S.K., and M.M. performed data analysis. J.R.C., J.G.-G., R.S.K., W.L.M., and M.M. wrote or contributed to the writing of the manuscript.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i129"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01545" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01545?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01545</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">HPLC Methods and traces (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_001.csv">jm0c01545_si_001.csv (2.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_002.pdf">jm0c01545_si_002.pdf (2.24 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01545" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John R. Cashman</span> - <span class="hlFld-Affiliation affiliation">Human BioMolecular Research Institute, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8628-9129" title="Orcid link">http://orcid.org/0000-0002-8628-9129</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6a20290b1902070b042a222838234405180d"><span class="__cf_email__" data-cfemail="c58f86a4b6ada8a4ab858d87978cebaab7a2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Ryan</span> - <span class="hlFld-Affiliation affiliation">Human BioMolecular Research Institute, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wesley L. McKeithan</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
Institute and Department of Medicine, Stanford
University, Stanford, California 94305, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate
School of Biomedical Sciences, Sanford Burnham
Prebys Medical Discovery Institute, San Diego, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karl Okolotowicz</span> - <span class="hlFld-Affiliation affiliation">Human BioMolecular Research Institute, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jorge Gomez-Galeno</span> - <span class="hlFld-Affiliation affiliation">Human BioMolecular Research Institute, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Johnson</span> - <span class="hlFld-Affiliation affiliation">Human BioMolecular Research Institute, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin J. Sampson</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert S. Kass</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arash Pezhouman</span> - <span class="hlFld-Affiliation affiliation">Division
of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hrayr S. Karagueuzian</span> - <span class="hlFld-Affiliation affiliation">Division
of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Mercola</span> - <span class="hlFld-Affiliation affiliation">Cardiovascular
Institute and Department of Medicine, Stanford
University, Stanford, California 94305, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Graduate
School of Biomedical Sciences, Sanford Burnham
Prebys Medical Discovery Institute, San Diego, California 92037, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i130">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82268" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82268" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful for the financial support of the California Institute for Regenerative Medicine (CIRM) (Grant number TR4-06857 to J.R.C. and M.M.). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of CIRM or any other agency of the State of California. Flow cytometry and high-throughput screening services were supported by NIH P30CA030199 at the Sanford-Burnham-Prebys Medical Discovery Institute. We are grateful to Dr. Jim Weiss (UCLA) for help with the data of Figure 4. Some HPLC traces were done at AxisPharm, San Diego, CA, 92121.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">APD</td><td class="NLM_def"><p class="first last">action potential duration</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">CF</td><td class="NLM_def"><p class="first last">conduction velocity</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">concentration max</p></td></tr><tr><td class="NLM_term">EADs</td><td class="NLM_def"><p class="first last">early after depolarizations</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go</p></td></tr><tr><td class="NLM_term">iPSC-CMs</td><td class="NLM_def"><p class="first last">induced pluripotent stem cell-derived cardiomyocytes</p></td></tr><tr><td class="NLM_term">I<sub>Kr</sub></td><td class="NLM_def"><p class="first last">potassium current</p></td></tr><tr><td class="NLM_term">ERG</td><td class="NLM_def"><p class="first last">inward potassium channel</p></td></tr><tr><td class="NLM_term">KIC</td><td class="NLM_def"><p class="first last">kinetic image cytometry</p></td></tr><tr><td class="NLM_term">I<sub>NaL</sub></td><td class="NLM_def"><p class="first last">late inward sodium current</p></td></tr><tr><td class="NLM_term">LQTS3</td><td class="NLM_def"><p class="first last">long QT syndrome Type 3</p></td></tr><tr><td class="NLM_term">I<sub>NaP</sub></td><td class="NLM_def"><p class="first last">peak sodium current</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TTX</td><td class="NLM_def"><p class="first last">tetradotoxin</p></td></tr><tr><td class="NLM_term">VT</td><td class="NLM_def"><p class="first last">ventricular tachycardia</p></td></tr><tr><td class="NLM_term">VF</td><td class="NLM_def"><p class="first last">ventricular fibrillation</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i132">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mareva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castor, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruskin, J.</span></span> <span> </span><span class="NLM_article-title">Economic burden and co-morbidities of atrial fibrillation in a privately insured population</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1185/030079905X65475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1185%2F030079905X65475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=16238910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BD2Mrmt1egsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2005&pages=1693-1699&author=E.+Q.+Wuauthor=H.+G.+Birnbaumauthor=M.+Marevaauthor=E.+Tuttleauthor=A.+R.+Castorauthor=W.+Jackmanauthor=J.+Ruskin&title=Economic+burden+and+co-morbidities+of+atrial+fibrillation+in+a+privately+insured+population&doi=10.1185%2F030079905X65475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Economic burden and co-morbidities of atrial fibrillation in a privately insured population</span></div><div class="casAuthors">Wu Eric Q; Birnbaum Howard G; Mareva Milena; Tuttle Edward; Castor Adam R; Jackman Warren; Ruskin Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Current medical research and opinion</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1693-9</span>
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study assesses the direct (medical and drugs) and indirect (work loss) annual costs associated with Atrial Fibrillation (AFIB) in a privately insured population.  BACKGROUND:  AFIB is the most common sustained rhythm disturbance, affecting 2.3 million people in the United States.  METHODS:  Cost and co-morbidity measures for AFIB patients were compared to matched controls using a privately insured administrative database (including medical, drug, and disability claims) for 2 million enrollees, 1999-2002 from 16 employers across the United States.  Patients with an AFIB diagnosis on at least two occasions were included in the co-morbidity analysis (n = 3944).  A non-AFIB control sample was randomly selected with a 1:1 ratio, with characteristics (i.e., age, gender, health plan) matched to AFIB patients.  Excess medical costs (i.e., employer payments) were estimated for AFIB patients, defined as the difference in average annual costs between AFIB and control patients (n = 3944); excess work-loss costs were defined similarly for employees with available work-loss data (n = 603).  Statistical significance in the descriptive analysis was measured by paired t-tests for cost, or Chi-square tests for co-morbidity comparisons.  A two-part multivariate model of excess cost was further estimated to control for co-existing conditions and other patient characteristics.  The excess costs of AFIB patients were estimated as the difference between the observed costs of AFIB patients and their estimated costs, assuming they did not have AFIB.  RESULTS:  The multivariate analysis found that the excess annual direct cost of AFIB was $12,349 (p < 0.01), with AFIB patients approximately 5 times as costly as non-AFIB individuals ($15,553 versus $3204, respectively).  The excess annual total cost was $14,875 (p < 0.01), with AFIB patients again approximately 5 times as costly as non-AFIB individuals ($18,454 versus $3,579, respectively).  AFIB was associated with increased incidence of atrial flutter (p < 0.01), heart failure (Relative Risk (RR) = 29, p < 0.01), other arrhythmias/conduction disorders (RR = 16, p < 0.01), heart attack (RR = 8, p < 0.01), and stroke (RR = 6, p < 0.01).  CONCLUSIONS:  AFIB is a costly disease and one for which more definitive therapies might offer some potential for reducing, not only the clinical impact, but also the economic burden of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTLpReW9u1oXRxY89Cm6SyfW6udTcc2eY0P9HHeBj1ELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mrmt1egsg%253D%253D&md5=ac32ae9e5a5a854cc6de2e28e3566ff7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1185%2F030079905X65475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F030079905X65475%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DE.%2BQ.%26aulast%3DBirnbaum%26aufirst%3DH.%2BG.%26aulast%3DMareva%26aufirst%3DM.%26aulast%3DTuttle%26aufirst%3DE.%26aulast%3DCastor%26aufirst%3DA.%2BR.%26aulast%3DJackman%26aufirst%3DW.%26aulast%3DRuskin%26aufirst%3DJ.%26atitle%3DEconomic%2520burden%2520and%2520co-morbidities%2520of%2520atrial%2520fibrillation%2520in%2520a%2520privately%2520insured%2520population%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2005%26volume%3D21%26spage%3D1693%26epage%3D1699%26doi%3D10.1185%2F030079905X65475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensah, G. A.</span></span> <span> </span><span class="NLM_article-title">Sudden cardiac death in the United States, 1989 to 1998</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2158</span>– <span class="NLM_lpage">2163</span>, <span class="refDoi"> DOI: 10.1161/hc4301.098254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1161%2Fhc4301.098254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=11684624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BD3MnhtVShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2001&pages=2158-2163&author=Z.+J.+Zhengauthor=J.+B.+Croftauthor=W.+H.+Gilesauthor=G.+A.+Mensah&title=Sudden+cardiac+death+in+the+United+States%2C+1989+to+1998&doi=10.1161%2Fhc4301.098254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sudden cardiac death in the United States, 1989 to 1998</span></div><div class="casAuthors">Zheng Z J; Croft J B; Giles W H; Mensah G A</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2158-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Sudden cardiac death (SCD) is a major clinical and public health problem.  METHODS AND RESULTS:  United States (US) vital statistics mortality data from 1989 to 1998 were analyzed.  SCD is defined as deaths occurring out of the hospital or in the emergency room or as "dead on arrival" with an underlying cause of death reported as a cardiac disease (ICD-9 code 390 to 398, 402, or 404 to 429).  Death rates were calculated for residents of the US aged >/=35 years and standardized to the 2000 US population.  Of 719 456 cardiac deaths among adults aged >/=35 years in 1998, 456 076 (63%) were defined as SCD.  Among decedents aged 35 to 44 years, 74% of cardiac deaths were SCD.  Of all SCDs in 1998, coronary heart disease (ICD-9 codes 410 to 414) was the underlying cause on 62% of death certificates.  Death rates for SCD increased with age and were higher in men than women, although there was no difference at age >/=85 years.  The black population had higher death rates for SCD than white, American Indian/Alaska Native, or Asian/Pacific Islander populations.  The Hispanic population had lower death rates for SCD than the non-Hispanic population.  From 1989 to 1998, SCD, as the proportion of all cardiac deaths, increased 12.4% (56.3% to 63.9%), and age-adjusted SCD rates declined 11.7% in men and 5.8% in women.  During the same time, age-specific death rates for SCD increased 21% among women aged 35 to 44 years.  CONCLUSIONS:  SCD remains an important public health problem in the US.  The increase in death rates for SCD among younger women warrants additional investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvGkqt39-s-kEgZCMqtRBifW6udTcc2ebR4WGrAw8k6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnhtVShtQ%253D%253D&md5=c1d2dbe5c37bd151d0dc7f448f598622</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2Fhc4301.098254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhc4301.098254%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.%2BJ.%26aulast%3DCroft%26aufirst%3DJ.%2BB.%26aulast%3DGiles%26aufirst%3DW.%2BH.%26aulast%3DMensah%26aufirst%3DG.%2BA.%26atitle%3DSudden%2520cardiac%2520death%2520in%2520the%2520United%2520States%252C%25201989%2520to%25201998%26jtitle%3DCirculation%26date%3D2001%26volume%3D104%26spage%3D2158%26epage%3D2163%26doi%3D10.1161%2Fhc4301.098254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koplan, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, W. G.</span></span> <span> </span><span class="NLM_article-title">Ventricular tachycardia and sudden cardiac death</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.4065/84.3.289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.4065%2F84.3.289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=19252119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BD1M7ns1Omtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2009&pages=289-297&author=B.+A.+Koplanauthor=W.+G.+Stevenson&title=Ventricular+tachycardia+and+sudden+cardiac+death&doi=10.4065%2F84.3.289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ventricular tachycardia and sudden cardiac death</span></div><div class="casAuthors">Koplan Bruce A; Stevenson William G</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ventricular tachycardia (VT), which most commonly occurs in patients with structural heart disease, can be associated with an increased risk of sudden death.  The most common cause of ventricular fibrillation is acute coronary ischemia, whereas a myocardial scar from prior infarct is the most common cause of sustained monomorphic VT in patients with structural heart disease.  More benign forms of idiopathic VT can also occur in the absence of structural heart disease.  Treatment of VT involves both emergent management and prevention of recurrence with medical and device therapy.  Appropriately selected patients who have experienced VT or those who are at risk of VT may be candidates for an implantable cardioverter-defibrillator.  The left ventricular ejection fraction is most frequently used to stratify patients with either ischemic or nonischemic cardiomyopathy who are at risk of sudden death and may be candidates for a prophylactic defibrillator.  Catheter ablation may also be an option for appropriately selected patients with many forms of VT.  This article discusses the etiologies and management of VT and its association with sudden death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDp3xHH0y_JjAEfvC7EH1LfW6udTcc2ebR4WGrAw8k6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7ns1Omtg%253D%253D&md5=82201b25421579cf1ced838292c49953</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4065%2F84.3.289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4065%252F84.3.289%26sid%3Dliteratum%253Aachs%26aulast%3DKoplan%26aufirst%3DB.%2BA.%26aulast%3DStevenson%26aufirst%3DW.%2BG.%26atitle%3DVentricular%2520tachycardia%2520and%2520sudden%2520cardiac%2520death%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2009%26volume%3D84%26spage%3D289%26epage%3D297%26doi%3D10.4065%2F84.3.289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span>; <span class="NLM_string-name">Kerndt, C.</span>; <span class="NLM_string-name">Zeltser, R.</span></span> <i>Mexiletine</i>; <span class="NLM_publisher-name">StatPearls</span>: <span class="NLM_publisher-loc">Treasure Island (FL)</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Singh&author=C.+Kerndt&author=R.+Zeltser&title=Mexiletine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26btitle%3DMexiletine%26pub%3DStatPearls%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khatib, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackerman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callans, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonarow, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammill, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hlatky, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joglar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matlock, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myerburg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, R. L.</span></span> <span> </span><span class="NLM_article-title">2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society</span>. <i>Heart Rhythm.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e190</span>– <span class="NLM_lpage">e252</span>, <span class="refDoi"> DOI: 10.1016/j.hrthm.2017.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.hrthm.2017.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=29097320" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=e190-e252&author=S.+M.+Al-Khatibauthor=W.+G.+Stevensonauthor=M.+J.+Ackermanauthor=W.+J.+Bryantauthor=D.+J.+Callansauthor=A.+B.+Curtisauthor=B.+J.+Dealauthor=T.+Dickfeldauthor=M.+E.+Fieldauthor=G.+C.+Fonarowauthor=A.+M.+Gillisauthor=C.+B.+Grangerauthor=S.+C.+Hammillauthor=M.+A.+Hlatkyauthor=J.+A.+Joglarauthor=G.+N.+Kayauthor=D.+D.+Matlockauthor=R.+J.+Myerburgauthor=R.+L.+Page&title=2017+AHA%2FACC%2FHRS+guideline+for+management+of+patients+with+ventricular+arrhythmias+and+the+prevention+of+sudden+cardiac+death%3A+A+report+of+the+American+college+of+cardiology%2FAmerican+heart+association+task+force+on+clinical+practice+guidelines+and+the+heart+rhythm+society&doi=10.1016%2Fj.hrthm.2017.10.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.hrthm.2017.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hrthm.2017.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Khatib%26aufirst%3DS.%2BM.%26aulast%3DStevenson%26aufirst%3DW.%2BG.%26aulast%3DAckerman%26aufirst%3DM.%2BJ.%26aulast%3DBryant%26aufirst%3DW.%2BJ.%26aulast%3DCallans%26aufirst%3DD.%2BJ.%26aulast%3DCurtis%26aufirst%3DA.%2BB.%26aulast%3DDeal%26aufirst%3DB.%2BJ.%26aulast%3DDickfeld%26aufirst%3DT.%26aulast%3DField%26aufirst%3DM.%2BE.%26aulast%3DFonarow%26aufirst%3DG.%2BC.%26aulast%3DGillis%26aufirst%3DA.%2BM.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DHammill%26aufirst%3DS.%2BC.%26aulast%3DHlatky%26aufirst%3DM.%2BA.%26aulast%3DJoglar%26aufirst%3DJ.%2BA.%26aulast%3DKay%26aufirst%3DG.%2BN.%26aulast%3DMatlock%26aufirst%3DD.%2BD.%26aulast%3DMyerburg%26aufirst%3DR.%2BJ.%26aulast%3DPage%26aufirst%3DR.%2BL.%26atitle%3D2017%2520AHA%252FACC%252FHRS%2520guideline%2520for%2520management%2520of%2520patients%2520with%2520ventricular%2520arrhythmias%2520and%2520the%2520prevention%2520of%2520sudden%2520cardiac%2520death%253A%2520A%2520report%2520of%2520the%2520American%2520college%2520of%2520cardiology%252FAmerican%2520heart%2520association%2520task%2520force%2520on%2520clinical%2520practice%2520guidelines%2520and%2520the%2520heart%2520rhythm%2520society%26jtitle%3DHeart%2520Rhythm.%26date%3D2017%26volume%3D15%26spage%3De190%26epage%3De252%26doi%3D10.1016%2Fj.hrthm.2017.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomstrom-Lundqvist, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blom, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borggrefe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzsimons, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindricks, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjeldsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Madrid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norekval, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaulding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group">ESC Scientific Document Group</span> <span> </span><span class="NLM_article-title">2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). Endorsed by: Association for European paediatric and congenital cardiology (AEPC)</span>. <i>Eur Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2793</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehv316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1093%2Feurheartj%2Fehv316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26320108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC287nt1Gjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=2793-2867&author=S.+G.+Prioriauthor=C.+Blomstrom-Lundqvistauthor=A.+Mazzantiauthor=N.+Blomauthor=M.+Borggrefeauthor=J.+Cammauthor=P.+M.+Elliottauthor=D.+Fitzsimonsauthor=R.+Hatalaauthor=G.+Hindricksauthor=P.+Kirchhofauthor=K.+Kjeldsenauthor=K.+H.+Kuckauthor=A.+Hernandez-Madridauthor=N.+Nikolaouauthor=T.+M.+Norekvalauthor=C.+Spauldingauthor=D.+J.+Van+Veldhuisenauthor=ESC+Scientific+Document+Group&title=2015+ESC+guidelines+for+the+management+of+patients+with+ventricular+arrhythmias+and+the+prevention+of+sudden+cardiac+death%3A+The+task+force+for+the+management+of+patients+with+ventricular+arrhythmias+and+the+prevention+of+sudden+cardiac+death+of+the+European+society+of+cardiology+%28ESC%29.+Endorsed+by%3A+Association+for+European+paediatric+and+congenital+cardiology+%28AEPC%29&doi=10.1093%2Feurheartj%2Fehv316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)</span></div><div class="casAuthors">Priori Silvia G; Blomstrom-Lundqvist Carina; Mazzanti Andrea; Blom Nico; Borggrefe Martin; Camm John; Elliott Perry Mark; Fitzsimons Donna; Hatala Robert; Hindricks Gerhard; Kirchhof Paulus; Kjeldsen Keld; Kuck Karl-Heinz; Hernandez-Madrid Antonio; Nikolaou Nikolaos; Norekval Tone M; Spaulding Christian; Van Veldhuisen Dirk J</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">2793-2867</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcJiEtRxzflNenUz0lpNqnfW6udTcc2eZ-NAUOV2wy7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nt1Gjuw%253D%253D&md5=b22bd45747e9037ff9b03b0d5780f328</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehv316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehv316%26sid%3Dliteratum%253Aachs%26aulast%3DPriori%26aufirst%3DS.%2BG.%26aulast%3DBlomstrom-Lundqvist%26aufirst%3DC.%26aulast%3DMazzanti%26aufirst%3DA.%26aulast%3DBlom%26aufirst%3DN.%26aulast%3DBorggrefe%26aufirst%3DM.%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DP.%2BM.%26aulast%3DFitzsimons%26aufirst%3DD.%26aulast%3DHatala%26aufirst%3DR.%26aulast%3DHindricks%26aufirst%3DG.%26aulast%3DKirchhof%26aufirst%3DP.%26aulast%3DKjeldsen%26aufirst%3DK.%26aulast%3DKuck%26aufirst%3DK.%2BH.%26aulast%3DHernandez-Madrid%26aufirst%3DA.%26aulast%3DNikolaou%26aufirst%3DN.%26aulast%3DNorekval%26aufirst%3DT.%2BM.%26aulast%3DSpaulding%26aufirst%3DC.%26aulast%3DVan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3D%26atitle%3D2015%2520ESC%2520guidelines%2520for%2520the%2520management%2520of%2520patients%2520with%2520ventricular%2520arrhythmias%2520and%2520the%2520prevention%2520of%2520sudden%2520cardiac%2520death%253A%2520The%2520task%2520force%2520for%2520the%2520management%2520of%2520patients%2520with%2520ventricular%2520arrhythmias%2520and%2520the%2520prevention%2520of%2520sudden%2520cardiac%2520death%2520of%2520the%2520European%2520society%2520of%2520cardiology%2520%2528ESC%2529.%2520Endorsed%2520by%253A%2520Association%2520for%2520European%2520paediatric%2520and%2520congenital%2520cardiology%2520%2528AEPC%2529%26jtitle%3DEur%2520Heart%2520J.%26date%3D2015%26volume%3D36%26spage%3D2793%26epage%3D2867%26doi%3D10.1093%2Feurheartj%2Fehv316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. L.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism for an inherited cardiac arrhythmia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1038/376683a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1038%2F376683a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=7651517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK2MXnslagtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=683-685&author=P.+B.+Bennettauthor=K.+Yazawaauthor=N.+Makitaauthor=A.+L.+George&title=Molecular+mechanism+for+an+inherited+cardiac+arrhythmia&doi=10.1038%2F376683a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for an inherited cardiac arrhythmia</span></div><div class="casAuthors">Bennett, Paul B.; Yazawa, Kazuto; Makita, Naomasa; George, Alfred L., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6542</span>),
    <span class="NLM_cas:pages">683-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">In the congenital long-QT syndrome, prolongation of the cardiac action potential occurs by an unknown mechanism and predisposes individuals to syncope and sudden death as a result of ventricular arrhythmias.  Genetic heterogeneity has been demonstrated for autosomal dominant long-QT syndrome by the identification of multiple distinct loci, and assocd. mutations in two candidate genes have recently been reported.  One form of hereditary long QT (LQT3) has been linked to a mutation in the gene encoding the human heart voltage-gated sodium-channel α-subunit (SCN5A on chromosome 3p21).  Here we characterize this mutation using heterologous expression of recombinant human heart sodium channels.  Mutant channels show a sustained inward current during membrane depolarization.  Single-channel recordings indicate that mutant channels fluctuate between normal and non-inactivating gating modes.  Persistent inward sodium current explains prolongation of cardiac action potentials, and provides a mol. mechanism for this form of congenital long-QT syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSmjEf4vROrVg90H21EOLACvtfcHk0liuiEA2K3g3vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnslagtb0%253D&md5=0aa76f9a9a7659a0dbf1dd1d852fc8c5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F376683a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376683a0%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DP.%2BB.%26aulast%3DYazawa%26aufirst%3DK.%26aulast%3DMakita%26aufirst%3DN.%26aulast%3DGeorge%26aufirst%3DA.%2BL.%26atitle%3DMolecular%2520mechanism%2520for%2520an%2520inherited%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D1995%26volume%3D376%26spage%3D683%26epage%3D685%26doi%3D10.1038%2F376683a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Splawski, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towbin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. T.</span></span> <span> </span><span class="NLM_article-title">SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">811</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(95)90359-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2F0092-8674%2895%2990359-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=7889574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK2MXksVahsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=805-811&author=Q.+Wangauthor=J.+Shenauthor=I.+Splawskiauthor=D.+Atkinsonauthor=Z.+Liauthor=J.+L.+Robinsonauthor=A.+J.+Mossauthor=J.+A.+Towbinauthor=M.+T.+Keating&title=SCN5A+mutations+associated+with+an+inherited+cardiac+arrhythmia%2C+long+QT+syndrome&doi=10.1016%2F0092-8674%2895%2990359-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome</span></div><div class="casAuthors">Wang, Qing; Shen, Jiaxiang; Splawski, Igor; Atkinson, Donald; Li, Zhizhong; Robinson, Jennifer; Moss, Arthur J.; Towbin, Jeffrey A.; Keating, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">805-11</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Long QT syndrome (LQT) is an inherited disorder that causes sudden death from cardiac arrhythmias, specifically torsade de pointes and ventricular fibrillation.  We previously mapped three LQT loci: LQT1 on chromosome 11p15.5, LQT2 on 7q35-36, and LQT3 on 3p21-24.  Here we report genetic linkage between LQT3 and polymorphisms within SCN5A, the cardiac sodium channel gene.  Single strand conformation polymorphism and DNA sequence analyses reveal identical intragenic deletions of SCN5A in affected members of two unrelated LQT families.  The deleted sequences reside in a region that is important for channel inactivation.  The data suggest that mutations in SCN5A cause chromosome 3-linked LQT and indicate a likely cellular mechanism for this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxQ3SS47ip2rVg90H21EOLACvtfcHk0lhqWr6vEOLtXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXksVahsL8%253D&md5=ba4cf3b8db0f88cbb8d327d33f04985d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990359-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990359-3%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DSplawski%26aufirst%3DI.%26aulast%3DAtkinson%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DRobinson%26aufirst%3DJ.%2BL.%26aulast%3DMoss%26aufirst%3DA.%2BJ.%26aulast%3DTowbin%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26atitle%3DSCN5A%2520mutations%2520associated%2520with%2520an%2520inherited%2520cardiac%2520arrhythmia%252C%2520long%2520QT%2520syndrome%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D805%26epage%3D811%26doi%3D10.1016%2F0092-8674%2895%2990359-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timothy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. T.</span></span> <span> </span><span class="NLM_article-title">Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1607</span>, <span class="refDoi"> DOI: 10.1093/hmg/4.9.1603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1093%2Fhmg%2F4.9.1603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=8541846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK2MXnvVensbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1995&pages=1603-1607&author=Q.+Wangauthor=J.+Shenauthor=Z.+Liauthor=K.+Timothyauthor=G.+M.+Vincentauthor=S.+G.+Prioriauthor=P.+J.+Schwartzauthor=M.+T.+Keating&title=Cardiac+sodium+channel+mutations+in+patients+with+long+QT+syndrome%2C+an+inherited+cardiac+arrhythmia&doi=10.1093%2Fhmg%2F4.9.1603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia</span></div><div class="casAuthors">Wang, Qing; Shen, Jiaxiang; Li, Zhizhong; Timothy, Katherine; Vincent, G. Michael; Priori, Silvia G.; Schwartz, Peter J.; Keating, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1603-7</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Long QT syndrome (LQT) is an inherited cardiac disorder that causes syncope, seizures and sudden death from ventricular tachyarrhythmias.  The authors used single-strand conformation polymorphism (SSCP) and DNA sequence analyses to identify mutations in the cardiac sodium channel gene, SCN5A, in affected members of four LQT families.  These mutations include two identical intragenic deletions and two missense mutations.  These data suggest that SCN5A mutations cause LQT.  The location and character of these mutations suggest that this form of LQT results from a delay in cardiac sodium channel fast inactivation or altered voltage-dependence of inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi0k648Fe6F7Vg90H21EOLACvtfcHk0lhqWr6vEOLtXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvVensbo%253D&md5=5a44783e1aa8a8b7915e9b825d738bdc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F4.9.1603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F4.9.1603%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTimothy%26aufirst%3DK.%26aulast%3DVincent%26aufirst%3DG.%2BM.%26aulast%3DPriori%26aufirst%3DS.%2BG.%26aulast%3DSchwartz%26aufirst%3DP.%2BJ.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26atitle%3DCardiac%2520sodium%2520channel%2520mutations%2520in%2520patients%2520with%2520long%2520QT%2520syndrome%252C%2520an%2520inherited%2520cardiac%2520arrhythmia%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D1995%26volume%3D4%26spage%3D1603%26epage%3D1607%26doi%3D10.1093%2Fhmg%2F4.9.1603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span> <span> </span><span class="NLM_article-title">Long QT syndrome: from channels to cardiac arrhythmias</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1172/JCI25537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1172%2FJCI25537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=16075042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCmt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2018-2024&author=A.+J.+Mossauthor=R.+S.+Kass&title=Long+QT+syndrome%3A+from+channels+to+cardiac+arrhythmias&doi=10.1172%2FJCI25537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Long QT syndrome: From channels to cardiac arrhythmias</span></div><div class="casAuthors">Moss, Arthur J.; Kass, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2018-2024</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Long QT syndrome, a rare genetic disorder assocd. with life-threatening arrhythmias, has provided a wealth of information about fundamental mechanisms underlying human cardiac electrophysiol. that has come about because of truly collaborative interactions between clin. and basic scientists.  Our understanding of the mechanisms that control the crit. plateau and repolarization phases of the human ventricular action potential has been raised to new levels through these studies, which have clarified the manner in which both potassium and sodium channels regulate this crit. period of elec. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVt_KGvZsuKrVg90H21EOLACvtfcHk0lhqWr6vEOLtXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCmt78%253D&md5=bb3b40480997574d10aa009eec8d51e0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI25537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI25537%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DA.%2BJ.%26aulast%3DKass%26aufirst%3DR.%2BS.%26atitle%3DLong%2520QT%2520syndrome%253A%2520from%2520channels%2520to%2520cardiac%2520arrhythmias%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2018%26epage%3D2024%26doi%3D10.1172%2FJCI25537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locati, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napolitano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantù, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towbin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammoude, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colatsky, T. J.</span></span> <span> </span><span class="NLM_article-title">Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na<sup>+</sup> channel blockade and to increases in heart rate: Implications for gene-specific therapy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">3381</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1161/01.cir.92.12.3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1161%2F01.CIR.92.12.3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=8521555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADyaK287gtlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=3381-3386&author=P.+J.+Schwartzauthor=S.+G.+Prioriauthor=E.+H.+Locatiauthor=C.+Napolitanoauthor=F.+Cant%C3%B9author=J.+A.+Towbinauthor=M.+T.+Keatingauthor=H.+Hammoudeauthor=A.+M.+Brownauthor=L.-S.+K.+Chenauthor=T.+J.+Colatsky&title=Long+QT+syndrome+patients+with+mutations+of+the+SCN5A+and+HERG+genes+have+differential+responses+to+Na%2B+channel+blockade+and+to+increases+in+heart+rate%3A+Implications+for+gene-specific+therapy&doi=10.1161%2F01.cir.92.12.3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy</span></div><div class="casAuthors">Schwartz P J; Priori S G; Locati E H; Napolitano C; Cantu F; Towbin J A; Keating M T; Hammoude H; Brown A M; Chen L S; Colatsky T J</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3381-6</span>
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    </div><div class="casAbstract">BACKGROUND:  The genes for the long QT syndrome (LQTS) linked to chromosomes 3 (LQT3) and 7 (LQT2) were identified as SCN5A, the cardiac Na+ channel gene, and as HERG, a K+ channel gene.  These findings opened the possibility of attempting gene-specific control of ventricular repolarization.  We tested the hypothesis that the QT interval would shorten more in LQT3 than in LQT2 patients in response to mexiletine and also in response to increases in heart rate.  METHODS AND RESULTS:  Fifteen LQTS patients were studied.  Six LQT3 and 7 LQT2 patients were treated with mexiletine, and its effects on QT and QTc were measured.  Mexiletine significantly shortened the QT interval among LQT3 patients (QTc from 535 +/- 32 to 445 +/- 31 ms, P < .005) but not among LQT2 patients (QTc from 530 +/- 79 to 503 +/- 60 ms, P = NS).  LQT3 patients (n = 7) shortened their QT interval in response to increases in heart rate much more than LQT2 patients (n = 4) and also more than 18 healthy control subjects (9.45 +/- 3.3 versus 3.95 +/- 1.97 and 2.83 +/- 1.33, P < .05; data expressed as percent reduction in QT per 100-ms shortening in RR).  Among these patients, there is also a trend for LQT2 patients to have syncope or cardiac arrest under emotional or physical stress and for LQT3 patients to have cardiac events either at rest or during sleep.  CONCLUSIONS:  This is the first study to demonstrate differential responses of LQTS patients to interventions targeted to their specific genetic defect.  These findings also suggest that LQT3 patients may be more likely to benefit from Na+ channel blockers and from cardiac pacing because they would be at higher risk of arrhythmia at slow heart rates.  Conversely, LQT2 patients may be at higher risk to develop syncope under stressful conditions because of the combined arrhythmogenic effect of catecholamines with the insufficient adaptation of their QT interval when heart rate increases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd79jG4o9BH1Zoq0fPSOTvfW6udTcc2eagf8hCSuBPjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287gtlShtQ%253D%253D&md5=27ec6920657ce07520ee792c8c67555a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.92.12.3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.92.12.3381%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BJ.%26aulast%3DPriori%26aufirst%3DS.%2BG.%26aulast%3DLocati%26aufirst%3DE.%2BH.%26aulast%3DNapolitano%26aufirst%3DC.%26aulast%3DCant%25C3%25B9%26aufirst%3DF.%26aulast%3DTowbin%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26aulast%3DHammoude%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DL.-S.%2BK.%26aulast%3DColatsky%26aufirst%3DT.%2BJ.%26atitle%3DLong%2520QT%2520syndrome%2520patients%2520with%2520mutations%2520of%2520the%2520SCN5A%2520and%2520HERG%2520genes%2520have%2520differential%2520responses%2520to%2520Na%252B%2520channel%2520blockade%2520and%2520to%2520increases%2520in%2520heart%2520rate%253A%2520Implications%2520for%2520gene-specific%2520therapy%26jtitle%3DCirculation%26date%3D1995%26volume%3D92%26spage%3D3381%26epage%3D3386%26doi%3D10.1161%2F01.cir.92.12.3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazzanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faragli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteforte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloise, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiardi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnardi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etheridge, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napolitano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span> <span> </span><span class="NLM_article-title">Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.jacc.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26940925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=1053-1058&author=A.+Mazzantiauthor=R.+Maragnaauthor=A.+Faragliauthor=N.+Monteforteauthor=R.+Bloiseauthor=M.+Memmiauthor=V.+Novelliauthor=P.+Baiardiauthor=V.+Bagnardiauthor=S.+P.+Etheridgeauthor=C.+Napolitanoauthor=S.+G.+Priori&title=Gene-specific+therapy+with+mexiletine+reduces+arrhythmic+events+in+patients+with+long+QT+syndrome+type+3&doi=10.1016%2Fj.jacc.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3</span></div><div class="casAuthors">Mazzanti, Andrea; Maragna, Riccardo; Faragli, Alessandro; Monteforte, Nicola; Bloise, Raffaella; Memmi, Mirella; Novelli, Valeria; Baiardi, Paola; Bagnardi, Vincenzo; Etheridge, Susan P.; Napolitano, Carlo; Priori, Silvia G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1053-1058</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Long QT syndrome type 3 (LQT3) is a lethal disease caused by gain-of-function mutations in the SCN5A gene, coding for the alpha-subunit of the sodium channel NaV1.5.  Mexiletine is used to block late sodium current and to shorten QT interval in LQT3 patients.  The aim of this study was to det. whether mexiletine prevents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden cardiac death) in LQT3 patients.  The endpoint of this retrospective cohort study, which studied consecutive LQT3 patients who were referred to our center and treated with mexiletine, was to evaluate the antiarrhythmic efficacy of mexiletine by comparing the no. of arrhythmic events per patient and the annual rate of arrhythmic events during observation periods of equal duration before and after the beginning of therapy with mexiletine.  The study population comprised 34 LQT3 patients, 19 (56%) of whom were male.  The median age at beginning of treatment with mexiletine was 22 years, and median QTc interval before therapy 509 ms.  The median duration of oral mexiletine therapy was 36 mo, at an av. daily dose of 8 ± 0.5 mg/kg.  Mexiletine significantly shortened QTc (by 63 ± 6 ms; p < 0.0001) and reduced the percentage of patients with arrhythmic events (from 22% to 3%; p = 0.031), the mean no. of arrhythmic events per patient (from 0.43 ± 0.17 to 0.03 ± 0.03; p = 0.027), and the annual rate of arrhythmic events (from 10.3% to 0.7%; p = 0.0097).  Besides shortening QTc interval, mexiletine caused a major redn. of life-threatening arrhythmic events in LQT3 patients, thus representing an efficacious therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreZe4fppIhprVg90H21EOLACvtfcHk0lgq9GJy6oARRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFKjsb4%253D&md5=7ce037c7b5636d2462d7af7145fee3b1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DMazzanti%26aufirst%3DA.%26aulast%3DMaragna%26aufirst%3DR.%26aulast%3DFaragli%26aufirst%3DA.%26aulast%3DMonteforte%26aufirst%3DN.%26aulast%3DBloise%26aufirst%3DR.%26aulast%3DMemmi%26aufirst%3DM.%26aulast%3DNovelli%26aufirst%3DV.%26aulast%3DBaiardi%26aufirst%3DP.%26aulast%3DBagnardi%26aufirst%3DV.%26aulast%3DEtheridge%26aufirst%3DS.%2BP.%26aulast%3DNapolitano%26aufirst%3DC.%26aulast%3DPriori%26aufirst%3DS.%2BG.%26atitle%3DGene-specific%2520therapy%2520with%2520mexiletine%2520reduces%2520arrhythmic%2520events%2520in%2520patients%2520with%2520long%2520QT%2520syndrome%2520type%25203%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2016%26volume%3D67%26spage%3D1053%26epage%3D1058%26doi%3D10.1016%2Fj.jacc.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeithan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerignoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruyneel, A. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span> <span> </span><span class="NLM_article-title">An automated platform for assessment of congenital and drug-induced arrhythmia with hiPSC-derived cardiomyocytes</span>. <i>Front. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">766</span>, <span class="refDoi"> DOI: 10.3389/fphys.2017.00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.3389%2Ffphys.2017.00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=29075196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ltVSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=766&author=W.+L.+McKeithanauthor=A.+Savchenkoauthor=M.+S.+Yuauthor=F.+Cerignoliauthor=A.+A.+N.+Bruyneelauthor=J.+H.+Priceauthor=A.+R.+Colasauthor=E.+W.+Millerauthor=J.+R.+Cashmanauthor=M.+Mercola&title=An+automated+platform+for+assessment+of+congenital+and+drug-induced+arrhythmia+with+hiPSC-derived+cardiomyocytes&doi=10.3389%2Ffphys.2017.00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes</span></div><div class="casAuthors">McKeithan Wesley L; Savchenko Alex; Bruyneel Arne A N; Mercola Mark; McKeithan Wesley L; Yu Michael S; Colas Alexandre R; Yu Michael S; Cerignoli Fabio; Price Jeffery H; Miller Evan W; Cashman John R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">766</span>
        ISSN:<span class="NLM_cas:issn">1664-042X</span>.
    </div><div class="casAbstract">The ability to produce unlimited numbers of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) harboring disease and patient-specific gene variants creates a new paradigm for modeling congenital heart diseases (CHDs) and predicting proarrhythmic liabilities of drug candidates.  However, a major roadblock to implementing hiPSC-CM technology in drug discovery is that conventional methods for monitoring action potential (AP) kinetics and arrhythmia phenotypes in vitro have been too costly or technically challenging to execute in high throughput.  Herein, we describe the first large-scale, fully automated and statistically robust analysis of AP kinetics and drug-induced proarrhythmia in hiPSC-CMs.  The platform combines the optical recording of a small molecule fluorescent voltage sensing probe (VoltageFluor2.1.Cl), an automated high throughput microscope and automated image analysis to rapidly generate physiological measurements of cardiomyocytes (CMs).  The technique can be readily adapted on any high content imager to study hiPSC-CM physiology and predict the proarrhythmic effects of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDKabaoW-fYZdYoSR9eyvsfW6udTcc2eYs7Egnlht8I7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ltVSitQ%253D%253D&md5=6e4c90e725360e9c48f946c32ca3aed8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3389%2Ffphys.2017.00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphys.2017.00766%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeithan%26aufirst%3DW.%2BL.%26aulast%3DSavchenko%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%2BS.%26aulast%3DCerignoli%26aufirst%3DF.%26aulast%3DBruyneel%26aufirst%3DA.%2BA.%2BN.%26aulast%3DPrice%26aufirst%3DJ.%2BH.%26aulast%3DColas%26aufirst%3DA.%2BR.%26aulast%3DMiller%26aufirst%3DE.%2BW.%26aulast%3DCashman%26aufirst%3DJ.%2BR.%26aulast%3DMercola%26aufirst%3DM.%26atitle%3DAn%2520automated%2520platform%2520for%2520assessment%2520of%2520congenital%2520and%2520drug-induced%2520arrhythmia%2520with%2520hiPSC-derived%2520cardiomyocytes%26jtitle%3DFront.%2520Physiol.%26date%3D2017%26volume%3D8%26spage%3D766%26doi%3D10.3389%2Ffphys.2017.00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gualdani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadini-Buoninsegni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roselli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defrenza, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite <i>m</i>-hydroxymexiletine</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e00160</span> <span class="refDoi"> DOI: 10.1002/prp2.160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1002%2Fprp2.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26516576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&author=R.+Gualdaniauthor=F.+Tadini-Buoninsegniauthor=M.+Roselliauthor=I.+Defrenzaauthor=M.+Continoauthor=N.+A.+Colabufoauthor=G.+Lentini&title=Inhibition+of+hERG+potassium+channel+by+the+antiarrhythmic+agent+mexiletine+and+its+metabolite+m-hydroxymexiletine&doi=10.1002%2Fprp2.160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine</span></div><div class="casAuthors">Gualdani, Roberta; Tadini-Buoninsegni, Francesco; Roselli, Mariagrazia; Defrenza, Ivana; Contino, Marialessandra; Colabufo, Nicola Antonio; Lentini, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e00160/1-e00160/14</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Mexiletine is a sodium channel blocker, primarily used in the treatment of ventricular arrhythmias.  Moreover, recent studies have demonstrated its therapeutic value to treat myotonic syndromes and to relieve neuropathic pain.  The present study aims at investigating the direct blockade of hERG potassium channel by mexiletine and its metabolite m-hydroxymexiletine (MHM).  Our data show that mexiletine inhibits hERG in a time- and voltage-dependent manner, with an IC50 of 3.7 ± 0.7 μmol/L.  Anal. of the initial onset of current inhibition during a depolarizing test pulse indicates mexiletine binds preferentially to the open state of the hERG channel.  Looking for a possible mexiletine alternative, we show that m-hydroxymexiletine (MHM), a minor mexiletine metabolite recently reported to be as active as the parent compd. in an arrhythmia animal model, is a weaker hERG channel blocker, compared to mexiletine (IC50 = 22.4 ± 1.2 μmol/L).  The hERG arom. residues located in the S6 helix (Tyr652 and Phe656) are crucial in the binding of mexiletine and the different affinities of mexiletine and MHM with hERG channel are interpreted by modeling their corresponding binding interactions through ab initio calcns.  The simulations demonstrate that the introduction of a hydroxyl group on the meta-position of the arom. portion of mexiletine weakens the interaction of the drug xylyloxy moiety with Tyr652.  These results provide further insights into the mol. basis of drug/hERG interactions and, in agreement with previously reported results on clofilium and ibutilide analogs, support the possibility of reducing hERG potency and related toxicity by modifying the arom. pattern of substitution of clin. relevant compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMyYE1ZIJhR7Vg90H21EOLACvtfcHk0lgnGkEaMwEktQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3P&md5=ea70ab23b389935456f317dec3cec63c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fprp2.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.160%26sid%3Dliteratum%253Aachs%26aulast%3DGualdani%26aufirst%3DR.%26aulast%3DTadini-Buoninsegni%26aufirst%3DF.%26aulast%3DRoselli%26aufirst%3DM.%26aulast%3DDefrenza%26aufirst%3DI.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DLentini%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520hERG%2520potassium%2520channel%2520by%2520the%2520antiarrhythmic%2520agent%2520mexiletine%2520and%2520its%2520metabolite%2520m-hydroxymexiletine%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2015%26volume%3D3%26doi%3D10.1002%2Fprp2.160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adgey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanks, R. G.</span></span> <span> </span><span class="NLM_article-title">The clinical pharmacology of mexiletine</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1978.tb00833.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1111%2Fj.1365-2125.1978.tb00833.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=678385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADyaE1c3jsFKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1978&pages=103-108&author=N.+P.+Campbellauthor=J.+G.+Kellyauthor=A.+A.+Adgeyauthor=R.+G.+Shanks&title=The+clinical+pharmacology+of+mexiletine&doi=10.1111%2Fj.1365-2125.1978.tb00833.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical pharmacology of mexiletine</span></div><div class="casAuthors">Campbell N P; Kelly J G; Adgey A A; Shanks R G</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-8</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">1.  Mexiletine was given to 156 patients by intravenous or oral routes of administration. 2.  There was great interpatient variation in kinetics and plasma concentrations with both routes of administration. 3.  The mean volume of distribution was 6.63 l/kg.  The mean plasma elimination haf-life after chronic oral therapy was 11.31 h. 4.  Plasma concentrations between 0.75 and 2.00 microgram/ml were usually effective.  Within this therapeutic range severe side effects were uncommon. 5.  Plasma concentrations within this range were achieved in 72% of patients when doses of 10--14 mg-1 kg-1 day were given orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpMo2s_fCQD_6BottYdIAWfW6udTcc2eZEMOjASfNl9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1c3jsFKhtQ%253D%253D&md5=9fa42b54d4116a9c610b9c87655abbc1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1978.tb00833.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1978.tb00833.x%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DN.%2BP.%26aulast%3DKelly%26aufirst%3DJ.%2BG.%26aulast%3DAdgey%26aufirst%3DA.%2BA.%26aulast%3DShanks%26aufirst%3DR.%2BG.%26atitle%3DThe%2520clinical%2520pharmacology%2520of%2520mexiletine%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1978%26volume%3D6%26spage%3D103%26epage%3D108%26doi%3D10.1111%2Fj.1365-2125.1978.tb00833.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudel, R.</span>; <span class="NLM_string-name">Lehamann, H. F.</span>; <span class="NLM_string-name">Ricker, K.</span></span> <span> </span><span class="NLM_article-title">The nondystrophic myotonias</span>. In  <i>Myology</i>, Chapt 49; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, A. G.</span>; <span class="NLM_string-name">Franzini-Armstrong, C.</span></span>, eds; pp 1291–1302, <span class="NLM_publisher-name">McGraw-Hill</span>: <span class="NLM_publisher-loc">New York</span> <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=R.+Rudel&author=H.+F.+Lehamann&author=K.+Rickerauthor=A.+G.+Engel&author=C.+Franzini-Armstrong&title=Myology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRudel%26aufirst%3DR.%26atitle%3DThe%2520nondystrophic%2520myotonias%26btitle%3DMyology%26aulast%3DEngel%26aufirst%3DA.%2BG.%26pub%3DMcGraw-Hill%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terrenoire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, K. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotton, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span> <span> </span><span class="NLM_article-title">Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics</span>. <i>J. Gen. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1085/jgp.201210899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1085%2Fjgp.201210899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=23277474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2013&pages=61-72&author=C.+Terrenoireauthor=K.+Wangauthor=K.+W.+C.+Tungauthor=W.+K.+Chungauthor=R.+H.+Passauthor=J.+T.+Luauthor=J.-C.+Jeanauthor=A.+Omariauthor=K.+J.+Sampsonauthor=D.+N.+Kottonauthor=G.+Kellerauthor=R.+S.+Kass&title=Induced+pluripotent+stem+cells+used+to+reveal+drug+actions+in+a+long+QT+syndrome+family+with+complex+genetics&doi=10.1085%2Fjgp.201210899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics</span></div><div class="casAuthors">Terrenoire, Cecile; Wang, Kai; Tung, Kelvin W. Chan; Chung, Wendy K.; Pass, Robert H.; Lu, Jonathan T.; Jean, Jyh-Chang; Omari, Amel; Sampson, Kevin J.; Kotton, Darrell N.; Keller, Gordon; Kass, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Physiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-72</span>CODEN:
                <span class="NLM_cas:coden">JGPLAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-1295</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Understanding the basis for differential responses to drug therapies remains a challenge despite advances in genetics and genomics.  Induced pluripotent stem cells (iPSCs) offer an unprecedented opportunity to investigate the pharmacol. of disease processes in therapeutically and genetically relevant primary cell types in vitro and to interweave clin. and basic mol. data.  We report here the derivation of iPSCs from a long QT syndrome patient with complex genetics.  The proband was found to have a de novo SCN5A LQT-3 mutation (F1473C) and a polymorphism (K897T) in KCNH2, the gene for LQT-2.  Anal. of the biophysics and mol. pharmacol. of ion channels expressed in cardiomyocytes (CMs) differentiated from these iPSCs (iPSC-CMs) demonstrates a primary LQT-3 (Na+ channel) defect responsible for the arrhythmias not influenced by the KCNH2 polymorphism.  The F1473C mutation occurs in the channel inactivation gate and enhances late Na+ channel current (INaL) that is carried by channels that fail to inactivate completely and conduct increased inward current during prolonged depolarization, resulting in delayed repolarization, a prolonged QT interval, and increased risk of fatal arrhythmia.  We find a very pronounced rate dependence of INaL such that increasing the pacing rate markedly reduces INaL and, in addn., increases its inhibition by the Na+ channel blocker mexiletine.  These rate-dependent properties and drug interactions, unique to the proband's iPSC-CMs, correlate with improved management of arrhythmias in the patient and provide support for this approach in developing patient-specific clin. regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXHxUVKmw7m7Vg90H21EOLACvtfcHk0lgnGkEaMwEktQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKhu7g%253D&md5=fcd46a1fb62eeddae5723c0ea93bd34e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1085%2Fjgp.201210899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1085%252Fjgp.201210899%26sid%3Dliteratum%253Aachs%26aulast%3DTerrenoire%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DTung%26aufirst%3DK.%2BW.%2BC.%26aulast%3DChung%26aufirst%3DW.%2BK.%26aulast%3DPass%26aufirst%3DR.%2BH.%26aulast%3DLu%26aufirst%3DJ.%2BT.%26aulast%3DJean%26aufirst%3DJ.-C.%26aulast%3DOmari%26aufirst%3DA.%26aulast%3DSampson%26aufirst%3DK.%2BJ.%26aulast%3DKotton%26aufirst%3DD.%2BN.%26aulast%3DKeller%26aufirst%3DG.%26aulast%3DKass%26aufirst%3DR.%2BS.%26atitle%3DInduced%2520pluripotent%2520stem%2520cells%2520used%2520to%2520reveal%2520drug%2520actions%2520in%2520a%2520long%2520QT%2520syndrome%2520family%2520with%2520complex%2520genetics%26jtitle%3DJ.%2520Gen.%2520Physiol.%26date%3D2013%26volume%3D141%26spage%3D61%26epage%3D72%26doi%3D10.1085%2Fjgp.201210899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Bellis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaphy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbonara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiny, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carocci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalluzzi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerino, D. C.</span></span> <span> </span><span class="NLM_article-title">Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2012.11.3830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.bpj.2012.11.3830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=23442856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=344-354&author=M.+De%0ABellisauthor=A.+De+Lucaauthor=J.+F.+Desaphyauthor=R.+Carbonaraauthor=J.+A.+Heinyauthor=A.+Kennedyauthor=A.+Carocciauthor=M.+M.+Cavalluzziauthor=G.+Lentiniauthor=C.+Franchiniauthor=D.+C.+Camerino&title=Combined+modifications+of+mexiletine+pharmacophores+for+new+lead+blockers+of+Na%28v%291.4+channels&doi=10.1016%2Fj.bpj.2012.11.3830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Modifications of Mexiletine Pharmacophores for New Lead Blockers of Nav1.4 Channels</span></div><div class="casAuthors">De Bellis, Michela; De Luca, Annamaria; Desaphy, Jean F.; Carbonara, Roberta; Heiny, Judith A.; Kennedy, Ann; Carocci, Alessia; Cavalluzzi, Maria M.; Lentini, Giovanni; Franchini, Carlo; Conte Camerino, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">344-354</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Previously identified potent and/or use-dependent mexiletine (Mex) analogs were used as template for the rational design of new Nav-channel blockers.  The effects of the novel analogs were tested on sodium currents of native myofibers.  Data and mol. modeling show that increasing basicity and optimal alkyl chain length enhance use-dependent block.  This was demonstrated by replacing the amino group with a more basic guanidine one while maintaining a proper distance between pos. charge and arom. ring (Me13) or with homologs having the chirality center nearby the amino group or the arom. ring.  Accordingly, a Ph group on the asym. center in the homologated alkyl chain (Me12), leads to a further increase of use-dependent behavior vs. the Ph Mex deriv. Me4.  A fluorine atom in paraposition and one ortho-Me group on the xylyloxy ring (Me15) increase potency and stereoselectivity vs. Me4.  Charge delocalization and greater flexibility of Me15 may increase its affinity for Tyr residues influencing steric drug interaction with the primary Phe residue of the binding site.  Me12 and Me15 show limited selectivity against Nav-isoforms, possibly due to the highly conserved binding site on Nav.  To our knowledge, the new compds. are the most potent Mex-like Nav blockers obtained to date and deserve further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42D2F0WMdYLVg90H21EOLACvtfcHk0liovlKyZBj-IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCjurk%253D&md5=eb33281b8948c442eb63d1388f17dff9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2012.11.3830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2012.11.3830%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBellis%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DDesaphy%26aufirst%3DJ.%2BF.%26aulast%3DCarbonara%26aufirst%3DR.%26aulast%3DHeiny%26aufirst%3DJ.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%26aulast%3DCarocci%26aufirst%3DA.%26aulast%3DCavalluzzi%26aufirst%3DM.%2BM.%26aulast%3DLentini%26aufirst%3DG.%26aulast%3DFranchini%26aufirst%3DC.%26aulast%3DCamerino%26aufirst%3DD.%2BC.%26atitle%3DCombined%2520modifications%2520of%2520mexiletine%2520pharmacophores%2520for%2520new%2520lead%2520blockers%2520of%2520Na%2528v%25291.4%2520channels%26jtitle%3DBiophys.%2520J.%26date%3D2013%26volume%3D104%26spage%3D344%26epage%3D354%26doi%3D10.1016%2Fj.bpj.2012.11.3830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natuzzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaphy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerino, D. C.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10648636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtVaktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=268-277&author=A.+De%0ALucaauthor=F.+Natuzziauthor=J.+F.+Desaphyauthor=G.+Loniauthor=G.+Lentiniauthor=C.+Franchiniauthor=V.+Tortorellaauthor=D.+C.+Camerino&title=Molecular+determinants+of+mexiletine+structure+for+potent+and+use-dependent+block+of+skeletal+muscle+sodium+channels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels</span></div><div class="casAuthors">De Luca, Annamaria; Natuzzi, Fedele; Desaphy, Jean-Francois; Loni, Gabriella; Lentini, Giovanni; Franchini, Carlo; Tortorella, Vincenzo; Camerino, Diana Conte</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-277</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">On the basis of the information about drug receptor on voltage-gated sodium channels, mexiletine (Mex) analogs with substitutions at either the asym. carbon atom or the arom. ring were synthesized as pure enantiomers.  The compds. were tested in vitro for their ability to produce voltage- and use-dependent block of sodium currents (INa) of frog muscle fibers by the vaseline-gap voltage-clamp method.  In all exptl. conditions, the drug potency was highly correlated with the lipophilicity of the group on the asym. center, the deriv. with a benzyl moiety (Me6) having IC50 values more than 10 times lower than those of Mex, followed by the Ph (Me4) and the iso-Pr (Me5) deriv.  All of the compds. showed a further redn. of IC50 values at depolarized membrane potentials and at high frequency of stimulation (10 Hz).  Mex and Me5, but not Me4, produced a stereoselective tonic block of INa, the R-(-) isomers being 2-fold more potent than the S-(+) ones.  The removal of both Me groups from the arom. ring of Mex (Me3) caused a 7-fold redn. of the potency, whereas similar substitutions on the Ph deriv. Me4 (Me7 and Me8) produced opposite effects.  In fact, the IC50 of R-(-) Me7 for use-dependent block of INa was 30 times lower than that of R-(-) Mex.  Me8 and Me7 were stereoselective during both tonic and use-dependent blockade.  All of the compds. left-shifted the steady-state inactivation curves in relation to their potency and to the duration of the inactivating prepulse.  Finally, the presence of apolar groups on the asym. center of mexiletine is pivotal to reinforce hydrophobic interactions with the proposed arom. residues at the receptor, and lead to potent and therapeutically interesting inactivated channel blockers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQmB8jVkE8LVg90H21EOLACvtfcHk0liovlKyZBj-IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtVaktrs%253D&md5=1e4b9c74ed5cd94cd67e4fbc7de85b07</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DNatuzzi%26aufirst%3DF.%26aulast%3DDesaphy%26aufirst%3DJ.%2BF.%26aulast%3DLoni%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DG.%26aulast%3DFranchini%26aufirst%3DC.%26aulast%3DTortorella%26aufirst%3DV.%26aulast%3DCamerino%26aufirst%3DD.%2BC.%26atitle%3DMolecular%2520determinants%2520of%2520mexiletine%2520structure%2520for%2520potent%2520and%2520use-dependent%2520block%2520of%2520skeletal%2520muscle%2520sodium%2520channels%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D268%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (<i>S</i>)-vasicol and (<i>S</i>)-3-hydroxy-2-pyrrolidinone</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1833</span>– <span class="NLM_lpage">1841</span>, <span class="refDoi"> DOI: 10.3987/COM-03-9800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.3987%2FCOM-03-9800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsFymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2003&pages=1833-1841&author=P.-Q.+Huangauthor=X.+Zhengauthor=H.+Wei&title=Synthesis+of+%28S%29-vasicol+and+%28S%29-3-hydroxy-2-pyrrolidinone&doi=10.3987%2FCOM-03-9800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (S)-vasicol and (S)-3-hydroxy-2-pyrrolidinone</span></div><div class="casAuthors">Huang, Pei-Qiang; Zheng, Xiao; Wei, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1833-1841</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    
            (<span class="NLM_cas:orgname">Japan Institute of Heterocyclic Chemistry</span>)
        </div><div class="casAbstract">Starting from (S)-malic acid, a flexible approach to (S)-3-hydroxy-2-pyrrolidinone and (S)-1-alkyl-3-hydroxy-2-pyrrolidinones was reported.  Using this method, the first total syntheses of (-)-vasicol (I; R = NH2) as well as deaminovasicol (I; R = H) were accomplished, which allowed the revision and clarification the confusion about the structure of naturally occurring (-)-vasicol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMsc6jtXeGKLVg90H21EOLACvtfcHk0liovlKyZBj-IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsFymur0%253D&md5=5a482d9fd487845f3cfe90a09d5582e7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3987%2FCOM-03-9800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-03-9800%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.-Q.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520%2528S%2529-vasicol%2520and%2520%2528S%2529-3-hydroxy-2-pyrrolidinone%26jtitle%3DHeterocycles%26date%3D2003%26volume%3D60%26spage%3D1833%26epage%3D1841%26doi%3D10.3987%2FCOM-03-9800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Marciales, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepanenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jesús, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, W.</span></span> <span> </span><span class="NLM_article-title">A Practical and efficient route for the highly enantioselective synthesis of mexiletine analogues and novel beta-thiophenoxy and pyridyl ethers</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6928</span>– <span class="NLM_lpage">6931</span>, <span class="refDoi"> DOI: 10.1021/jo801181d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801181d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Knt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=6928-6931&author=K.+Huangauthor=M.+Ortiz-Marcialesauthor=V.+Stepanenkoauthor=M.+De+Jes%C3%BAsauthor=W.+Correa&title=A+Practical+and+efficient+route+for+the+highly+enantioselective+synthesis+of+mexiletine+analogues+and+novel+beta-thiophenoxy+and+pyridyl+ethers&doi=10.1021%2Fjo801181d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical and Efficient Route for the Highly Enantioselective Synthesis of Mexiletine Analogues and Novel β-Thiophenoxy and Pyridyl Ethers</span></div><div class="casAuthors">Huang, Kun; Ortiz-Marciales, Margarita; Stepanenko, Viatcheslav; De Jesus, Melvin; Correa, Wildeliz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6928-6931</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical and efficient procedure for the enantioselective synthesis of mexiletine analogs, e.g. I, with use of 10% of spiroborate ester II as chirality transfer agent is presented.  A variety of mexiletine analogs were prepd. in good yield with excellent enantioselectivities (91-97% ee) from readily available starting materials.  The developed methodol. was also successfully applied for the synthesis of novel β-amino ethers contg. thiophenyl and pyridyl fragments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPNouvCkceELVg90H21EOLACvtfcHk0liN3bActQWAOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Knt7w%253D&md5=f6eb642e6520f5ee9cb6df14e0d60467</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo801181d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801181d%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DOrtiz-Marciales%26aufirst%3DM.%26aulast%3DStepanenko%26aufirst%3DV.%26aulast%3DDe%2BJes%25C3%25BAs%26aufirst%3DM.%26aulast%3DCorrea%26aufirst%3DW.%26atitle%3DA%2520Practical%2520and%2520efficient%2520route%2520for%2520the%2520highly%2520enantioselective%2520synthesis%2520of%2520mexiletine%2520analogues%2520and%2520novel%2520beta-thiophenoxy%2520and%2520pyridyl%2520ethers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D6928%26epage%3D6931%26doi%3D10.1021%2Fjo801181d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giardinà, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucianelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulini, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagratini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships among novel phenoxybenzamine-related beta-chloroethylamines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(01)00395-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2FS0968-0896%2801%2900395-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=11886792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslSks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=1291-1303&author=D.+Giardin%C3%A0author=M.+Crucianelliauthor=P.+Angeliauthor=M.+Buccioniauthor=U.+Guliniauthor=G.+Marucciauthor=G.+Sagratiniauthor=C.+Melchiorre&title=Structure-activity+relationships+among+novel+phenoxybenzamine-related+beta-chloroethylamines&doi=10.1016%2FS0968-0896%2801%2900395-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity relationships among novel phenoxybenzamine-Related β-Chloroethylamines</span></div><div class="casAuthors">Giardina, Dario; Crucianelli, Mauro; Angeli, Piero; Buccioni, Michela; Gulini, Ugo; Marucci, Gabriella; Sagratini, Gianni; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1291-1303</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of β-chloroethylamines, structurally related to the irreversible α1-adrenoceptor antagonist phenoxybenzamine [PB, N-benzyl-N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)amine hydrochloride, 1] and the competitive antagonist WB4101 [N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-N-[2-(2,6-dimethoxyphenoxy)ethyl]amine hydrochloride, 2], were synthesized and evaluated for their activity at α-adrenoceptors of the epididymal and the prostatic portion of young CD rat vas deferens.  All compds. displayed irreversible antagonist activity.  Most of them showed similar antagonism at both α1- and α2-adrenoceptors, whereas some of compds. lacking substituents on both the phenoxy group and the oxyamino carbon chain, displayed a moderate α1-adrenoceptor selectivity (10-35 times), which was comparable to that of PB.  Some of the compds. belonging to the benzyl series and bearing, resp., a 2-ethoxyphenoxy and a 2-i-propoxyphenoxy moiety, were the most potent α1-adrenoceptor antagonists with an affinity value similar to that of PB (pIC50 values of 7.17 and 7.06 vs. 7.27).  Interestingly, several compds. were able to distinguish two α1-adrenoceptor subtypes in the epididymal tissue, as revealed by the discontinuity of their inhibition curves.  A mean ratio of 24:76 for these α1-adrenoceptors was detd. from different compds.  Furthermore, some compds. showed higher affinity towards the minor population of receptors, whereas compds. others preferentially inhibited the major population of α1-adrenoceptors.  In addn., selected pharmacol. expts. demonstrated the complementary antagonism of the two series of compds. and their different, preferential affinity for one of the two α1-adrenoceptor subtypes.  In conclusion, we found β-chloroethylamines that demonstrate a multiplicity of α1-adrenoceptors in the epididymal portion of young CD rat vas deferens and, as a consequence, they are possible useful tools for α1-adrenoceptor characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtX5bT2qP7bVg90H21EOLACvtfcHk0liN3bActQWAOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslSks74%253D&md5=77d3e8790ec7f6c7359e50c52b609c97</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2801%2900395-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252801%252900395-9%26sid%3Dliteratum%253Aachs%26aulast%3DGiardin%25C3%25A0%26aufirst%3DD.%26aulast%3DCrucianelli%26aufirst%3DM.%26aulast%3DAngeli%26aufirst%3DP.%26aulast%3DBuccioni%26aufirst%3DM.%26aulast%3DGulini%26aufirst%3DU.%26aulast%3DMarucci%26aufirst%3DG.%26aulast%3DSagratini%26aufirst%3DG.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DStructure-activity%2520relationships%2520among%2520novel%2520phenoxybenzamine-related%2520beta-chloroethylamines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D1291%26epage%3D1303%26doi%3D10.1016%2FS0968-0896%2801%2900395-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of cyclic sulfamidates by using chiral rhodium-catalyzed asymmetric transfer hydrogenation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4184</span>– <span class="NLM_lpage">4187</span>, <span class="refDoi"> DOI: 10.1021/ol1017905</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol1017905" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=4184-4187&author=S.+Kangauthor=J.+Hanauthor=E.+S.+Leeauthor=E.+B.+Choiauthor=H.+K.+Lee&title=Enantioselective+synthesis+of+cyclic+sulfamidates+by+using+chiral+rhodium-catalyzed+asymmetric+transfer+hydrogenation&doi=10.1021%2Fol1017905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Synthesis of Cyclic Sulfamidates by Using Chiral Rhodium-Catalyzed Asymmetric Transfer Hydrogenation</span></div><div class="casAuthors">Kang, Soyeong; Han, Juae; Lee, Eun Sil; Choi, Eun Bok; Lee, Hyeon-Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4184-4187</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Asym. transfer hydrogenation (ATH) of cyclic sulfamidate imines, e.g., I, using a HCO2H/Et3N mixt. as the hydrogen source and well-defined chiral Rh catalysts (S,S)- or (R,R)-Cp*RhCl(TsDPEN), effectively produces the corresponding cyclic sulfamidates with excellent yields and enantioselectivities at room temp. within 0.5 h.  ATH of 4,5-disubstituted imines II, having preexisting stereogenic centers, is shown to take place with dynamic kinetic resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjv3lhsrFzS7Vg90H21EOLACvtfcHk0ljDB49rLL1o9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7fI&md5=5783927723ffd8d8c425ea4d33eb5d99</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fol1017905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol1017905%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DChoi%26aufirst%3DE.%2BB.%26aulast%3DLee%26aufirst%3DH.%2BK.%26atitle%3DEnantioselective%2520synthesis%2520of%2520cyclic%2520sulfamidates%2520by%2520using%2520chiral%2520rhodium-catalyzed%2520asymmetric%2520transfer%2520hydrogenation%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D4184%26epage%3D4187%26doi%3D10.1021%2Fol1017905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyosue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K<sup>+</sup> current of guinea-pig ventricular myocytes</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1006/jmcc.1996.0084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1006%2Fjmcc.1996.0084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=8762029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Ons70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1996&pages=893-903&author=D.+W.+Wangauthor=T.+Kiyosueauthor=T.+Satoauthor=M.+Arita&title=Comparison+of+the+effects+of+class+I+anti-arrhythmic+drugs%2C+cibenzoline%2C+mexiletine+and+flecainide%2C+on+the+delayed+rectifier+K%2B+current+of+guinea-pig+ventricular+myocytes&doi=10.1006%2Fjmcc.1996.0084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea pig ventricular myocytes</span></div><div class="casAuthors">Wang, Dao Wu; Kiyosue, Tatsuto; Sato, Toshiaki; Arita, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">893-903</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">The effect of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the derived rectifier potassium current (IK) in guinea-pig ventricular myocytes was studied using whole cell voltage clamp techniques and under blockade of the L-type calcium current by 5 μM nitrendipine.  IK consisted of two different systems, as reported by Sanguinetti and Jurkiewicz (1990), i.e. an E4031-sensitive rapidly activating component (IKr) with a strong inward-going rectification property and an E4031-insensitive slowly activating component (IKs) with little rectification.  Cibenzoline (30 μM) decreased both IKr and IKs, while flecainide (10 and 30 μM) decreased the IKr exclusively.  Mexiletine (30 μM), in contrast, affected neither IKr nor IKs.  Since the inhibition of IKr and/or IKs prolongs duration of action potentials and refractory periods, class I drugs which also possess the class III effect may have addnl. effects in treating certain re-entrant arrhythmias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7awgEmt8tJLVg90H21EOLACvtfcHk0ljDB49rLL1o9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Ons70%253D&md5=e50ca86076bad7f1c647c90693edac30</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1006%2Fjmcc.1996.0084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmcc.1996.0084%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%2BW.%26aulast%3DKiyosue%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DM.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520class%2520I%2520anti-arrhythmic%2520drugs%252C%2520cibenzoline%252C%2520mexiletine%2520and%2520flecainide%252C%2520on%2520the%2520delayed%2520rectifier%2520K%252B%2520current%2520of%2520guinea-pig%2520ventricular%2520myocytes%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D1996%26volume%3D28%26spage%3D893%26epage%3D903%26doi%3D10.1006%2Fjmcc.1996.0084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenster, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comess, K. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacology and clinical use of mexiletine</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1986.tb03442.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1002%2Fj.1875-9114.1986.tb03442.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=3513138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADyaL287kvVOhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1986&pages=1-7&author=P.+E.+Fensterauthor=K.+A.+Comess&title=Pharmacology+and+clinical+use+of+mexiletine&doi=10.1002%2Fj.1875-9114.1986.tb03442.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and clinical use of mexiletine</span></div><div class="casAuthors">Fenster P E; Comess K A</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    </div><div class="casAbstract">Mexiletine is an antiarrhythmic agent with structural and electrophysiologic properties similar to those of lidocaine.  Mexiletine decreases ventricular automaticity while shortening both action potential duration and effective refractory period.  The drug may be administered orally or intravenously.  Hepatic metabolism is the major route of elimination.  The elimination half-life is approximately 10 hours, but longer in patients with acute myocardial infarction, chronic congestive heart failure or hepatic insufficiency.  Mexiletine suppresses ventricular ectopy in the acute phase of myocardial infarction.  The drug is effective for some patients in whom lidocaine has failed.  It suppresses chronic ventricular ectopy and is well tolerated in approximately two-thirds of stable outpatients treated with this agent.  In that population, mexiletine is comparable in efficacy to quinidine, procainamide and disopyramide.  It is effective in 30-50% of patients with ventricular arrhythmias refractory to other antiarrhythmic drugs.  In patients with refractory arrhythmias, the efficacy of mexiletine may be enhanced by combination with propranolol, quinidine or amiodarone.  Adverse reactions limit use of mexiletine in approximately 20% of patients.  Gastrointestinal and central nervous system side effects are the most common.  Mexiletine does not depress myocardial function.  Aggravation of arrhythmias is uncommonly observed.  The usual intravenous dose of mexiletine is 150-250 mg over at least 10 minutes.  Long-term oral dosages are usually 200-300 mg 3 or 4 times daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl7gK5P2ElrUodMGTatQ7LfW6udTcc2eYmurXnUciR47ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL287kvVOhsg%253D%253D&md5=e490e7270ce8836148d8c8059e5b8509</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1986.tb03442.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1986.tb03442.x%26sid%3Dliteratum%253Aachs%26aulast%3DFenster%26aufirst%3DP.%2BE.%26aulast%3DComess%26aufirst%3DK.%2BA.%26atitle%3DPharmacology%2520and%2520clinical%2520use%2520of%2520mexiletine%26jtitle%3DPharmacotherapy%26date%3D1986%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.1002%2Fj.1875-9114.1986.tb03442.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopeloff, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjie, N.</span></span> <span> </span><span class="NLM_article-title">Mexiletine: biphasic action on convulsive seizures in rodents</span>. <i>Neurobehav. Toxicol. Teratol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=3736751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaL28XlsVKjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1986&pages=231-235&author=G.+J.+Alexanderauthor=L.+M.+Kopeloffauthor=R.+B.+Alexanderauthor=N.+Chatterjie&title=Mexiletine%3A+biphasic+action+on+convulsive+seizures+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mexiletine:  biphasic action on convulsive seizures in rodents</span></div><div class="casAuthors">Alexander, George J.; Kopeloff, Lenore M.; Alexander, Rita B.; Chatterjie, Nithiananda</div><div class="citationInfo"><span class="NLM_cas:title">Neurobehavioral Toxicology and Teratology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">231-5</span>CODEN:
                <span class="NLM_cas:coden">NTOTDY</span>;
        ISSN:<span class="NLM_cas:issn">0275-1380</span>.
    </div><div class="casAbstract">Mexiletine (I)  [31828-71-4], an an antiarrhythmic drug, exerted a protective effect in mice against convulsive seizures induced by electroshock or the chem. convulsant, pentylenetetrazol, and against seizures induced in inbred audiosusceptible mice by a sound signal.  Administered in large doses, mexiletine produced a hyperkinetic myoclonic syndrome of 30-60 min duration.  The hyperkinesia could be controlled by dimethylaminoethanol  [108-01-0], phenobarbital  [50-06-6], and by an exptl. anticonvulsive agent, eboracin  [57310-23-3].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFTrCYczygULVg90H21EOLACvtfcHk0lgpX-5HpxbsEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XlsVKjsLY%253D&md5=e637040c0a6dec993d02cd068b07e865</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DG.%2BJ.%26aulast%3DKopeloff%26aufirst%3DL.%2BM.%26aulast%3DAlexander%26aufirst%3DR.%2BB.%26aulast%3DChatterjie%26aufirst%3DN.%26atitle%3DMexiletine%253A%2520biphasic%2520action%2520on%2520convulsive%2520seizures%2520in%2520rodents%26jtitle%3DNeurobehav.%2520Toxicol.%2520Teratol.%26date%3D1986%26volume%3D8%26spage%3D231%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akıncı, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yüzbaşioglu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coşkun, F.</span></span> <span> </span><span class="NLM_article-title">Hemodialysis as an alternative treatment of mexiletine intoxication</span>. <i>Am. J. Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1235.e6</span>, <span class="refDoi"> DOI: 10.1016/j.ajem.2010.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.ajem.2010.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=20971596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC3MbosFSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1235-1235.e6&author=E.+Ak%C4%B1nc%C4%B1author=Y.+Y%C3%BCzba%C5%9Fiogluauthor=F.+Co%C5%9Fkun&title=Hemodialysis+as+an+alternative+treatment+of+mexiletine+intoxication&doi=10.1016%2Fj.ajem.2010.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Hemodialysis as an alternative treatment of mexiletine intoxication</span></div><div class="casAuthors">Akinci Emine; Yuzbasioglu Yucel; Coskun Figen</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of emergency medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1235.e5-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mexiletine is a class IB antiarrhythmic agent.  Although it is primarily used in treating ventricular arrhythmias, recent indications for use of mexiletine include chronic and neuropathic pains.  At high doses, mexiletine causes drowsiness, confusion, nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, atrioventricular heart block, ventricular arrhythmias, asystole, cardiovascular collapse, and coma.  A 23-year-old male patient presented to the emergency department with intentional ingestion of high-dose mexiletine.  Despite decontamination and supportive treatment, his vitals deteriorated during the observation period; and he developed stupor and dysarthria.  Patient then underwent hemodialysis.  His vital signs and overall condition improved rapidly following hemodialysis treatment.  In this case report, we aimed to emphasize hemodialysis as a useful alternative therapy for severe mexiletine intoxications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRK9kO0ukAVAHO4gDb7JggCfW6udTcc2eZJUwiGSoZu07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbosFSiuw%253D%253D&md5=43d1c79815357c3d18d1b737dedc16ca</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ajem.2010.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajem.2010.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DAk%25C4%25B1nc%25C4%25B1%26aufirst%3DE.%26aulast%3DY%25C3%25BCzba%25C5%259Fioglu%26aufirst%3DY.%26aulast%3DCo%25C5%259Fkun%26aufirst%3DF.%26atitle%3DHemodialysis%2520as%2520an%2520alternative%2520treatment%2520of%2520mexiletine%2520intoxication%26jtitle%3DAm.%2520J.%2520Emerg.%2520Med.%26date%3D2011%26volume%3D29%26spage%3D1235%26epage%3D1235.e6%26doi%3D10.1016%2Fj.ajem.2010.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karagueuzian, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezhouman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcese, R.</span></span> <span> </span><span class="NLM_article-title">Enhanced late Na and Ca currents as effective antiarrhythmic drug targets</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.3389%2Ffphar.2017.00036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=28220073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ovVKqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=36&author=H.+S.+Karagueuzianauthor=A.+Pezhoumanauthor=M.+Angeliniauthor=R.+Olcese&title=Enhanced+late+Na+and+Ca+currents+as+effective+antiarrhythmic+drug+targets&doi=10.3389%2Ffphar.2017.00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets</span></div><div class="casAuthors">Karagueuzian Hrayr S; Pezhouman Arash; Angelini Marina; Olcese Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">While recent advances clarified the molecular and cellular modes of action of antiarrhythmic drugs (AADs), their link to suppression of dynamical arrhythmia mechanisms remains only partially understood.  The current classifications of AADs (Classes I, III, and IV) rely on blocking peak Na, K and L-type calcium currents (ICa,L), with Class II with dominant beta receptor blocking activity and Class V including drugs with diverse classes of actions.  The discovery that the calcium and redox sensor, cardiac Ca/calmodulin-dependent protein kinase II (CaMKII) enhances both the late Na (INa-L) and the late ICa,L in patients at high risk of VT/VF provided a new and a rational AAD target.  Pathological rise of either or both of INa-L and late ICa,L are demonstrated to promote cellular early afterdepolarizations (EADs) and EAD-mediated triggered activity that can initiate VT/VF in remodeled hearts.  Selective inhibition of the INa-L without affecting their peak transients with the highly specific prototype drug, GS-967 suppresses these EAD-mediated VT/VFs.  As in the case of INa-L, selective inhibition of the late ICa,L without affecting its peak with the prototype drug, roscovitine suppressed oxidative EAD-mediated VT/VF.  These findings indicate that specific blockers of the late inward currents without affecting their peaks (gating modifiers), offer a new and effective AAD class action i.e., "Class VI." The development of safe drugs with selective Class VI actions provides a rational and effective approach to treat VT/VF particularly in cardiac conditions associated with enhanced CaMKII activity such as heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB7PD5PEpZsEHdcurJClFcfW6udTcc2eZJUwiGSoZu07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ovVKqtA%253D%253D&md5=ef6faa920d4cd54d0f288fc82257f6da</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00036%26sid%3Dliteratum%253Aachs%26aulast%3DKaragueuzian%26aufirst%3DH.%2BS.%26aulast%3DPezhouman%26aufirst%3DA.%26aulast%3DAngelini%26aufirst%3DM.%26aulast%3DOlcese%26aufirst%3DR.%26atitle%3DEnhanced%2520late%2520Na%2520and%2520Ca%2520currents%2520as%2520effective%2520antiarrhythmic%2520drug%2520targets%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D36%26doi%3D10.3389%2Ffphar.2017.00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burridge, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diecke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordwinkin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plews, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abilez, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span> <span> </span><span class="NLM_article-title">Chemically defined generation of human cardiomyocytes</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/nmeth.2999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1038%2Fnmeth.2999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=24930130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=855-860&author=P.+W.+Burridgeauthor=E.+Matsaauthor=P.+Shuklaauthor=Z.+C.+Linauthor=J.+M.+Churkoauthor=A.+D.+Ebertauthor=F.+Lanauthor=S.+Dieckeauthor=B.+Huberauthor=N.+M.+Mordwinkinauthor=J.+R.+Plewsauthor=O.+J.+Abilezauthor=B.+Cuiauthor=J.+D.+Goldauthor=J.+C.+Wu&title=Chemically+defined+generation+of+human+cardiomyocytes&doi=10.1038%2Fnmeth.2999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically defined generation of human cardiomyocytes</span></div><div class="casAuthors">Burridge, Paul W.; Matsa, Elena; Shukla, Praveen; Lin, Ziliang C.; Churko, Jared M.; Ebert, Antje D.; Lan, Feng; Diecke, Sebastian; Huber, Bruno; Mordwinkin, Nicholas M.; Plews, Jordan R.; Abilez, Oscar J.; Cui, Bianxiao; Gold, Joseph D.; Wu, Joseph C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">855-860</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Existing methods for human induced pluripotent stem cell (hiPSC) cardiac differentiation are efficient but require complex, undefined medium constituents that hinder further elucidation of the mol. mechanisms of cardiomyogenesis.  Using hiPSCs derived under chem. defined conditions on synthetic matrixes, we systematically developed an optimized cardiac differentiation strategy, using a chem. defined medium consisting of just three components: the basal medium RPMI 1640, L-ascorbic acid 2-phosphate and rice-derived recombinant human albumin.  Along with small mol.-based induction of differentiation, this protocol produced contractile sheets of up to 95% TNNT2+ cardiomyocytes at a yield of up to 100 cardiomyocytes for every input pluripotent cell and was effective in 11 hiPSC lines tested.  This chem. defined platform for cardiac specification of hiPSCs will allow the elucidation of cardiomyocyte macromol. and metabolic requirements and will provide a minimal system for the study of maturation and subtype specification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4kKlfNA1fLVg90H21EOLACvtfcHk0liLAUHGMA_--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslGis7c%253D&md5=153be90e038f00ce022ac16e9919cfcc</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.2999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.2999%26sid%3Dliteratum%253Aachs%26aulast%3DBurridge%26aufirst%3DP.%2BW.%26aulast%3DMatsa%26aufirst%3DE.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DZ.%2BC.%26aulast%3DChurko%26aufirst%3DJ.%2BM.%26aulast%3DEbert%26aufirst%3DA.%2BD.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DDiecke%26aufirst%3DS.%26aulast%3DHuber%26aufirst%3DB.%26aulast%3DMordwinkin%26aufirst%3DN.%2BM.%26aulast%3DPlews%26aufirst%3DJ.%2BR.%26aulast%3DAbilez%26aufirst%3DO.%2BJ.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DGold%26aufirst%3DJ.%2BD.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26atitle%3DChemically%2520defined%2520generation%2520of%2520human%2520cardiomyocytes%26jtitle%3DNat.%2520Methods%26date%3D2014%26volume%3D11%26spage%3D855%26epage%3D860%26doi%3D10.1038%2Fnmeth.2999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeithan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiering, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrette, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushway, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Lozano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umbhauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duester, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, A. R.</span></span> <span> </span><span class="NLM_article-title">Id genes are essential for early heart formation</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.1101/gad.300400.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1101%2Fgad.300400.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=28794185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlOnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1325-1338&author=T.+J.+Cunninghamauthor=M.+S.+Yuauthor=W.+L.+McKeithanauthor=S.+Spieringauthor=F.+Carretteauthor=C.+T.+Huangauthor=P.+J.+Bushwayauthor=M.+Tierneyauthor=S.+Albiniauthor=M.+Giaccaauthor=M.+Manoauthor=P.+L.+Puriauthor=A.+Saccoauthor=P.+Ruiz-Lozanoauthor=J.+F.+Riouauthor=M.+Umbhauerauthor=G.+Duesterauthor=M.+Mercolaauthor=A.+R.+Colas&title=Id+genes+are+essential+for+early+heart+formation&doi=10.1101%2Fgad.300400.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Id genes are essential for early heart formation</span></div><div class="casAuthors">Cunningham, Thomas J.; Yu, Michael S.; McKeithan, Wesley L.; Spiering, Sean; Carrette, Florent; Huang, Chun-Teng; Bushway, Paul J.; Tierney, Matthew; Albini, Sonia; Giacca, Mauro; Mano, Miguel; Puri, Pier Lorenzo; Sacco, Alessandra; Ruiz-Lozano, Pilar; Riou, Jean-Francois; Umbhauer, Muriel; Duester, Gregg; Mercola, Mark; Colas, Alexandre R.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1325-1338</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Deciphering the fundamental mechanisms controlling cardiac specification is crit. for our understanding of how heart formation is initiated during embryonic development and for applying stem cell biol. to regenerative medicine and disease modeling.  Using systematic and unbiased functional screening approaches, we discovered that the Id family of helix-loop-helix proteins is both necessary and sufficient to direct cardiac mesoderm formation in frog embryos and human embryonic stem cells.  Mechanistically, Id proteins specify cardiac cell fate by repressing two inhibitors of cardiogenic mesoderm formation-Tcf3 and Foxa2-and activating inducers Evx1, Grrp1, and Mesp1.  Most importantly, CRISPR/Cas9-mediated ablation of the entire Id (Id1-4) family in mouse embryos leads to failure of anterior cardiac progenitor specification and the development of heartless embryos.  Thus, Id proteins play a central and evolutionarily conserved role during heart formation and provide a novel means to efficiently produce cardiovascular progenitors for regenerative medicine and drug discovery applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtCAjfxPveLVg90H21EOLACvtfcHk0liLAUHGMA_--A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlOnu7s%253D&md5=6d2a26f05a9356be7ff171074cb139cd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1101%2Fgad.300400.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.300400.117%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DT.%2BJ.%26aulast%3DYu%26aufirst%3DM.%2BS.%26aulast%3DMcKeithan%26aufirst%3DW.%2BL.%26aulast%3DSpiering%26aufirst%3DS.%26aulast%3DCarrette%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DBushway%26aufirst%3DP.%2BJ.%26aulast%3DTierney%26aufirst%3DM.%26aulast%3DAlbini%26aufirst%3DS.%26aulast%3DGiacca%26aufirst%3DM.%26aulast%3DMano%26aufirst%3DM.%26aulast%3DPuri%26aufirst%3DP.%2BL.%26aulast%3DSacco%26aufirst%3DA.%26aulast%3DRuiz-Lozano%26aufirst%3DP.%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DUmbhauer%26aufirst%3DM.%26aulast%3DDuester%26aufirst%3DG.%26aulast%3DMercola%26aufirst%3DM.%26aulast%3DColas%26aufirst%3DA.%2BR.%26atitle%3DId%2520genes%2520are%2520essential%2520for%2520early%2520heart%2520formation%26jtitle%3DGenes%2520Dev.%26date%3D2017%26volume%3D31%26spage%3D1325%26epage%3D1338%26doi%3D10.1101%2Fgad.300400.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. W.</span></span> <span> </span><span class="NLM_article-title">Small molecule fluorescent voltage indicators for studying membrane potential</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2016.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.cbpa.2016.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=27318561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=74-80&author=E.+W.+Miller&title=Small+molecule+fluorescent+voltage+indicators+for+studying+membrane+potential&doi=10.1016%2Fj.cbpa.2016.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule fluorescent voltage indicators for studying membrane potential</span></div><div class="casAuthors">Miller, Evan W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-80</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Voltage imaging has the potential to unravel the contributions that rapid changes in membrane voltage make to cellular physiol., esp. in the context of neuroscience.  In particular, small mol. fluorophores are esp. attractive because they can, in theory, provide fast and sensitive measurements of membrane potential dynamics.  A no. of classes of small mol. voltage indicators will be discussed, including dyes with improved two-photon voltage sensing, near IR optical profiles for use in in vivo applications, and newly developed electron-transfer based indicators, or VoltageFluors, that can be tuned across a range of wavelengths to enable all-optical voltage manipulation and measurement.  Limitations and a 'wish-list' for voltage indicators will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rInIZDIpAbVg90H21EOLACvtfcHk0liNo_gcitF7VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlt7fJ&md5=19c7b115efe8704ca01d70edc78b64a7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2016.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2016.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DE.%2BW.%26atitle%3DSmall%2520molecule%2520fluorescent%2520voltage%2520indicators%2520for%2520studying%2520membrane%2520potential%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D33%26spage%3D74%26epage%3D80%26doi%3D10.1016%2Fj.cbpa.2016.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerignoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingermanson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehalot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonough, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span> <span> </span><span class="NLM_article-title">High throughput measurement of Ca<sup>2+</sup> dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2012.08.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.vascn.2012.08.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=22926323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2rsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=246-256&author=F.+Cerignoliauthor=D.+Charlotauthor=R.+Whittakerauthor=R.+Ingermansonauthor=P.+Gehalotauthor=A.+Savchenkoauthor=D.+J.+Gallacherauthor=R.+Towartauthor=J.+H.+Priceauthor=P.+M.+McDonoughauthor=M.+Mercola&title=High+throughput+measurement+of+Ca2%2B+dynamics+for+drug+risk+assessment+in+human+stem+cell-derived+cardiomyocytes+by+kinetic+image+cytometry&doi=10.1016%2Fj.vascn.2012.08.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput measurement of Ca2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry</span></div><div class="casAuthors">Cerignoli, Fabio; Charlot, David; Whittaker, Ross; Ingermanson, Randy; Gehalot, Piyush; Savchenko, Alex; Gallacher, David J.; Towart, Rob; Price, Jeffrey H.; McDonough, Patrick M.; Mercola, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-256</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Current methods to measure physiol. properties of cardiomyocytes and predict fatal arrhythmias that can cause sudden death, such as Torsade de Pointes, lack either the automation and throughput needed for early-stage drug discovery and/or have poor predictive value.  To increase throughput and predictive power of in vitro assays, we developed kinetic imaging cytometry (KIC) for automated cell-by-cell analyses via intracellular fluorescence Ca2+ indicators.  The KIC instrument simultaneously records and analyzes intracellular calcium concn. [Ca2+]i at 30-ms resoln. from hundreds of individual cells/well of 96-well plates in seconds, providing kinetic details not previously possible with well averaging technologies such as plate readers.  Analyses of human embryonic stem cell and induced pluripotent stem cell-derived cardiomyocytes revealed effects of known cardiotoxic and arrhythmogenic drugs on kinetic parameters of Ca2+ dynamics, suggesting that KIC will aid in the assessment of cardiotoxic risk and in the elucidation of pathogenic mechanisms of heart disease assocd. with drugs treatment and/or genetic background.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT-tv2e7NlGrVg90H21EOLACvtfcHk0liNo_gcitF7VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2rsrbP&md5=ce55217aa45873af8fb192c86f04c9c5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2012.08.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2012.08.167%26sid%3Dliteratum%253Aachs%26aulast%3DCerignoli%26aufirst%3DF.%26aulast%3DCharlot%26aufirst%3DD.%26aulast%3DWhittaker%26aufirst%3DR.%26aulast%3DIngermanson%26aufirst%3DR.%26aulast%3DGehalot%26aufirst%3DP.%26aulast%3DSavchenko%26aufirst%3DA.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26aulast%3DTowart%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DJ.%2BH.%26aulast%3DMcDonough%26aufirst%3DP.%2BM.%26aulast%3DMercola%26aufirst%3DM.%26atitle%3DHigh%2520throughput%2520measurement%2520of%2520Ca2%252B%2520dynamics%2520for%2520drug%2520risk%2520assessment%2520in%2520human%2520stem%2520cell-derived%2520cardiomyocytes%2520by%2520kinetic%2520image%2520cytometry%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2012%26volume%3D66%26spage%3D246%26epage%3D256%26doi%3D10.1016%2Fj.vascn.2012.08.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerignoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span> <span> </span><span class="NLM_article-title">High throughput measurement of Ca<sup>++</sup> dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometery: A cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1093%2Ftoxsci%2Fkfv201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26358003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFagsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=503-516&author=H.+R.+Luauthor=R.+Whittakerauthor=J.+H.+Priceauthor=R.+Vegaauthor=E.+R.+Pfeifferauthor=F.+Cerignoliauthor=R.+Towartauthor=D.+J.+Gallacher&title=High+throughput+measurement+of+Ca%2B%2B+dynamics+in+human+stem+cell-derived+cardiomyocytes+by+kinetic+image+cytometery%3A+A+cardiac+risk+assessment+characterization+using+a+large+panel+of+cardioactive+and+inactive+compounds&doi=10.1093%2Ftoxsci%2Fkfv201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput measurement of Ca++ dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometry: a cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds</span></div><div class="casAuthors">Lu, Hua Rong; Whittaker, Ross; Price, Jeffrey H.; Vega, Raquel; Pfeiffer, Emily R.; Cerignoli, Fabio; Towart, Rob; Gallacher, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">503-516</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are emerging as a powerful in vitro model for cardiac safety assessment which may allow for better identification of compds. with poor arrhythmogenic liability profiles early in the drug discovery process.  Here, we describe our examn. of the Kinetic Image Cytometer (KIC) system's ability to predict adverse compd. effects using hiPS-CMs and a library of 53 compds., the majority of which are known to be cardioactive compds., and several neg. controls.  The KIC provides a high throughput method for analyzing intracellular calcium transients.  In the cardiomyocyte, intracellular calcium transients integrate the electrochem. signals of the action potential (AP) with the mol. signaling pathways regulating contraction.  Drug-induced alterations in the shape and duration of AP result in changes to the shape and duration of the intracellular calcium transient.  By examg. calcium transient dynamics in hiPS-CMs, KIC can be used as a phenotypic screen to assess compd. effects across multiple ion channel types (MITs), detecting MITs, calcium handling and signaling effects.  The results of this blinded study indicate that using hiPS-CMs, KIC is able to accurately detect drug-induced changes in Ca2+ transient dynamics (ie, duration and beat rate) and therefore, may be useful in predicting drug-induced arrhythmogenic liabilities in early de-risking within the drug discovery phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSPtVMgTMM7Vg90H21EOLACvtfcHk0lguQ-jGhv66JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFagsLs%253D&md5=1505649f8fd0b8fae8d14a3a1a68db58</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv201%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%2BR.%26aulast%3DWhittaker%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DJ.%2BH.%26aulast%3DVega%26aufirst%3DR.%26aulast%3DPfeiffer%26aufirst%3DE.%2BR.%26aulast%3DCerignoli%26aufirst%3DF.%26aulast%3DTowart%26aufirst%3DR.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26atitle%3DHigh%2520throughput%2520measurement%2520of%2520Ca%252B%252B%2520dynamics%2520in%2520human%2520stem%2520cell-derived%2520cardiomyocytes%2520by%2520kinetic%2520image%2520cytometery%253A%2520A%2520cardiac%2520risk%2520assessment%2520characterization%2520using%2520a%2520large%2520panel%2520of%2520cardioactive%2520and%2520inactive%2520compounds%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D148%26spage%3D503%26epage%3D516%26doi%3D10.1093%2Ftoxsci%2Fkfv201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fertig, N.</span></span> <span> </span><span class="NLM_article-title">HTS techniques for patch clamp-based ion channel screening - advances and economy</span>. <i>Expert. Opin. Drug. Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.682056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1517%2F17460441.2012.682056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=22507077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1Srt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=515-524&author=C.+Farreauthor=N.+Fertig&title=HTS+techniques+for+patch+clamp-based+ion+channel+screening+-+advances+and+economy&doi=10.1517%2F17460441.2012.682056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">HTS techniques for patch clamp-based ion channel screening - advances and economy</span></div><div class="casAuthors">Farre, Cecilia; Fertig, Niels</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">515-524</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Ten years ago, the first publication appeared showing patch clamp recordings performed on a planar glass chip instead of using a conventional patch clamp pipet.  "Going planar" proved to revolutionize ion channel drug screening as we know it, by allowing high quality measurements of ion channels and their effectors at a higher throughput and at the same time de-skilling the highly laborious technique.  Over the years, platforms evolved in response to user requirements regarding exptl. features, data handling plus storage, and suitable target diversity.Areas covered: This article gives a snapshot image of patch clamp-based ion channel screening with focus on platforms developed to meet requirements of high-throughput screening environments.  The com. available platforms are described, along with their benefits and drawbacks in ion channel drug screening.Expert opinion: Automated patch clamp (APC) platforms allow faster investigation of a larger no. of ion channel active compds. or cell clones than previously possible.  Since patch clamp is the only method allowing direct, real-time measurements of ion channel activity, APC holds the promise of picking up high quality leads, where they otherwise would have been overseen using indirect methods.  In addn., drug candidate safety profiling can be performed earlier in the drug discovery process, avoiding late-phase compd. withdrawal due to safety liability issues, which is highly costly and inefficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tSCyX217D7Vg90H21EOLACvtfcHk0lguQ-jGhv66JA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1Srt7k%253D&md5=f4b59fbeba561efe68afe4b0c78fcdef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.682056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.682056%26sid%3Dliteratum%253Aachs%26aulast%3DFarre%26aufirst%3DC.%26aulast%3DFertig%26aufirst%3DN.%26atitle%3DHTS%2520techniques%2520for%2520patch%2520clamp-based%2520ion%2520channel%2520screening%2520-%2520advances%2520and%2520economy%26jtitle%3DExpert.%2520Opin.%2520Drug.%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D515%26epage%3D524%26doi%3D10.1517%2F17460441.2012.682056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bankston, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span> <span> </span><span class="NLM_article-title">A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e1258</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0001258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1371%2Fjournal.pone.0001258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=18060054" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&author=J.+R.+Bankstonauthor=M.+Yueauthor=W.+Chungauthor=M.+Spyresauthor=R.+H.+Passauthor=E.+Silverauthor=K.+J.+Sampsonauthor=R.+S.+Kass&title=A+novel+and+lethal+de+novo+LQT-3+mutation+in+a+newborn+with+distinct+molecular+pharmacology+and+therapeutic+response&doi=10.1371%2Fjournal.pone.0001258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0001258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0001258%26sid%3Dliteratum%253Aachs%26aulast%3DBankston%26aufirst%3DJ.%2BR.%26aulast%3DYue%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DSpyres%26aufirst%3DM.%26aulast%3DPass%26aufirst%3DR.%2BH.%26aulast%3DSilver%26aufirst%3DE.%26aulast%3DSampson%26aufirst%3DK.%2BJ.%26aulast%3DKass%26aufirst%3DR.%2BS.%26atitle%3DA%2520novel%2520and%2520lethal%2520de%2520novo%2520LQT-3%2520mutation%2520in%2520a%2520newborn%2520with%2520distinct%2520molecular%2520pharmacology%2520and%2520therapeutic%2520response%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D2%26doi%3D10.1371%2Fjournal.pone.0001258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of cardiac cell membrane action potential (AP) and its relation with surface electrocardiogram.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Effect of slow membrane depolarization on the QT interval on a surface electrocardiogram.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Regions of Mexiletine Modified to Lead to Greater Potency, Selectivity, and Less Toxicity. Region I (red) Is Alpha to the Amine, Region II (Green) Is the Phenoxy Moiety, and Region III (Blue) Contained N-Substituents</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of Mexiletine Analogues and <i>N</i>-Substituted Mexiletine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) PhCH<sub>2</sub>ONH<sub>2</sub>-HCl, pyridine, ethanol, 21 °C. (b) BH<sub>3</sub>-THF, 65 °C, followed by treatment with HCl-ether. (c) <i>R</i>′-NH<sub>2</sub>, NaBH<sub>3</sub>CN, ethanol, 21 °C, followed by treatment with HCl-ether.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Syntheses of Chiral Analogues (<i>R</i>)-<b>30</b> and (<i>R</i>)-<b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>(a) 2-Trifluoromethylphenol (for <b>(</b><i>R</i>)-<b>30</b>, R = <i>tert</i>-BuO−) or 2,3-dimethylphenol (for (<i>R</i>)-<b>59</b>, R = CH<sub>2</sub>OCH<sub>3</sub>), NaH, DMF, 21 °C, 16 h. (b) For (<i>R</i>)-<b>30</b>: HCl, methanol, 21 °C, 16 h. For (<i>R</i>)-<b>59</b>: LiAlH<sub>4</sub>, THF, 75 °C, 16 h.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Traces of automated patch clamp studies. Panel (A) shows low-gain Na<sup>+</sup> channel signals where peak block was measured for a given concentration and high-gain (inset) traces for late current. Panel (B) shows dose–response relationships for the peak and late Na<sup>+</sup> current. Panels (C) and (D) show the analogous information for I<sub>Kr</sub> block with current traces in panel (C) and dose–response in panel (D). Recordings were analyzed at low (I<sub>NaP</sub>) and high (I<sub>NaL</sub>) gains for each compound concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/medium/jm0c01545_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Initiation of early after depolarizations-mediated ectopic ventricular beats and ventricular fibrillation in an isolated perfused aged rat heart exposed to hydrogen peroxide. (B) Representative example of administration of compound (<i>R</i>)-<b>30</b> (10 μM) after 20 min to an aged rat heart perfused with H<sub>2</sub>O<sub>2</sub> (0.1 mM). Note that compound (<i>R</i>)-<b>30</b> suppressed ventricular fibrillation (VF) by conversion to monomorphic ventricular tachycardia (VT) and then to sinus rhythm. (C) In the aged rat heart (treated as in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) with continued perfusion of H<sub>2</sub>O<sub>2</sub> (0.1 mM) and treatment with compound (<i>R</i>)-<b>30</b> (10 μM) after 40 min, the heart continued to show sustained sinus rhythm. Complete resolution of all forms of arrhythmias to normal sinus rhythm 30–40 min after perfusion of compound (<i>R</i>)-<b>30</b> (10 μM) was observed in an isolated perfused aged heart in the presence of hydrogen peroxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-9/acs.jmedchem.0c01545/20210506/images/large/jm0c01545_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01545&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i132">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34023" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34023" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, E. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birnbaum, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mareva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuttle, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castor, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruskin, J.</span></span> <span> </span><span class="NLM_article-title">Economic burden and co-morbidities of atrial fibrillation in a privately insured population</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1693</span>– <span class="NLM_lpage">1699</span>, <span class="refDoi"> DOI: 10.1185/030079905X65475</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1185%2F030079905X65475" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=16238910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BD2Mrmt1egsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2005&pages=1693-1699&author=E.+Q.+Wuauthor=H.+G.+Birnbaumauthor=M.+Marevaauthor=E.+Tuttleauthor=A.+R.+Castorauthor=W.+Jackmanauthor=J.+Ruskin&title=Economic+burden+and+co-morbidities+of+atrial+fibrillation+in+a+privately+insured+population&doi=10.1185%2F030079905X65475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Economic burden and co-morbidities of atrial fibrillation in a privately insured population</span></div><div class="casAuthors">Wu Eric Q; Birnbaum Howard G; Mareva Milena; Tuttle Edward; Castor Adam R; Jackman Warren; Ruskin Jeremy</div><div class="citationInfo"><span class="NLM_cas:title">Current medical research and opinion</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1693-9</span>
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    </div><div class="casAbstract">OBJECTIVE:  This study assesses the direct (medical and drugs) and indirect (work loss) annual costs associated with Atrial Fibrillation (AFIB) in a privately insured population.  BACKGROUND:  AFIB is the most common sustained rhythm disturbance, affecting 2.3 million people in the United States.  METHODS:  Cost and co-morbidity measures for AFIB patients were compared to matched controls using a privately insured administrative database (including medical, drug, and disability claims) for 2 million enrollees, 1999-2002 from 16 employers across the United States.  Patients with an AFIB diagnosis on at least two occasions were included in the co-morbidity analysis (n = 3944).  A non-AFIB control sample was randomly selected with a 1:1 ratio, with characteristics (i.e., age, gender, health plan) matched to AFIB patients.  Excess medical costs (i.e., employer payments) were estimated for AFIB patients, defined as the difference in average annual costs between AFIB and control patients (n = 3944); excess work-loss costs were defined similarly for employees with available work-loss data (n = 603).  Statistical significance in the descriptive analysis was measured by paired t-tests for cost, or Chi-square tests for co-morbidity comparisons.  A two-part multivariate model of excess cost was further estimated to control for co-existing conditions and other patient characteristics.  The excess costs of AFIB patients were estimated as the difference between the observed costs of AFIB patients and their estimated costs, assuming they did not have AFIB.  RESULTS:  The multivariate analysis found that the excess annual direct cost of AFIB was $12,349 (p < 0.01), with AFIB patients approximately 5 times as costly as non-AFIB individuals ($15,553 versus $3204, respectively).  The excess annual total cost was $14,875 (p < 0.01), with AFIB patients again approximately 5 times as costly as non-AFIB individuals ($18,454 versus $3,579, respectively).  AFIB was associated with increased incidence of atrial flutter (p < 0.01), heart failure (Relative Risk (RR) = 29, p < 0.01), other arrhythmias/conduction disorders (RR = 16, p < 0.01), heart attack (RR = 8, p < 0.01), and stroke (RR = 6, p < 0.01).  CONCLUSIONS:  AFIB is a costly disease and one for which more definitive therapies might offer some potential for reducing, not only the clinical impact, but also the economic burden of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTLpReW9u1oXRxY89Cm6SyfW6udTcc2eYLQi_F_ky_Grntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mrmt1egsg%253D%253D&md5=ac32ae9e5a5a854cc6de2e28e3566ff7</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1185%2F030079905X65475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F030079905X65475%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DE.%2BQ.%26aulast%3DBirnbaum%26aufirst%3DH.%2BG.%26aulast%3DMareva%26aufirst%3DM.%26aulast%3DTuttle%26aufirst%3DE.%26aulast%3DCastor%26aufirst%3DA.%2BR.%26aulast%3DJackman%26aufirst%3DW.%26aulast%3DRuskin%26aufirst%3DJ.%26atitle%3DEconomic%2520burden%2520and%2520co-morbidities%2520of%2520atrial%2520fibrillation%2520in%2520a%2520privately%2520insured%2520population%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2005%26volume%3D21%26spage%3D1693%26epage%3D1699%26doi%3D10.1185%2F030079905X65475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giles, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensah, G. A.</span></span> <span> </span><span class="NLM_article-title">Sudden cardiac death in the United States, 1989 to 1998</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">2158</span>– <span class="NLM_lpage">2163</span>, <span class="refDoi"> DOI: 10.1161/hc4301.098254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1161%2Fhc4301.098254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=11684624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BD3MnhtVShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2001&pages=2158-2163&author=Z.+J.+Zhengauthor=J.+B.+Croftauthor=W.+H.+Gilesauthor=G.+A.+Mensah&title=Sudden+cardiac+death+in+the+United+States%2C+1989+to+1998&doi=10.1161%2Fhc4301.098254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Sudden cardiac death in the United States, 1989 to 1998</span></div><div class="casAuthors">Zheng Z J; Croft J B; Giles W H; Mensah G A</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2158-63</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Sudden cardiac death (SCD) is a major clinical and public health problem.  METHODS AND RESULTS:  United States (US) vital statistics mortality data from 1989 to 1998 were analyzed.  SCD is defined as deaths occurring out of the hospital or in the emergency room or as "dead on arrival" with an underlying cause of death reported as a cardiac disease (ICD-9 code 390 to 398, 402, or 404 to 429).  Death rates were calculated for residents of the US aged >/=35 years and standardized to the 2000 US population.  Of 719 456 cardiac deaths among adults aged >/=35 years in 1998, 456 076 (63%) were defined as SCD.  Among decedents aged 35 to 44 years, 74% of cardiac deaths were SCD.  Of all SCDs in 1998, coronary heart disease (ICD-9 codes 410 to 414) was the underlying cause on 62% of death certificates.  Death rates for SCD increased with age and were higher in men than women, although there was no difference at age >/=85 years.  The black population had higher death rates for SCD than white, American Indian/Alaska Native, or Asian/Pacific Islander populations.  The Hispanic population had lower death rates for SCD than the non-Hispanic population.  From 1989 to 1998, SCD, as the proportion of all cardiac deaths, increased 12.4% (56.3% to 63.9%), and age-adjusted SCD rates declined 11.7% in men and 5.8% in women.  During the same time, age-specific death rates for SCD increased 21% among women aged 35 to 44 years.  CONCLUSIONS:  SCD remains an important public health problem in the US.  The increase in death rates for SCD among younger women warrants additional investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTvGkqt39-s-kEgZCMqtRBifW6udTcc2ebwo9pNq2Fojbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MnhtVShtQ%253D%253D&md5=c1d2dbe5c37bd151d0dc7f448f598622</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1161%2Fhc4301.098254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252Fhc4301.098254%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DZ.%2BJ.%26aulast%3DCroft%26aufirst%3DJ.%2BB.%26aulast%3DGiles%26aufirst%3DW.%2BH.%26aulast%3DMensah%26aufirst%3DG.%2BA.%26atitle%3DSudden%2520cardiac%2520death%2520in%2520the%2520United%2520States%252C%25201989%2520to%25201998%26jtitle%3DCirculation%26date%3D2001%26volume%3D104%26spage%3D2158%26epage%3D2163%26doi%3D10.1161%2Fhc4301.098254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koplan, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, W. G.</span></span> <span> </span><span class="NLM_article-title">Ventricular tachycardia and sudden cardiac death</span>. <i>Mayo Clin. Proc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">297</span>, <span class="refDoi"> DOI: 10.4065/84.3.289</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.4065%2F84.3.289" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=19252119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BD1M7ns1Omtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2009&pages=289-297&author=B.+A.+Koplanauthor=W.+G.+Stevenson&title=Ventricular+tachycardia+and+sudden+cardiac+death&doi=10.4065%2F84.3.289"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Ventricular tachycardia and sudden cardiac death</span></div><div class="casAuthors">Koplan Bruce A; Stevenson William G</div><div class="citationInfo"><span class="NLM_cas:title">Mayo Clinic proceedings</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">289-97</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ventricular tachycardia (VT), which most commonly occurs in patients with structural heart disease, can be associated with an increased risk of sudden death.  The most common cause of ventricular fibrillation is acute coronary ischemia, whereas a myocardial scar from prior infarct is the most common cause of sustained monomorphic VT in patients with structural heart disease.  More benign forms of idiopathic VT can also occur in the absence of structural heart disease.  Treatment of VT involves both emergent management and prevention of recurrence with medical and device therapy.  Appropriately selected patients who have experienced VT or those who are at risk of VT may be candidates for an implantable cardioverter-defibrillator.  The left ventricular ejection fraction is most frequently used to stratify patients with either ischemic or nonischemic cardiomyopathy who are at risk of sudden death and may be candidates for a prophylactic defibrillator.  Catheter ablation may also be an option for appropriately selected patients with many forms of VT.  This article discusses the etiologies and management of VT and its association with sudden death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTDp3xHH0y_JjAEfvC7EH1LfW6udTcc2ebB2cj22vrfnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7ns1Omtg%253D%253D&md5=82201b25421579cf1ced838292c49953</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4065%2F84.3.289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4065%252F84.3.289%26sid%3Dliteratum%253Aachs%26aulast%3DKoplan%26aufirst%3DB.%2BA.%26aulast%3DStevenson%26aufirst%3DW.%2BG.%26atitle%3DVentricular%2520tachycardia%2520and%2520sudden%2520cardiac%2520death%26jtitle%3DMayo%2520Clin.%2520Proc.%26date%3D2009%26volume%3D84%26spage%3D289%26epage%3D297%26doi%3D10.4065%2F84.3.289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singh, S.</span>; <span class="NLM_string-name">Kerndt, C.</span>; <span class="NLM_string-name">Zeltser, R.</span></span> <i>Mexiletine</i>; <span class="NLM_publisher-name">StatPearls</span>: <span class="NLM_publisher-loc">Treasure Island (FL)</span>, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Singh&author=C.+Kerndt&author=R.+Zeltser&title=Mexiletine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DS.%26btitle%3DMexiletine%26pub%3DStatPearls%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Khatib, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ackerman, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryant, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callans, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deal, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fonarow, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granger, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammill, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hlatky, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joglar, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matlock, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myerburg, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, R. L.</span></span> <span> </span><span class="NLM_article-title">2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society</span>. <i>Heart Rhythm.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">e190</span>– <span class="NLM_lpage">e252</span>, <span class="refDoi"> DOI: 10.1016/j.hrthm.2017.10.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.hrthm.2017.10.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=29097320" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=e190-e252&author=S.+M.+Al-Khatibauthor=W.+G.+Stevensonauthor=M.+J.+Ackermanauthor=W.+J.+Bryantauthor=D.+J.+Callansauthor=A.+B.+Curtisauthor=B.+J.+Dealauthor=T.+Dickfeldauthor=M.+E.+Fieldauthor=G.+C.+Fonarowauthor=A.+M.+Gillisauthor=C.+B.+Grangerauthor=S.+C.+Hammillauthor=M.+A.+Hlatkyauthor=J.+A.+Joglarauthor=G.+N.+Kayauthor=D.+D.+Matlockauthor=R.+J.+Myerburgauthor=R.+L.+Page&title=2017+AHA%2FACC%2FHRS+guideline+for+management+of+patients+with+ventricular+arrhythmias+and+the+prevention+of+sudden+cardiac+death%3A+A+report+of+the+American+college+of+cardiology%2FAmerican+heart+association+task+force+on+clinical+practice+guidelines+and+the+heart+rhythm+society&doi=10.1016%2Fj.hrthm.2017.10.035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.hrthm.2017.10.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.hrthm.2017.10.035%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Khatib%26aufirst%3DS.%2BM.%26aulast%3DStevenson%26aufirst%3DW.%2BG.%26aulast%3DAckerman%26aufirst%3DM.%2BJ.%26aulast%3DBryant%26aufirst%3DW.%2BJ.%26aulast%3DCallans%26aufirst%3DD.%2BJ.%26aulast%3DCurtis%26aufirst%3DA.%2BB.%26aulast%3DDeal%26aufirst%3DB.%2BJ.%26aulast%3DDickfeld%26aufirst%3DT.%26aulast%3DField%26aufirst%3DM.%2BE.%26aulast%3DFonarow%26aufirst%3DG.%2BC.%26aulast%3DGillis%26aufirst%3DA.%2BM.%26aulast%3DGranger%26aufirst%3DC.%2BB.%26aulast%3DHammill%26aufirst%3DS.%2BC.%26aulast%3DHlatky%26aufirst%3DM.%2BA.%26aulast%3DJoglar%26aufirst%3DJ.%2BA.%26aulast%3DKay%26aufirst%3DG.%2BN.%26aulast%3DMatlock%26aufirst%3DD.%2BD.%26aulast%3DMyerburg%26aufirst%3DR.%2BJ.%26aulast%3DPage%26aufirst%3DR.%2BL.%26atitle%3D2017%2520AHA%252FACC%252FHRS%2520guideline%2520for%2520management%2520of%2520patients%2520with%2520ventricular%2520arrhythmias%2520and%2520the%2520prevention%2520of%2520sudden%2520cardiac%2520death%253A%2520A%2520report%2520of%2520the%2520American%2520college%2520of%2520cardiology%252FAmerican%2520heart%2520association%2520task%2520force%2520on%2520clinical%2520practice%2520guidelines%2520and%2520the%2520heart%2520rhythm%2520society%26jtitle%3DHeart%2520Rhythm.%26date%3D2017%26volume%3D15%26spage%3De190%26epage%3De252%26doi%3D10.1016%2Fj.hrthm.2017.10.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomstrom-Lundqvist, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazzanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blom, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borggrefe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzsimons, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatala, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindricks, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhof, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjeldsen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Madrid, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolaou, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norekval, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaulding, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Veldhuisen, D. J.</span></span>; <span class="NLM_contrib-group">ESC Scientific Document Group</span> <span> </span><span class="NLM_article-title">2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). Endorsed by: Association for European paediatric and congenital cardiology (AEPC)</span>. <i>Eur Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2793</span>– <span class="NLM_lpage">2867</span>, <span class="refDoi"> DOI: 10.1093/eurheartj/ehv316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1093%2Feurheartj%2Fehv316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26320108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC287nt1Gjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=2793-2867&author=S.+G.+Prioriauthor=C.+Blomstrom-Lundqvistauthor=A.+Mazzantiauthor=N.+Blomauthor=M.+Borggrefeauthor=J.+Cammauthor=P.+M.+Elliottauthor=D.+Fitzsimonsauthor=R.+Hatalaauthor=G.+Hindricksauthor=P.+Kirchhofauthor=K.+Kjeldsenauthor=K.+H.+Kuckauthor=A.+Hernandez-Madridauthor=N.+Nikolaouauthor=T.+M.+Norekvalauthor=C.+Spauldingauthor=D.+J.+Van+Veldhuisenauthor=ESC+Scientific+Document+Group&title=2015+ESC+guidelines+for+the+management+of+patients+with+ventricular+arrhythmias+and+the+prevention+of+sudden+cardiac+death%3A+The+task+force+for+the+management+of+patients+with+ventricular+arrhythmias+and+the+prevention+of+sudden+cardiac+death+of+the+European+society+of+cardiology+%28ESC%29.+Endorsed+by%3A+Association+for+European+paediatric+and+congenital+cardiology+%28AEPC%29&doi=10.1093%2Feurheartj%2Fehv316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)</span></div><div class="casAuthors">Priori Silvia G; Blomstrom-Lundqvist Carina; Mazzanti Andrea; Blom Nico; Borggrefe Martin; Camm John; Elliott Perry Mark; Fitzsimons Donna; Hatala Robert; Hindricks Gerhard; Kirchhof Paulus; Kjeldsen Keld; Kuck Karl-Heinz; Hernandez-Madrid Antonio; Nikolaou Nikolaos; Norekval Tone M; Spaulding Christian; Van Veldhuisen Dirk J</div><div class="citationInfo"><span class="NLM_cas:title">European heart journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">2793-2867</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcJiEtRxzflNenUz0lpNqnfW6udTcc2eaFw2exO-7U0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287nt1Gjuw%253D%253D&md5=b22bd45747e9037ff9b03b0d5780f328</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Feurheartj%2Fehv316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Feurheartj%252Fehv316%26sid%3Dliteratum%253Aachs%26aulast%3DPriori%26aufirst%3DS.%2BG.%26aulast%3DBlomstrom-Lundqvist%26aufirst%3DC.%26aulast%3DMazzanti%26aufirst%3DA.%26aulast%3DBlom%26aufirst%3DN.%26aulast%3DBorggrefe%26aufirst%3DM.%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DElliott%26aufirst%3DP.%2BM.%26aulast%3DFitzsimons%26aufirst%3DD.%26aulast%3DHatala%26aufirst%3DR.%26aulast%3DHindricks%26aufirst%3DG.%26aulast%3DKirchhof%26aufirst%3DP.%26aulast%3DKjeldsen%26aufirst%3DK.%26aulast%3DKuck%26aufirst%3DK.%2BH.%26aulast%3DHernandez-Madrid%26aufirst%3DA.%26aulast%3DNikolaou%26aufirst%3DN.%26aulast%3DNorekval%26aufirst%3DT.%2BM.%26aulast%3DSpaulding%26aufirst%3DC.%26aulast%3DVan%2BVeldhuisen%26aufirst%3DD.%2BJ.%26aulast%3D%26atitle%3D2015%2520ESC%2520guidelines%2520for%2520the%2520management%2520of%2520patients%2520with%2520ventricular%2520arrhythmias%2520and%2520the%2520prevention%2520of%2520sudden%2520cardiac%2520death%253A%2520The%2520task%2520force%2520for%2520the%2520management%2520of%2520patients%2520with%2520ventricular%2520arrhythmias%2520and%2520the%2520prevention%2520of%2520sudden%2520cardiac%2520death%2520of%2520the%2520European%2520society%2520of%2520cardiology%2520%2528ESC%2529.%2520Endorsed%2520by%253A%2520Association%2520for%2520European%2520paediatric%2520and%2520congenital%2520cardiology%2520%2528AEPC%2529%26jtitle%3DEur%2520Heart%2520J.%26date%3D2015%26volume%3D36%26spage%3D2793%26epage%3D2867%26doi%3D10.1093%2Feurheartj%2Fehv316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. L.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanism for an inherited cardiac arrhythmia</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">685</span>, <span class="refDoi"> DOI: 10.1038/376683a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1038%2F376683a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=7651517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK2MXnslagtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=1995&pages=683-685&author=P.+B.+Bennettauthor=K.+Yazawaauthor=N.+Makitaauthor=A.+L.+George&title=Molecular+mechanism+for+an+inherited+cardiac+arrhythmia&doi=10.1038%2F376683a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanism for an inherited cardiac arrhythmia</span></div><div class="casAuthors">Bennett, Paul B.; Yazawa, Kazuto; Makita, Naomasa; George, Alfred L., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">6542</span>),
    <span class="NLM_cas:pages">683-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">In the congenital long-QT syndrome, prolongation of the cardiac action potential occurs by an unknown mechanism and predisposes individuals to syncope and sudden death as a result of ventricular arrhythmias.  Genetic heterogeneity has been demonstrated for autosomal dominant long-QT syndrome by the identification of multiple distinct loci, and assocd. mutations in two candidate genes have recently been reported.  One form of hereditary long QT (LQT3) has been linked to a mutation in the gene encoding the human heart voltage-gated sodium-channel α-subunit (SCN5A on chromosome 3p21).  Here we characterize this mutation using heterologous expression of recombinant human heart sodium channels.  Mutant channels show a sustained inward current during membrane depolarization.  Single-channel recordings indicate that mutant channels fluctuate between normal and non-inactivating gating modes.  Persistent inward sodium current explains prolongation of cardiac action potentials, and provides a mol. mechanism for this form of congenital long-QT syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBSmjEf4vROrVg90H21EOLACvtfcHk0lhZiKdpO0mOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnslagtb0%253D&md5=0aa76f9a9a7659a0dbf1dd1d852fc8c5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F376683a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F376683a0%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DP.%2BB.%26aulast%3DYazawa%26aufirst%3DK.%26aulast%3DMakita%26aufirst%3DN.%26aulast%3DGeorge%26aufirst%3DA.%2BL.%26atitle%3DMolecular%2520mechanism%2520for%2520an%2520inherited%2520cardiac%2520arrhythmia%26jtitle%3DNature%26date%3D1995%26volume%3D376%26spage%3D683%26epage%3D685%26doi%3D10.1038%2F376683a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Splawski, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towbin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. T.</span></span> <span> </span><span class="NLM_article-title">SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">805</span>– <span class="NLM_lpage">811</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(95)90359-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2F0092-8674%2895%2990359-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=7889574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK2MXksVahsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=805-811&author=Q.+Wangauthor=J.+Shenauthor=I.+Splawskiauthor=D.+Atkinsonauthor=Z.+Liauthor=J.+L.+Robinsonauthor=A.+J.+Mossauthor=J.+A.+Towbinauthor=M.+T.+Keating&title=SCN5A+mutations+associated+with+an+inherited+cardiac+arrhythmia%2C+long+QT+syndrome&doi=10.1016%2F0092-8674%2895%2990359-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome</span></div><div class="casAuthors">Wang, Qing; Shen, Jiaxiang; Splawski, Igor; Atkinson, Donald; Li, Zhizhong; Robinson, Jennifer; Moss, Arthur J.; Towbin, Jeffrey A.; Keating, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, Massachusetts)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">805-11</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Long QT syndrome (LQT) is an inherited disorder that causes sudden death from cardiac arrhythmias, specifically torsade de pointes and ventricular fibrillation.  We previously mapped three LQT loci: LQT1 on chromosome 11p15.5, LQT2 on 7q35-36, and LQT3 on 3p21-24.  Here we report genetic linkage between LQT3 and polymorphisms within SCN5A, the cardiac sodium channel gene.  Single strand conformation polymorphism and DNA sequence analyses reveal identical intragenic deletions of SCN5A in affected members of two unrelated LQT families.  The deleted sequences reside in a region that is important for channel inactivation.  The data suggest that mutations in SCN5A cause chromosome 3-linked LQT and indicate a likely cellular mechanism for this disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxQ3SS47ip2rVg90H21EOLACvtfcHk0lhZiKdpO0mOVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXksVahsL8%253D&md5=ba4cf3b8db0f88cbb8d327d33f04985d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2895%2990359-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252895%252990359-3%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DSplawski%26aufirst%3DI.%26aulast%3DAtkinson%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DRobinson%26aufirst%3DJ.%2BL.%26aulast%3DMoss%26aufirst%3DA.%2BJ.%26aulast%3DTowbin%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26atitle%3DSCN5A%2520mutations%2520associated%2520with%2520an%2520inherited%2520cardiac%2520arrhythmia%252C%2520long%2520QT%2520syndrome%26jtitle%3DCell%26date%3D1995%26volume%3D80%26spage%3D805%26epage%3D811%26doi%3D10.1016%2F0092-8674%2895%2990359-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timothy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. T.</span></span> <span> </span><span class="NLM_article-title">Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1603</span>– <span class="NLM_lpage">1607</span>, <span class="refDoi"> DOI: 10.1093/hmg/4.9.1603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1093%2Fhmg%2F4.9.1603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=8541846" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK2MXnvVensbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1995&pages=1603-1607&author=Q.+Wangauthor=J.+Shenauthor=Z.+Liauthor=K.+Timothyauthor=G.+M.+Vincentauthor=S.+G.+Prioriauthor=P.+J.+Schwartzauthor=M.+T.+Keating&title=Cardiac+sodium+channel+mutations+in+patients+with+long+QT+syndrome%2C+an+inherited+cardiac+arrhythmia&doi=10.1093%2Fhmg%2F4.9.1603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia</span></div><div class="casAuthors">Wang, Qing; Shen, Jiaxiang; Li, Zhizhong; Timothy, Katherine; Vincent, G. Michael; Priori, Silvia G.; Schwartz, Peter J.; Keating, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1603-7</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Long QT syndrome (LQT) is an inherited cardiac disorder that causes syncope, seizures and sudden death from ventricular tachyarrhythmias.  The authors used single-strand conformation polymorphism (SSCP) and DNA sequence analyses to identify mutations in the cardiac sodium channel gene, SCN5A, in affected members of four LQT families.  These mutations include two identical intragenic deletions and two missense mutations.  These data suggest that SCN5A mutations cause LQT.  The location and character of these mutations suggest that this form of LQT results from a delay in cardiac sodium channel fast inactivation or altered voltage-dependence of inactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi0k648Fe6F7Vg90H21EOLACvtfcHk0li1qb7IZU_BaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXnvVensbo%253D&md5=5a44783e1aa8a8b7915e9b825d738bdc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F4.9.1603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F4.9.1603%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DTimothy%26aufirst%3DK.%26aulast%3DVincent%26aufirst%3DG.%2BM.%26aulast%3DPriori%26aufirst%3DS.%2BG.%26aulast%3DSchwartz%26aufirst%3DP.%2BJ.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26atitle%3DCardiac%2520sodium%2520channel%2520mutations%2520in%2520patients%2520with%2520long%2520QT%2520syndrome%252C%2520an%2520inherited%2520cardiac%2520arrhythmia%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D1995%26volume%3D4%26spage%3D1603%26epage%3D1607%26doi%3D10.1093%2Fhmg%2F4.9.1603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moss, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span> <span> </span><span class="NLM_article-title">Long QT syndrome: from channels to cardiac arrhythmias</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">2018</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1172/JCI25537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1172%2FJCI25537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=16075042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFCmt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2018-2024&author=A.+J.+Mossauthor=R.+S.+Kass&title=Long+QT+syndrome%3A+from+channels+to+cardiac+arrhythmias&doi=10.1172%2FJCI25537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Long QT syndrome: From channels to cardiac arrhythmias</span></div><div class="casAuthors">Moss, Arthur J.; Kass, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2018-2024</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Long QT syndrome, a rare genetic disorder assocd. with life-threatening arrhythmias, has provided a wealth of information about fundamental mechanisms underlying human cardiac electrophysiol. that has come about because of truly collaborative interactions between clin. and basic scientists.  Our understanding of the mechanisms that control the crit. plateau and repolarization phases of the human ventricular action potential has been raised to new levels through these studies, which have clarified the manner in which both potassium and sodium channels regulate this crit. period of elec. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVt_KGvZsuKrVg90H21EOLACvtfcHk0li1qb7IZU_BaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFCmt78%253D&md5=bb3b40480997574d10aa009eec8d51e0</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI25537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI25537%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%26aufirst%3DA.%2BJ.%26aulast%3DKass%26aufirst%3DR.%2BS.%26atitle%3DLong%2520QT%2520syndrome%253A%2520from%2520channels%2520to%2520cardiac%2520arrhythmias%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2018%26epage%3D2024%26doi%3D10.1172%2FJCI25537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locati, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napolitano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantù, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towbin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammoude, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colatsky, T. J.</span></span> <span> </span><span class="NLM_article-title">Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na<sup>+</sup> channel blockade and to increases in heart rate: Implications for gene-specific therapy</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">3381</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1161/01.cir.92.12.3381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1161%2F01.CIR.92.12.3381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=8521555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADyaK287gtlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=1995&pages=3381-3386&author=P.+J.+Schwartzauthor=S.+G.+Prioriauthor=E.+H.+Locatiauthor=C.+Napolitanoauthor=F.+Cant%C3%B9author=J.+A.+Towbinauthor=M.+T.+Keatingauthor=H.+Hammoudeauthor=A.+M.+Brownauthor=L.-S.+K.+Chenauthor=T.+J.+Colatsky&title=Long+QT+syndrome+patients+with+mutations+of+the+SCN5A+and+HERG+genes+have+differential+responses+to+Na%2B+channel+blockade+and+to+increases+in+heart+rate%3A+Implications+for+gene-specific+therapy&doi=10.1161%2F01.cir.92.12.3381"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy</span></div><div class="casAuthors">Schwartz P J; Priori S G; Locati E H; Napolitano C; Cantu F; Towbin J A; Keating M T; Hammoude H; Brown A M; Chen L S; Colatsky T J</div><div class="citationInfo"><span class="NLM_cas:title">Circulation</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3381-6</span>
        ISSN:<span class="NLM_cas:issn">0009-7322</span>.
    </div><div class="casAbstract">BACKGROUND:  The genes for the long QT syndrome (LQTS) linked to chromosomes 3 (LQT3) and 7 (LQT2) were identified as SCN5A, the cardiac Na+ channel gene, and as HERG, a K+ channel gene.  These findings opened the possibility of attempting gene-specific control of ventricular repolarization.  We tested the hypothesis that the QT interval would shorten more in LQT3 than in LQT2 patients in response to mexiletine and also in response to increases in heart rate.  METHODS AND RESULTS:  Fifteen LQTS patients were studied.  Six LQT3 and 7 LQT2 patients were treated with mexiletine, and its effects on QT and QTc were measured.  Mexiletine significantly shortened the QT interval among LQT3 patients (QTc from 535 +/- 32 to 445 +/- 31 ms, P < .005) but not among LQT2 patients (QTc from 530 +/- 79 to 503 +/- 60 ms, P = NS).  LQT3 patients (n = 7) shortened their QT interval in response to increases in heart rate much more than LQT2 patients (n = 4) and also more than 18 healthy control subjects (9.45 +/- 3.3 versus 3.95 +/- 1.97 and 2.83 +/- 1.33, P < .05; data expressed as percent reduction in QT per 100-ms shortening in RR).  Among these patients, there is also a trend for LQT2 patients to have syncope or cardiac arrest under emotional or physical stress and for LQT3 patients to have cardiac events either at rest or during sleep.  CONCLUSIONS:  This is the first study to demonstrate differential responses of LQTS patients to interventions targeted to their specific genetic defect.  These findings also suggest that LQT3 patients may be more likely to benefit from Na+ channel blockers and from cardiac pacing because they would be at higher risk of arrhythmia at slow heart rates.  Conversely, LQT2 patients may be at higher risk to develop syncope under stressful conditions because of the combined arrhythmogenic effect of catecholamines with the insufficient adaptation of their QT interval when heart rate increases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQd79jG4o9BH1Zoq0fPSOTvfW6udTcc2eavPO64Qna_f7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK287gtlShtQ%253D%253D&md5=27ec6920657ce07520ee792c8c67555a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.92.12.3381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.92.12.3381%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BJ.%26aulast%3DPriori%26aufirst%3DS.%2BG.%26aulast%3DLocati%26aufirst%3DE.%2BH.%26aulast%3DNapolitano%26aufirst%3DC.%26aulast%3DCant%25C3%25B9%26aufirst%3DF.%26aulast%3DTowbin%26aufirst%3DJ.%2BA.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26aulast%3DHammoude%26aufirst%3DH.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DL.-S.%2BK.%26aulast%3DColatsky%26aufirst%3DT.%2BJ.%26atitle%3DLong%2520QT%2520syndrome%2520patients%2520with%2520mutations%2520of%2520the%2520SCN5A%2520and%2520HERG%2520genes%2520have%2520differential%2520responses%2520to%2520Na%252B%2520channel%2520blockade%2520and%2520to%2520increases%2520in%2520heart%2520rate%253A%2520Implications%2520for%2520gene-specific%2520therapy%26jtitle%3DCirculation%26date%3D1995%26volume%3D92%26spage%3D3381%26epage%3D3386%26doi%3D10.1161%2F01.cir.92.12.3381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mazzanti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maragna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faragli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteforte, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloise, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baiardi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnardi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etheridge, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napolitano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priori, S. G.</span></span> <span> </span><span class="NLM_article-title">Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3</span>. <i>J. Am. Coll. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">1053</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1016/j.jacc.2015.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.jacc.2015.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26940925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC28XjsFKjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2016&pages=1053-1058&author=A.+Mazzantiauthor=R.+Maragnaauthor=A.+Faragliauthor=N.+Monteforteauthor=R.+Bloiseauthor=M.+Memmiauthor=V.+Novelliauthor=P.+Baiardiauthor=V.+Bagnardiauthor=S.+P.+Etheridgeauthor=C.+Napolitanoauthor=S.+G.+Priori&title=Gene-specific+therapy+with+mexiletine+reduces+arrhythmic+events+in+patients+with+long+QT+syndrome+type+3&doi=10.1016%2Fj.jacc.2015.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3</span></div><div class="casAuthors">Mazzanti, Andrea; Maragna, Riccardo; Faragli, Alessandro; Monteforte, Nicola; Bloise, Raffaella; Memmi, Mirella; Novelli, Valeria; Baiardi, Paola; Bagnardi, Vincenzo; Etheridge, Susan P.; Napolitano, Carlo; Priori, Silvia G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Cardiology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1053-1058</span>CODEN:
                <span class="NLM_cas:coden">JACCDI</span>;
        ISSN:<span class="NLM_cas:issn">0735-1097</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Long QT syndrome type 3 (LQT3) is a lethal disease caused by gain-of-function mutations in the SCN5A gene, coding for the alpha-subunit of the sodium channel NaV1.5.  Mexiletine is used to block late sodium current and to shorten QT interval in LQT3 patients.  The aim of this study was to det. whether mexiletine prevents arrhythmic events (arrhythmic syncope, aborted cardiac arrest, or sudden cardiac death) in LQT3 patients.  The endpoint of this retrospective cohort study, which studied consecutive LQT3 patients who were referred to our center and treated with mexiletine, was to evaluate the antiarrhythmic efficacy of mexiletine by comparing the no. of arrhythmic events per patient and the annual rate of arrhythmic events during observation periods of equal duration before and after the beginning of therapy with mexiletine.  The study population comprised 34 LQT3 patients, 19 (56%) of whom were male.  The median age at beginning of treatment with mexiletine was 22 years, and median QTc interval before therapy 509 ms.  The median duration of oral mexiletine therapy was 36 mo, at an av. daily dose of 8 ± 0.5 mg/kg.  Mexiletine significantly shortened QTc (by 63 ± 6 ms; p < 0.0001) and reduced the percentage of patients with arrhythmic events (from 22% to 3%; p = 0.031), the mean no. of arrhythmic events per patient (from 0.43 ± 0.17 to 0.03 ± 0.03; p = 0.027), and the annual rate of arrhythmic events (from 10.3% to 0.7%; p = 0.0097).  Besides shortening QTc interval, mexiletine caused a major redn. of life-threatening arrhythmic events in LQT3 patients, thus representing an efficacious therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreZe4fppIhprVg90H21EOLACvtfcHk0liOR8UCeUYcOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjsFKjsb4%253D&md5=7ce037c7b5636d2462d7af7145fee3b1</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.jacc.2015.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jacc.2015.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DMazzanti%26aufirst%3DA.%26aulast%3DMaragna%26aufirst%3DR.%26aulast%3DFaragli%26aufirst%3DA.%26aulast%3DMonteforte%26aufirst%3DN.%26aulast%3DBloise%26aufirst%3DR.%26aulast%3DMemmi%26aufirst%3DM.%26aulast%3DNovelli%26aufirst%3DV.%26aulast%3DBaiardi%26aufirst%3DP.%26aulast%3DBagnardi%26aufirst%3DV.%26aulast%3DEtheridge%26aufirst%3DS.%2BP.%26aulast%3DNapolitano%26aufirst%3DC.%26aulast%3DPriori%26aufirst%3DS.%2BG.%26atitle%3DGene-specific%2520therapy%2520with%2520mexiletine%2520reduces%2520arrhythmic%2520events%2520in%2520patients%2520with%2520long%2520QT%2520syndrome%2520type%25203%26jtitle%3DJ.%2520Am.%2520Coll.%2520Cardiol.%26date%3D2016%26volume%3D67%26spage%3D1053%26epage%3D1058%26doi%3D10.1016%2Fj.jacc.2015.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McKeithan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerignoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruyneel, A. A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span> <span> </span><span class="NLM_article-title">An automated platform for assessment of congenital and drug-induced arrhythmia with hiPSC-derived cardiomyocytes</span>. <i>Front. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">766</span>, <span class="refDoi"> DOI: 10.3389/fphys.2017.00766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.3389%2Ffphys.2017.00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=29075196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC1M7ltVSitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=766&author=W.+L.+McKeithanauthor=A.+Savchenkoauthor=M.+S.+Yuauthor=F.+Cerignoliauthor=A.+A.+N.+Bruyneelauthor=J.+H.+Priceauthor=A.+R.+Colasauthor=E.+W.+Millerauthor=J.+R.+Cashmanauthor=M.+Mercola&title=An+automated+platform+for+assessment+of+congenital+and+drug-induced+arrhythmia+with+hiPSC-derived+cardiomyocytes&doi=10.3389%2Ffphys.2017.00766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes</span></div><div class="casAuthors">McKeithan Wesley L; Savchenko Alex; Bruyneel Arne A N; Mercola Mark; McKeithan Wesley L; Yu Michael S; Colas Alexandre R; Yu Michael S; Cerignoli Fabio; Price Jeffery H; Miller Evan W; Cashman John R</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in physiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">766</span>
        ISSN:<span class="NLM_cas:issn">1664-042X</span>.
    </div><div class="casAbstract">The ability to produce unlimited numbers of human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) harboring disease and patient-specific gene variants creates a new paradigm for modeling congenital heart diseases (CHDs) and predicting proarrhythmic liabilities of drug candidates.  However, a major roadblock to implementing hiPSC-CM technology in drug discovery is that conventional methods for monitoring action potential (AP) kinetics and arrhythmia phenotypes in vitro have been too costly or technically challenging to execute in high throughput.  Herein, we describe the first large-scale, fully automated and statistically robust analysis of AP kinetics and drug-induced proarrhythmia in hiPSC-CMs.  The platform combines the optical recording of a small molecule fluorescent voltage sensing probe (VoltageFluor2.1.Cl), an automated high throughput microscope and automated image analysis to rapidly generate physiological measurements of cardiomyocytes (CMs).  The technique can be readily adapted on any high content imager to study hiPSC-CM physiology and predict the proarrhythmic effects of drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDKabaoW-fYZdYoSR9eyvsfW6udTcc2eYi_FJJEaMGzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7ltVSitQ%253D%253D&md5=6e4c90e725360e9c48f946c32ca3aed8</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3389%2Ffphys.2017.00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphys.2017.00766%26sid%3Dliteratum%253Aachs%26aulast%3DMcKeithan%26aufirst%3DW.%2BL.%26aulast%3DSavchenko%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DM.%2BS.%26aulast%3DCerignoli%26aufirst%3DF.%26aulast%3DBruyneel%26aufirst%3DA.%2BA.%2BN.%26aulast%3DPrice%26aufirst%3DJ.%2BH.%26aulast%3DColas%26aufirst%3DA.%2BR.%26aulast%3DMiller%26aufirst%3DE.%2BW.%26aulast%3DCashman%26aufirst%3DJ.%2BR.%26aulast%3DMercola%26aufirst%3DM.%26atitle%3DAn%2520automated%2520platform%2520for%2520assessment%2520of%2520congenital%2520and%2520drug-induced%2520arrhythmia%2520with%2520hiPSC-derived%2520cardiomyocytes%26jtitle%3DFront.%2520Physiol.%26date%3D2017%26volume%3D8%26spage%3D766%26doi%3D10.3389%2Ffphys.2017.00766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gualdani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadini-Buoninsegni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roselli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defrenza, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, G.</span></span> <span> </span><span class="NLM_article-title">Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite <i>m</i>-hydroxymexiletine</span>. <i>Pharmacol. Res. Perspect.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>, <span class="NLM_elocation-id">e00160</span> <span class="refDoi"> DOI: 10.1002/prp2.160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1002%2Fprp2.160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26516576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&author=R.+Gualdaniauthor=F.+Tadini-Buoninsegniauthor=M.+Roselliauthor=I.+Defrenzaauthor=M.+Continoauthor=N.+A.+Colabufoauthor=G.+Lentini&title=Inhibition+of+hERG+potassium+channel+by+the+antiarrhythmic+agent+mexiletine+and+its+metabolite+m-hydroxymexiletine&doi=10.1002%2Fprp2.160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine</span></div><div class="casAuthors">Gualdani, Roberta; Tadini-Buoninsegni, Francesco; Roselli, Mariagrazia; Defrenza, Ivana; Contino, Marialessandra; Colabufo, Nicola Antonio; Lentini, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology Research & Perspectives</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e00160/1-e00160/14</span>CODEN:
                <span class="NLM_cas:coden">PRPHCA</span>;
        ISSN:<span class="NLM_cas:issn">2052-1707</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Mexiletine is a sodium channel blocker, primarily used in the treatment of ventricular arrhythmias.  Moreover, recent studies have demonstrated its therapeutic value to treat myotonic syndromes and to relieve neuropathic pain.  The present study aims at investigating the direct blockade of hERG potassium channel by mexiletine and its metabolite m-hydroxymexiletine (MHM).  Our data show that mexiletine inhibits hERG in a time- and voltage-dependent manner, with an IC50 of 3.7 ± 0.7 μmol/L.  Anal. of the initial onset of current inhibition during a depolarizing test pulse indicates mexiletine binds preferentially to the open state of the hERG channel.  Looking for a possible mexiletine alternative, we show that m-hydroxymexiletine (MHM), a minor mexiletine metabolite recently reported to be as active as the parent compd. in an arrhythmia animal model, is a weaker hERG channel blocker, compared to mexiletine (IC50 = 22.4 ± 1.2 μmol/L).  The hERG arom. residues located in the S6 helix (Tyr652 and Phe656) are crucial in the binding of mexiletine and the different affinities of mexiletine and MHM with hERG channel are interpreted by modeling their corresponding binding interactions through ab initio calcns.  The simulations demonstrate that the introduction of a hydroxyl group on the meta-position of the arom. portion of mexiletine weakens the interaction of the drug xylyloxy moiety with Tyr652.  These results provide further insights into the mol. basis of drug/hERG interactions and, in agreement with previously reported results on clofilium and ibutilide analogs, support the possibility of reducing hERG potency and related toxicity by modifying the arom. pattern of substitution of clin. relevant compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMyYE1ZIJhR7Vg90H21EOLACvtfcHk0lga85L0HAoI2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3P&md5=ea70ab23b389935456f317dec3cec63c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fprp2.160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprp2.160%26sid%3Dliteratum%253Aachs%26aulast%3DGualdani%26aufirst%3DR.%26aulast%3DTadini-Buoninsegni%26aufirst%3DF.%26aulast%3DRoselli%26aufirst%3DM.%26aulast%3DDefrenza%26aufirst%3DI.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DLentini%26aufirst%3DG.%26atitle%3DInhibition%2520of%2520hERG%2520potassium%2520channel%2520by%2520the%2520antiarrhythmic%2520agent%2520mexiletine%2520and%2520its%2520metabolite%2520m-hydroxymexiletine%26jtitle%3DPharmacol.%2520Res.%2520Perspect.%26date%3D2015%26volume%3D3%26doi%3D10.1002%2Fprp2.160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adgey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanks, R. G.</span></span> <span> </span><span class="NLM_article-title">The clinical pharmacology of mexiletine</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1978</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">108</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.1978.tb00833.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1111%2Fj.1365-2125.1978.tb00833.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=678385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADyaE1c3jsFKhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1978&pages=103-108&author=N.+P.+Campbellauthor=J.+G.+Kellyauthor=A.+A.+Adgeyauthor=R.+G.+Shanks&title=The+clinical+pharmacology+of+mexiletine&doi=10.1111%2Fj.1365-2125.1978.tb00833.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The clinical pharmacology of mexiletine</span></div><div class="casAuthors">Campbell N P; Kelly J G; Adgey A A; Shanks R G</div><div class="citationInfo"><span class="NLM_cas:title">British journal of clinical pharmacology</span>
        (<span class="NLM_cas:date">1978</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">103-8</span>
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    </div><div class="casAbstract">1.  Mexiletine was given to 156 patients by intravenous or oral routes of administration. 2.  There was great interpatient variation in kinetics and plasma concentrations with both routes of administration. 3.  The mean volume of distribution was 6.63 l/kg.  The mean plasma elimination haf-life after chronic oral therapy was 11.31 h. 4.  Plasma concentrations between 0.75 and 2.00 microgram/ml were usually effective.  Within this therapeutic range severe side effects were uncommon. 5.  Plasma concentrations within this range were achieved in 72% of patients when doses of 10--14 mg-1 kg-1 day were given orally.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpMo2s_fCQD_6BottYdIAWfW6udTcc2ea0ioO8a91WGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE1c3jsFKhtQ%253D%253D&md5=9fa42b54d4116a9c610b9c87655abbc1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.1978.tb00833.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.1978.tb00833.x%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DN.%2BP.%26aulast%3DKelly%26aufirst%3DJ.%2BG.%26aulast%3DAdgey%26aufirst%3DA.%2BA.%26aulast%3DShanks%26aufirst%3DR.%2BG.%26atitle%3DThe%2520clinical%2520pharmacology%2520of%2520mexiletine%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1978%26volume%3D6%26spage%3D103%26epage%3D108%26doi%3D10.1111%2Fj.1365-2125.1978.tb00833.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudel, R.</span>; <span class="NLM_string-name">Lehamann, H. F.</span>; <span class="NLM_string-name">Ricker, K.</span></span> <span> </span><span class="NLM_article-title">The nondystrophic myotonias</span>. In  <i>Myology</i>, Chapt 49; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, A. G.</span>; <span class="NLM_string-name">Franzini-Armstrong, C.</span></span>, eds; pp 1291–1302, <span class="NLM_publisher-name">McGraw-Hill</span>: <span class="NLM_publisher-loc">New York</span> <span class="NLM_year">1994</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1994&author=R.+Rudel&author=H.+F.+Lehamann&author=K.+Rickerauthor=A.+G.+Engel&author=C.+Franzini-Armstrong&title=Myology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRudel%26aufirst%3DR.%26atitle%3DThe%2520nondystrophic%2520myotonias%26btitle%3DMyology%26aulast%3DEngel%26aufirst%3DA.%2BG.%26pub%3DMcGraw-Hill%26date%3D1994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terrenoire, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, K. W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jean, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotton, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span> <span> </span><span class="NLM_article-title">Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics</span>. <i>J. Gen. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1085/jgp.201210899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1085%2Fjgp.201210899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=23277474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFKhu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2013&pages=61-72&author=C.+Terrenoireauthor=K.+Wangauthor=K.+W.+C.+Tungauthor=W.+K.+Chungauthor=R.+H.+Passauthor=J.+T.+Luauthor=J.-C.+Jeanauthor=A.+Omariauthor=K.+J.+Sampsonauthor=D.+N.+Kottonauthor=G.+Kellerauthor=R.+S.+Kass&title=Induced+pluripotent+stem+cells+used+to+reveal+drug+actions+in+a+long+QT+syndrome+family+with+complex+genetics&doi=10.1085%2Fjgp.201210899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics</span></div><div class="casAuthors">Terrenoire, Cecile; Wang, Kai; Tung, Kelvin W. Chan; Chung, Wendy K.; Pass, Robert H.; Lu, Jonathan T.; Jean, Jyh-Chang; Omari, Amel; Sampson, Kevin J.; Kotton, Darrell N.; Keller, Gordon; Kass, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of General Physiology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-72</span>CODEN:
                <span class="NLM_cas:coden">JGPLAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-1295</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Understanding the basis for differential responses to drug therapies remains a challenge despite advances in genetics and genomics.  Induced pluripotent stem cells (iPSCs) offer an unprecedented opportunity to investigate the pharmacol. of disease processes in therapeutically and genetically relevant primary cell types in vitro and to interweave clin. and basic mol. data.  We report here the derivation of iPSCs from a long QT syndrome patient with complex genetics.  The proband was found to have a de novo SCN5A LQT-3 mutation (F1473C) and a polymorphism (K897T) in KCNH2, the gene for LQT-2.  Anal. of the biophysics and mol. pharmacol. of ion channels expressed in cardiomyocytes (CMs) differentiated from these iPSCs (iPSC-CMs) demonstrates a primary LQT-3 (Na+ channel) defect responsible for the arrhythmias not influenced by the KCNH2 polymorphism.  The F1473C mutation occurs in the channel inactivation gate and enhances late Na+ channel current (INaL) that is carried by channels that fail to inactivate completely and conduct increased inward current during prolonged depolarization, resulting in delayed repolarization, a prolonged QT interval, and increased risk of fatal arrhythmia.  We find a very pronounced rate dependence of INaL such that increasing the pacing rate markedly reduces INaL and, in addn., increases its inhibition by the Na+ channel blocker mexiletine.  These rate-dependent properties and drug interactions, unique to the proband's iPSC-CMs, correlate with improved management of arrhythmias in the patient and provide support for this approach in developing patient-specific clin. regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXHxUVKmw7m7Vg90H21EOLACvtfcHk0lgEI5ZhdmsaRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFKhu7g%253D&md5=fcd46a1fb62eeddae5723c0ea93bd34e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1085%2Fjgp.201210899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1085%252Fjgp.201210899%26sid%3Dliteratum%253Aachs%26aulast%3DTerrenoire%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DTung%26aufirst%3DK.%2BW.%2BC.%26aulast%3DChung%26aufirst%3DW.%2BK.%26aulast%3DPass%26aufirst%3DR.%2BH.%26aulast%3DLu%26aufirst%3DJ.%2BT.%26aulast%3DJean%26aufirst%3DJ.-C.%26aulast%3DOmari%26aufirst%3DA.%26aulast%3DSampson%26aufirst%3DK.%2BJ.%26aulast%3DKotton%26aufirst%3DD.%2BN.%26aulast%3DKeller%26aufirst%3DG.%26aulast%3DKass%26aufirst%3DR.%2BS.%26atitle%3DInduced%2520pluripotent%2520stem%2520cells%2520used%2520to%2520reveal%2520drug%2520actions%2520in%2520a%2520long%2520QT%2520syndrome%2520family%2520with%2520complex%2520genetics%26jtitle%3DJ.%2520Gen.%2520Physiol.%26date%3D2013%26volume%3D141%26spage%3D61%26epage%3D72%26doi%3D10.1085%2Fjgp.201210899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Bellis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaphy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbonara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heiny, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carocci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalluzzi, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerino, D. C.</span></span> <span> </span><span class="NLM_article-title">Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">344</span>– <span class="NLM_lpage">354</span>, <span class="refDoi"> DOI: 10.1016/j.bpj.2012.11.3830</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.bpj.2012.11.3830" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=23442856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCjurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2013&pages=344-354&author=M.+De%0ABellisauthor=A.+De+Lucaauthor=J.+F.+Desaphyauthor=R.+Carbonaraauthor=J.+A.+Heinyauthor=A.+Kennedyauthor=A.+Carocciauthor=M.+M.+Cavalluzziauthor=G.+Lentiniauthor=C.+Franchiniauthor=D.+C.+Camerino&title=Combined+modifications+of+mexiletine+pharmacophores+for+new+lead+blockers+of+Na%28v%291.4+channels&doi=10.1016%2Fj.bpj.2012.11.3830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Combined Modifications of Mexiletine Pharmacophores for New Lead Blockers of Nav1.4 Channels</span></div><div class="casAuthors">De Bellis, Michela; De Luca, Annamaria; Desaphy, Jean F.; Carbonara, Roberta; Heiny, Judith A.; Kennedy, Ann; Carocci, Alessia; Cavalluzzi, Maria M.; Lentini, Giovanni; Franchini, Carlo; Conte Camerino, Diana</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">344-354</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Previously identified potent and/or use-dependent mexiletine (Mex) analogs were used as template for the rational design of new Nav-channel blockers.  The effects of the novel analogs were tested on sodium currents of native myofibers.  Data and mol. modeling show that increasing basicity and optimal alkyl chain length enhance use-dependent block.  This was demonstrated by replacing the amino group with a more basic guanidine one while maintaining a proper distance between pos. charge and arom. ring (Me13) or with homologs having the chirality center nearby the amino group or the arom. ring.  Accordingly, a Ph group on the asym. center in the homologated alkyl chain (Me12), leads to a further increase of use-dependent behavior vs. the Ph Mex deriv. Me4.  A fluorine atom in paraposition and one ortho-Me group on the xylyloxy ring (Me15) increase potency and stereoselectivity vs. Me4.  Charge delocalization and greater flexibility of Me15 may increase its affinity for Tyr residues influencing steric drug interaction with the primary Phe residue of the binding site.  Me12 and Me15 show limited selectivity against Nav-isoforms, possibly due to the highly conserved binding site on Nav.  To our knowledge, the new compds. are the most potent Mex-like Nav blockers obtained to date and deserve further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42D2F0WMdYLVg90H21EOLACvtfcHk0limGDUax_F9aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCjurk%253D&md5=eb33281b8948c442eb63d1388f17dff9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2012.11.3830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2012.11.3830%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBellis%26aufirst%3DM.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DDesaphy%26aufirst%3DJ.%2BF.%26aulast%3DCarbonara%26aufirst%3DR.%26aulast%3DHeiny%26aufirst%3DJ.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%26aulast%3DCarocci%26aufirst%3DA.%26aulast%3DCavalluzzi%26aufirst%3DM.%2BM.%26aulast%3DLentini%26aufirst%3DG.%26aulast%3DFranchini%26aufirst%3DC.%26aulast%3DCamerino%26aufirst%3DD.%2BC.%26atitle%3DCombined%2520modifications%2520of%2520mexiletine%2520pharmacophores%2520for%2520new%2520lead%2520blockers%2520of%2520Na%2528v%25291.4%2520channels%26jtitle%3DBiophys.%2520J.%26date%3D2013%26volume%3D104%26spage%3D344%26epage%3D354%26doi%3D10.1016%2Fj.bpj.2012.11.3830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Luca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natuzzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desaphy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franchini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerino, D. C.</span></span> <span> </span><span class="NLM_article-title">Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">277</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10648636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtVaktrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2000&pages=268-277&author=A.+De%0ALucaauthor=F.+Natuzziauthor=J.+F.+Desaphyauthor=G.+Loniauthor=G.+Lentiniauthor=C.+Franchiniauthor=V.+Tortorellaauthor=D.+C.+Camerino&title=Molecular+determinants+of+mexiletine+structure+for+potent+and+use-dependent+block+of+skeletal+muscle+sodium+channels"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular determinants of mexiletine structure for potent and use-dependent block of skeletal muscle sodium channels</span></div><div class="casAuthors">De Luca, Annamaria; Natuzzi, Fedele; Desaphy, Jean-Francois; Loni, Gabriella; Lentini, Giovanni; Franchini, Carlo; Tortorella, Vincenzo; Camerino, Diana Conte</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-277</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">On the basis of the information about drug receptor on voltage-gated sodium channels, mexiletine (Mex) analogs with substitutions at either the asym. carbon atom or the arom. ring were synthesized as pure enantiomers.  The compds. were tested in vitro for their ability to produce voltage- and use-dependent block of sodium currents (INa) of frog muscle fibers by the vaseline-gap voltage-clamp method.  In all exptl. conditions, the drug potency was highly correlated with the lipophilicity of the group on the asym. center, the deriv. with a benzyl moiety (Me6) having IC50 values more than 10 times lower than those of Mex, followed by the Ph (Me4) and the iso-Pr (Me5) deriv.  All of the compds. showed a further redn. of IC50 values at depolarized membrane potentials and at high frequency of stimulation (10 Hz).  Mex and Me5, but not Me4, produced a stereoselective tonic block of INa, the R-(-) isomers being 2-fold more potent than the S-(+) ones.  The removal of both Me groups from the arom. ring of Mex (Me3) caused a 7-fold redn. of the potency, whereas similar substitutions on the Ph deriv. Me4 (Me7 and Me8) produced opposite effects.  In fact, the IC50 of R-(-) Me7 for use-dependent block of INa was 30 times lower than that of R-(-) Mex.  Me8 and Me7 were stereoselective during both tonic and use-dependent blockade.  All of the compds. left-shifted the steady-state inactivation curves in relation to their potency and to the duration of the inactivating prepulse.  Finally, the presence of apolar groups on the asym. center of mexiletine is pivotal to reinforce hydrophobic interactions with the proposed arom. residues at the receptor, and lead to potent and therapeutically interesting inactivated channel blockers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqQmB8jVkE8LVg90H21EOLACvtfcHk0limGDUax_F9aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtVaktrs%253D&md5=1e4b9c74ed5cd94cd67e4fbc7de85b07</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DNatuzzi%26aufirst%3DF.%26aulast%3DDesaphy%26aufirst%3DJ.%2BF.%26aulast%3DLoni%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DG.%26aulast%3DFranchini%26aufirst%3DC.%26aulast%3DTortorella%26aufirst%3DV.%26aulast%3DCamerino%26aufirst%3DD.%2BC.%26atitle%3DMolecular%2520determinants%2520of%2520mexiletine%2520structure%2520for%2520potent%2520and%2520use-dependent%2520block%2520of%2520skeletal%2520muscle%2520sodium%2520channels%26jtitle%3DMol.%2520Pharmacol.%26date%3D2000%26volume%3D57%26spage%3D268%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (<i>S</i>)-vasicol and (<i>S</i>)-3-hydroxy-2-pyrrolidinone</span>. <i>Heterocycles</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1833</span>– <span class="NLM_lpage">1841</span>, <span class="refDoi"> DOI: 10.3987/COM-03-9800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.3987%2FCOM-03-9800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsFymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2003&pages=1833-1841&author=P.-Q.+Huangauthor=X.+Zhengauthor=H.+Wei&title=Synthesis+of+%28S%29-vasicol+and+%28S%29-3-hydroxy-2-pyrrolidinone&doi=10.3987%2FCOM-03-9800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (S)-vasicol and (S)-3-hydroxy-2-pyrrolidinone</span></div><div class="casAuthors">Huang, Pei-Qiang; Zheng, Xiao; Wei, Hua</div><div class="citationInfo"><span class="NLM_cas:title">Heterocycles</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1833-1841</span>CODEN:
                <span class="NLM_cas:coden">HTCYAM</span>;
        ISSN:<span class="NLM_cas:issn">0385-5414</span>.
    
            (<span class="NLM_cas:orgname">Japan Institute of Heterocyclic Chemistry</span>)
        </div><div class="casAbstract">Starting from (S)-malic acid, a flexible approach to (S)-3-hydroxy-2-pyrrolidinone and (S)-1-alkyl-3-hydroxy-2-pyrrolidinones was reported.  Using this method, the first total syntheses of (-)-vasicol (I; R = NH2) as well as deaminovasicol (I; R = H) were accomplished, which allowed the revision and clarification the confusion about the structure of naturally occurring (-)-vasicol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMsc6jtXeGKLVg90H21EOLACvtfcHk0lhEBhZ7lB_RsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsFymur0%253D&md5=5a482d9fd487845f3cfe90a09d5582e7</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3987%2FCOM-03-9800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3987%252FCOM-03-9800%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.-Q.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520%2528S%2529-vasicol%2520and%2520%2528S%2529-3-hydroxy-2-pyrrolidinone%26jtitle%3DHeterocycles%26date%3D2003%26volume%3D60%26spage%3D1833%26epage%3D1841%26doi%3D10.3987%2FCOM-03-9800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz-Marciales, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stepanenko, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jesús, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, W.</span></span> <span> </span><span class="NLM_article-title">A Practical and efficient route for the highly enantioselective synthesis of mexiletine analogues and novel beta-thiophenoxy and pyridyl ethers</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">6928</span>– <span class="NLM_lpage">6931</span>, <span class="refDoi"> DOI: 10.1021/jo801181d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801181d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Knt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=6928-6931&author=K.+Huangauthor=M.+Ortiz-Marcialesauthor=V.+Stepanenkoauthor=M.+De+Jes%C3%BAsauthor=W.+Correa&title=A+Practical+and+efficient+route+for+the+highly+enantioselective+synthesis+of+mexiletine+analogues+and+novel+beta-thiophenoxy+and+pyridyl+ethers&doi=10.1021%2Fjo801181d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">A Practical and Efficient Route for the Highly Enantioselective Synthesis of Mexiletine Analogues and Novel β-Thiophenoxy and Pyridyl Ethers</span></div><div class="casAuthors">Huang, Kun; Ortiz-Marciales, Margarita; Stepanenko, Viatcheslav; De Jesus, Melvin; Correa, Wildeliz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">6928-6931</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical and efficient procedure for the enantioselective synthesis of mexiletine analogs, e.g. I, with use of 10% of spiroborate ester II as chirality transfer agent is presented.  A variety of mexiletine analogs were prepd. in good yield with excellent enantioselectivities (91-97% ee) from readily available starting materials.  The developed methodol. was also successfully applied for the synthesis of novel β-amino ethers contg. thiophenyl and pyridyl fragments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPNouvCkceELVg90H21EOLACvtfcHk0lhEBhZ7lB_RsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Knt7w%253D&md5=f6eb642e6520f5ee9cb6df14e0d60467</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjo801181d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801181d%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DK.%26aulast%3DOrtiz-Marciales%26aufirst%3DM.%26aulast%3DStepanenko%26aufirst%3DV.%26aulast%3DDe%2BJes%25C3%25BAs%26aufirst%3DM.%26aulast%3DCorrea%26aufirst%3DW.%26atitle%3DA%2520Practical%2520and%2520efficient%2520route%2520for%2520the%2520highly%2520enantioselective%2520synthesis%2520of%2520mexiletine%2520analogues%2520and%2520novel%2520beta-thiophenoxy%2520and%2520pyridyl%2520ethers%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D6928%26epage%3D6931%26doi%3D10.1021%2Fjo801181d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giardinà, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crucianelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulini, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marucci, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagratini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationships among novel phenoxybenzamine-related beta-chloroethylamines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(01)00395-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2FS0968-0896%2801%2900395-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=11886792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BD38XhslSks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=1291-1303&author=D.+Giardin%C3%A0author=M.+Crucianelliauthor=P.+Angeliauthor=M.+Buccioniauthor=U.+Guliniauthor=G.+Marucciauthor=G.+Sagratiniauthor=C.+Melchiorre&title=Structure-activity+relationships+among+novel+phenoxybenzamine-related+beta-chloroethylamines&doi=10.1016%2FS0968-0896%2801%2900395-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity relationships among novel phenoxybenzamine-Related β-Chloroethylamines</span></div><div class="casAuthors">Giardina, Dario; Crucianelli, Mauro; Angeli, Piero; Buccioni, Michela; Gulini, Ugo; Marucci, Gabriella; Sagratini, Gianni; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1291-1303</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A series of β-chloroethylamines, structurally related to the irreversible α1-adrenoceptor antagonist phenoxybenzamine [PB, N-benzyl-N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)amine hydrochloride, 1] and the competitive antagonist WB4101 [N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-N-[2-(2,6-dimethoxyphenoxy)ethyl]amine hydrochloride, 2], were synthesized and evaluated for their activity at α-adrenoceptors of the epididymal and the prostatic portion of young CD rat vas deferens.  All compds. displayed irreversible antagonist activity.  Most of them showed similar antagonism at both α1- and α2-adrenoceptors, whereas some of compds. lacking substituents on both the phenoxy group and the oxyamino carbon chain, displayed a moderate α1-adrenoceptor selectivity (10-35 times), which was comparable to that of PB.  Some of the compds. belonging to the benzyl series and bearing, resp., a 2-ethoxyphenoxy and a 2-i-propoxyphenoxy moiety, were the most potent α1-adrenoceptor antagonists with an affinity value similar to that of PB (pIC50 values of 7.17 and 7.06 vs. 7.27).  Interestingly, several compds. were able to distinguish two α1-adrenoceptor subtypes in the epididymal tissue, as revealed by the discontinuity of their inhibition curves.  A mean ratio of 24:76 for these α1-adrenoceptors was detd. from different compds.  Furthermore, some compds. showed higher affinity towards the minor population of receptors, whereas compds. others preferentially inhibited the major population of α1-adrenoceptors.  In addn., selected pharmacol. expts. demonstrated the complementary antagonism of the two series of compds. and their different, preferential affinity for one of the two α1-adrenoceptor subtypes.  In conclusion, we found β-chloroethylamines that demonstrate a multiplicity of α1-adrenoceptors in the epididymal portion of young CD rat vas deferens and, as a consequence, they are possible useful tools for α1-adrenoceptor characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtX5bT2qP7bVg90H21EOLACvtfcHk0lg4k6y6RUpTZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhslSks74%253D&md5=77d3e8790ec7f6c7359e50c52b609c97</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2801%2900395-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252801%252900395-9%26sid%3Dliteratum%253Aachs%26aulast%3DGiardin%25C3%25A0%26aufirst%3DD.%26aulast%3DCrucianelli%26aufirst%3DM.%26aulast%3DAngeli%26aufirst%3DP.%26aulast%3DBuccioni%26aufirst%3DM.%26aulast%3DGulini%26aufirst%3DU.%26aulast%3DMarucci%26aufirst%3DG.%26aulast%3DSagratini%26aufirst%3DG.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DStructure-activity%2520relationships%2520among%2520novel%2520phenoxybenzamine-related%2520beta-chloroethylamines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D1291%26epage%3D1303%26doi%3D10.1016%2FS0968-0896%2801%2900395-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. K.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of cyclic sulfamidates by using chiral rhodium-catalyzed asymmetric transfer hydrogenation</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4184</span>– <span class="NLM_lpage">4187</span>, <span class="refDoi"> DOI: 10.1021/ol1017905</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol1017905" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=4184-4187&author=S.+Kangauthor=J.+Hanauthor=E.+S.+Leeauthor=E.+B.+Choiauthor=H.+K.+Lee&title=Enantioselective+synthesis+of+cyclic+sulfamidates+by+using+chiral+rhodium-catalyzed+asymmetric+transfer+hydrogenation&doi=10.1021%2Fol1017905"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Synthesis of Cyclic Sulfamidates by Using Chiral Rhodium-Catalyzed Asymmetric Transfer Hydrogenation</span></div><div class="casAuthors">Kang, Soyeong; Han, Juae; Lee, Eun Sil; Choi, Eun Bok; Lee, Hyeon-Kyu</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4184-4187</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Asym. transfer hydrogenation (ATH) of cyclic sulfamidate imines, e.g., I, using a HCO2H/Et3N mixt. as the hydrogen source and well-defined chiral Rh catalysts (S,S)- or (R,R)-Cp*RhCl(TsDPEN), effectively produces the corresponding cyclic sulfamidates with excellent yields and enantioselectivities at room temp. within 0.5 h.  ATH of 4,5-disubstituted imines II, having preexisting stereogenic centers, is shown to take place with dynamic kinetic resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjv3lhsrFzS7Vg90H21EOLACvtfcHk0lg4k6y6RUpTZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7fI&md5=5783927723ffd8d8c425ea4d33eb5d99</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fol1017905&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol1017905%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BS.%26aulast%3DChoi%26aufirst%3DE.%2BB.%26aulast%3DLee%26aufirst%3DH.%2BK.%26atitle%3DEnantioselective%2520synthesis%2520of%2520cyclic%2520sulfamidates%2520by%2520using%2520chiral%2520rhodium-catalyzed%2520asymmetric%2520transfer%2520hydrogenation%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D4184%26epage%3D4187%26doi%3D10.1021%2Fol1017905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyosue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arita, M.</span></span> <span> </span><span class="NLM_article-title">Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K<sup>+</sup> current of guinea-pig ventricular myocytes</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">893</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1006/jmcc.1996.0084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1006%2Fjmcc.1996.0084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=8762029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaK28Xjt1Ons70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1996&pages=893-903&author=D.+W.+Wangauthor=T.+Kiyosueauthor=T.+Satoauthor=M.+Arita&title=Comparison+of+the+effects+of+class+I+anti-arrhythmic+drugs%2C+cibenzoline%2C+mexiletine+and+flecainide%2C+on+the+delayed+rectifier+K%2B+current+of+guinea-pig+ventricular+myocytes&doi=10.1006%2Fjmcc.1996.0084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the effects of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the delayed rectifier K+ current of guinea pig ventricular myocytes</span></div><div class="casAuthors">Wang, Dao Wu; Kiyosue, Tatsuto; Sato, Toshiaki; Arita, Makoto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">893-903</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">The effect of class I anti-arrhythmic drugs, cibenzoline, mexiletine and flecainide, on the derived rectifier potassium current (IK) in guinea-pig ventricular myocytes was studied using whole cell voltage clamp techniques and under blockade of the L-type calcium current by 5 μM nitrendipine.  IK consisted of two different systems, as reported by Sanguinetti and Jurkiewicz (1990), i.e. an E4031-sensitive rapidly activating component (IKr) with a strong inward-going rectification property and an E4031-insensitive slowly activating component (IKs) with little rectification.  Cibenzoline (30 μM) decreased both IKr and IKs, while flecainide (10 and 30 μM) decreased the IKr exclusively.  Mexiletine (30 μM), in contrast, affected neither IKr nor IKs.  Since the inhibition of IKr and/or IKs prolongs duration of action potentials and refractory periods, class I drugs which also possess the class III effect may have addnl. effects in treating certain re-entrant arrhythmias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7awgEmt8tJLVg90H21EOLACvtfcHk0lg4k6y6RUpTZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xjt1Ons70%253D&md5=e50ca86076bad7f1c647c90693edac30</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1006%2Fjmcc.1996.0084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmcc.1996.0084%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%2BW.%26aulast%3DKiyosue%26aufirst%3DT.%26aulast%3DSato%26aufirst%3DT.%26aulast%3DArita%26aufirst%3DM.%26atitle%3DComparison%2520of%2520the%2520effects%2520of%2520class%2520I%2520anti-arrhythmic%2520drugs%252C%2520cibenzoline%252C%2520mexiletine%2520and%2520flecainide%252C%2520on%2520the%2520delayed%2520rectifier%2520K%252B%2520current%2520of%2520guinea-pig%2520ventricular%2520myocytes%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D1996%26volume%3D28%26spage%3D893%26epage%3D903%26doi%3D10.1006%2Fjmcc.1996.0084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenster, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comess, K. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacology and clinical use of mexiletine</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1002/j.1875-9114.1986.tb03442.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1002%2Fj.1875-9114.1986.tb03442.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=3513138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADyaL287kvVOhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1986&pages=1-7&author=P.+E.+Fensterauthor=K.+A.+Comess&title=Pharmacology+and+clinical+use+of+mexiletine&doi=10.1002%2Fj.1875-9114.1986.tb03442.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology and clinical use of mexiletine</span></div><div class="casAuthors">Fenster P E; Comess K A</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-9</span>
        ISSN:<span class="NLM_cas:issn">0277-0008</span>.
    </div><div class="casAbstract">Mexiletine is an antiarrhythmic agent with structural and electrophysiologic properties similar to those of lidocaine.  Mexiletine decreases ventricular automaticity while shortening both action potential duration and effective refractory period.  The drug may be administered orally or intravenously.  Hepatic metabolism is the major route of elimination.  The elimination half-life is approximately 10 hours, but longer in patients with acute myocardial infarction, chronic congestive heart failure or hepatic insufficiency.  Mexiletine suppresses ventricular ectopy in the acute phase of myocardial infarction.  The drug is effective for some patients in whom lidocaine has failed.  It suppresses chronic ventricular ectopy and is well tolerated in approximately two-thirds of stable outpatients treated with this agent.  In that population, mexiletine is comparable in efficacy to quinidine, procainamide and disopyramide.  It is effective in 30-50% of patients with ventricular arrhythmias refractory to other antiarrhythmic drugs.  In patients with refractory arrhythmias, the efficacy of mexiletine may be enhanced by combination with propranolol, quinidine or amiodarone.  Adverse reactions limit use of mexiletine in approximately 20% of patients.  Gastrointestinal and central nervous system side effects are the most common.  Mexiletine does not depress myocardial function.  Aggravation of arrhythmias is uncommonly observed.  The usual intravenous dose of mexiletine is 150-250 mg over at least 10 minutes.  Long-term oral dosages are usually 200-300 mg 3 or 4 times daily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRl7gK5P2ElrUodMGTatQ7LfW6udTcc2ebRRKyfjbiXqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL287kvVOhsg%253D%253D&md5=e490e7270ce8836148d8c8059e5b8509</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fj.1875-9114.1986.tb03442.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1875-9114.1986.tb03442.x%26sid%3Dliteratum%253Aachs%26aulast%3DFenster%26aufirst%3DP.%2BE.%26aulast%3DComess%26aufirst%3DK.%2BA.%26atitle%3DPharmacology%2520and%2520clinical%2520use%2520of%2520mexiletine%26jtitle%3DPharmacotherapy%26date%3D1986%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.1002%2Fj.1875-9114.1986.tb03442.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopeloff, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjie, N.</span></span> <span> </span><span class="NLM_article-title">Mexiletine: biphasic action on convulsive seizures in rodents</span>. <i>Neurobehav. Toxicol. Teratol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">235</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=3736751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADyaL28XlsVKjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1986&pages=231-235&author=G.+J.+Alexanderauthor=L.+M.+Kopeloffauthor=R.+B.+Alexanderauthor=N.+Chatterjie&title=Mexiletine%3A+biphasic+action+on+convulsive+seizures+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Mexiletine:  biphasic action on convulsive seizures in rodents</span></div><div class="casAuthors">Alexander, George J.; Kopeloff, Lenore M.; Alexander, Rita B.; Chatterjie, Nithiananda</div><div class="citationInfo"><span class="NLM_cas:title">Neurobehavioral Toxicology and Teratology</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">231-5</span>CODEN:
                <span class="NLM_cas:coden">NTOTDY</span>;
        ISSN:<span class="NLM_cas:issn">0275-1380</span>.
    </div><div class="casAbstract">Mexiletine (I)  [31828-71-4], an an antiarrhythmic drug, exerted a protective effect in mice against convulsive seizures induced by electroshock or the chem. convulsant, pentylenetetrazol, and against seizures induced in inbred audiosusceptible mice by a sound signal.  Administered in large doses, mexiletine produced a hyperkinetic myoclonic syndrome of 30-60 min duration.  The hyperkinesia could be controlled by dimethylaminoethanol  [108-01-0], phenobarbital  [50-06-6], and by an exptl. anticonvulsive agent, eboracin  [57310-23-3].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFTrCYczygULVg90H21EOLACvtfcHk0ljFlZf4_Q5qFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XlsVKjsLY%253D&md5=e637040c0a6dec993d02cd068b07e865</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DG.%2BJ.%26aulast%3DKopeloff%26aufirst%3DL.%2BM.%26aulast%3DAlexander%26aufirst%3DR.%2BB.%26aulast%3DChatterjie%26aufirst%3DN.%26atitle%3DMexiletine%253A%2520biphasic%2520action%2520on%2520convulsive%2520seizures%2520in%2520rodents%26jtitle%3DNeurobehav.%2520Toxicol.%2520Teratol.%26date%3D1986%26volume%3D8%26spage%3D231%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akıncı, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yüzbaşioglu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coşkun, F.</span></span> <span> </span><span class="NLM_article-title">Hemodialysis as an alternative treatment of mexiletine intoxication</span>. <i>Am. J. Emerg. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1235</span>– <span class="NLM_lpage">1235.e6</span>, <span class="refDoi"> DOI: 10.1016/j.ajem.2010.08.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.ajem.2010.08.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=20971596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC3MbosFSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1235-1235.e6&author=E.+Ak%C4%B1nc%C4%B1author=Y.+Y%C3%BCzba%C5%9Fiogluauthor=F.+Co%C5%9Fkun&title=Hemodialysis+as+an+alternative+treatment+of+mexiletine+intoxication&doi=10.1016%2Fj.ajem.2010.08.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Hemodialysis as an alternative treatment of mexiletine intoxication</span></div><div class="casAuthors">Akinci Emine; Yuzbasioglu Yucel; Coskun Figen</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of emergency medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1235.e5-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mexiletine is a class IB antiarrhythmic agent.  Although it is primarily used in treating ventricular arrhythmias, recent indications for use of mexiletine include chronic and neuropathic pains.  At high doses, mexiletine causes drowsiness, confusion, nausea, hypotension, sinus bradycardia, paresthesia, seizures, bundle branch block, atrioventricular heart block, ventricular arrhythmias, asystole, cardiovascular collapse, and coma.  A 23-year-old male patient presented to the emergency department with intentional ingestion of high-dose mexiletine.  Despite decontamination and supportive treatment, his vitals deteriorated during the observation period; and he developed stupor and dysarthria.  Patient then underwent hemodialysis.  His vital signs and overall condition improved rapidly following hemodialysis treatment.  In this case report, we aimed to emphasize hemodialysis as a useful alternative therapy for severe mexiletine intoxications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRK9kO0ukAVAHO4gDb7JggCfW6udTcc2eYCgkfW509YbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbosFSiuw%253D%253D&md5=43d1c79815357c3d18d1b737dedc16ca</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ajem.2010.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajem.2010.08.027%26sid%3Dliteratum%253Aachs%26aulast%3DAk%25C4%25B1nc%25C4%25B1%26aufirst%3DE.%26aulast%3DY%25C3%25BCzba%25C5%259Fioglu%26aufirst%3DY.%26aulast%3DCo%25C5%259Fkun%26aufirst%3DF.%26atitle%3DHemodialysis%2520as%2520an%2520alternative%2520treatment%2520of%2520mexiletine%2520intoxication%26jtitle%3DAm.%2520J.%2520Emerg.%2520Med.%26date%3D2011%26volume%3D29%26spage%3D1235%26epage%3D1235.e6%26doi%3D10.1016%2Fj.ajem.2010.08.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karagueuzian, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezhouman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olcese, R.</span></span> <span> </span><span class="NLM_article-title">Enhanced late Na and Ca currents as effective antiarrhythmic drug targets</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">36</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.3389%2Ffphar.2017.00036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=28220073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A280%3ADC%252BC1c3ovVKqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=36&author=H.+S.+Karagueuzianauthor=A.+Pezhoumanauthor=M.+Angeliniauthor=R.+Olcese&title=Enhanced+late+Na+and+Ca+currents+as+effective+antiarrhythmic+drug+targets&doi=10.3389%2Ffphar.2017.00036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced Late Na and Ca Currents as Effective Antiarrhythmic Drug Targets</span></div><div class="casAuthors">Karagueuzian Hrayr S; Pezhouman Arash; Angelini Marina; Olcese Riccardo</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">While recent advances clarified the molecular and cellular modes of action of antiarrhythmic drugs (AADs), their link to suppression of dynamical arrhythmia mechanisms remains only partially understood.  The current classifications of AADs (Classes I, III, and IV) rely on blocking peak Na, K and L-type calcium currents (ICa,L), with Class II with dominant beta receptor blocking activity and Class V including drugs with diverse classes of actions.  The discovery that the calcium and redox sensor, cardiac Ca/calmodulin-dependent protein kinase II (CaMKII) enhances both the late Na (INa-L) and the late ICa,L in patients at high risk of VT/VF provided a new and a rational AAD target.  Pathological rise of either or both of INa-L and late ICa,L are demonstrated to promote cellular early afterdepolarizations (EADs) and EAD-mediated triggered activity that can initiate VT/VF in remodeled hearts.  Selective inhibition of the INa-L without affecting their peak transients with the highly specific prototype drug, GS-967 suppresses these EAD-mediated VT/VFs.  As in the case of INa-L, selective inhibition of the late ICa,L without affecting its peak with the prototype drug, roscovitine suppressed oxidative EAD-mediated VT/VF.  These findings indicate that specific blockers of the late inward currents without affecting their peaks (gating modifiers), offer a new and effective AAD class action i.e., "Class VI." The development of safe drugs with selective Class VI actions provides a rational and effective approach to treat VT/VF particularly in cardiac conditions associated with enhanced CaMKII activity such as heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB7PD5PEpZsEHdcurJClFcfW6udTcc2eZYhR27JM5Vp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3ovVKqtA%253D%253D&md5=ef6faa920d4cd54d0f288fc82257f6da</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00036%26sid%3Dliteratum%253Aachs%26aulast%3DKaragueuzian%26aufirst%3DH.%2BS.%26aulast%3DPezhouman%26aufirst%3DA.%26aulast%3DAngelini%26aufirst%3DM.%26aulast%3DOlcese%26aufirst%3DR.%26atitle%3DEnhanced%2520late%2520Na%2520and%2520Ca%2520currents%2520as%2520effective%2520antiarrhythmic%2520drug%2520targets%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D36%26doi%3D10.3389%2Ffphar.2017.00036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burridge, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Churko, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebert, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diecke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mordwinkin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plews, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abilez, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span> <span> </span><span class="NLM_article-title">Chemically defined generation of human cardiomyocytes</span>. <i>Nat. Methods</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1038/nmeth.2999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1038%2Fnmeth.2999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=24930130" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpslGis7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=855-860&author=P.+W.+Burridgeauthor=E.+Matsaauthor=P.+Shuklaauthor=Z.+C.+Linauthor=J.+M.+Churkoauthor=A.+D.+Ebertauthor=F.+Lanauthor=S.+Dieckeauthor=B.+Huberauthor=N.+M.+Mordwinkinauthor=J.+R.+Plewsauthor=O.+J.+Abilezauthor=B.+Cuiauthor=J.+D.+Goldauthor=J.+C.+Wu&title=Chemically+defined+generation+of+human+cardiomyocytes&doi=10.1038%2Fnmeth.2999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically defined generation of human cardiomyocytes</span></div><div class="casAuthors">Burridge, Paul W.; Matsa, Elena; Shukla, Praveen; Lin, Ziliang C.; Churko, Jared M.; Ebert, Antje D.; Lan, Feng; Diecke, Sebastian; Huber, Bruno; Mordwinkin, Nicholas M.; Plews, Jordan R.; Abilez, Oscar J.; Cui, Bianxiao; Gold, Joseph D.; Wu, Joseph C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Methods</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">855-860</span>CODEN:
                <span class="NLM_cas:coden">NMAEA3</span>;
        ISSN:<span class="NLM_cas:issn">1548-7091</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Existing methods for human induced pluripotent stem cell (hiPSC) cardiac differentiation are efficient but require complex, undefined medium constituents that hinder further elucidation of the mol. mechanisms of cardiomyogenesis.  Using hiPSCs derived under chem. defined conditions on synthetic matrixes, we systematically developed an optimized cardiac differentiation strategy, using a chem. defined medium consisting of just three components: the basal medium RPMI 1640, L-ascorbic acid 2-phosphate and rice-derived recombinant human albumin.  Along with small mol.-based induction of differentiation, this protocol produced contractile sheets of up to 95% TNNT2+ cardiomyocytes at a yield of up to 100 cardiomyocytes for every input pluripotent cell and was effective in 11 hiPSC lines tested.  This chem. defined platform for cardiac specification of hiPSCs will allow the elucidation of cardiomyocyte macromol. and metabolic requirements and will provide a minimal system for the study of maturation and subtype specification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpI4kKlfNA1fLVg90H21EOLACvtfcHk0ljs8V6sLz2teA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpslGis7c%253D&md5=153be90e038f00ce022ac16e9919cfcc</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnmeth.2999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnmeth.2999%26sid%3Dliteratum%253Aachs%26aulast%3DBurridge%26aufirst%3DP.%2BW.%26aulast%3DMatsa%26aufirst%3DE.%26aulast%3DShukla%26aufirst%3DP.%26aulast%3DLin%26aufirst%3DZ.%2BC.%26aulast%3DChurko%26aufirst%3DJ.%2BM.%26aulast%3DEbert%26aufirst%3DA.%2BD.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DDiecke%26aufirst%3DS.%26aulast%3DHuber%26aufirst%3DB.%26aulast%3DMordwinkin%26aufirst%3DN.%2BM.%26aulast%3DPlews%26aufirst%3DJ.%2BR.%26aulast%3DAbilez%26aufirst%3DO.%2BJ.%26aulast%3DCui%26aufirst%3DB.%26aulast%3DGold%26aufirst%3DJ.%2BD.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26atitle%3DChemically%2520defined%2520generation%2520of%2520human%2520cardiomyocytes%26jtitle%3DNat.%2520Methods%26date%3D2014%26volume%3D11%26spage%3D855%26epage%3D860%26doi%3D10.1038%2Fnmeth.2999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKeithan, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiering, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrette, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushway, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Lozano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riou, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umbhauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duester, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colas, A. R.</span></span> <span> </span><span class="NLM_article-title">Id genes are essential for early heart formation</span>. <i>Genes Dev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1338</span>, <span class="refDoi"> DOI: 10.1101/gad.300400.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1101%2Fgad.300400.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=28794185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlOnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=1325-1338&author=T.+J.+Cunninghamauthor=M.+S.+Yuauthor=W.+L.+McKeithanauthor=S.+Spieringauthor=F.+Carretteauthor=C.+T.+Huangauthor=P.+J.+Bushwayauthor=M.+Tierneyauthor=S.+Albiniauthor=M.+Giaccaauthor=M.+Manoauthor=P.+L.+Puriauthor=A.+Saccoauthor=P.+Ruiz-Lozanoauthor=J.+F.+Riouauthor=M.+Umbhauerauthor=G.+Duesterauthor=M.+Mercolaauthor=A.+R.+Colas&title=Id+genes+are+essential+for+early+heart+formation&doi=10.1101%2Fgad.300400.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Id genes are essential for early heart formation</span></div><div class="casAuthors">Cunningham, Thomas J.; Yu, Michael S.; McKeithan, Wesley L.; Spiering, Sean; Carrette, Florent; Huang, Chun-Teng; Bushway, Paul J.; Tierney, Matthew; Albini, Sonia; Giacca, Mauro; Mano, Miguel; Puri, Pier Lorenzo; Sacco, Alessandra; Ruiz-Lozano, Pilar; Riou, Jean-Francois; Umbhauer, Muriel; Duester, Gregg; Mercola, Mark; Colas, Alexandre R.</div><div class="citationInfo"><span class="NLM_cas:title">Genes & Development</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1325-1338</span>CODEN:
                <span class="NLM_cas:coden">GEDEEP</span>;
        ISSN:<span class="NLM_cas:issn">0890-9369</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Deciphering the fundamental mechanisms controlling cardiac specification is crit. for our understanding of how heart formation is initiated during embryonic development and for applying stem cell biol. to regenerative medicine and disease modeling.  Using systematic and unbiased functional screening approaches, we discovered that the Id family of helix-loop-helix proteins is both necessary and sufficient to direct cardiac mesoderm formation in frog embryos and human embryonic stem cells.  Mechanistically, Id proteins specify cardiac cell fate by repressing two inhibitors of cardiogenic mesoderm formation-Tcf3 and Foxa2-and activating inducers Evx1, Grrp1, and Mesp1.  Most importantly, CRISPR/Cas9-mediated ablation of the entire Id (Id1-4) family in mouse embryos leads to failure of anterior cardiac progenitor specification and the development of heartless embryos.  Thus, Id proteins play a central and evolutionarily conserved role during heart formation and provide a novel means to efficiently produce cardiovascular progenitors for regenerative medicine and drug discovery applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBtCAjfxPveLVg90H21EOLACvtfcHk0lhRRRnWp14ucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlOnu7s%253D&md5=6d2a26f05a9356be7ff171074cb139cd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1101%2Fgad.300400.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fgad.300400.117%26sid%3Dliteratum%253Aachs%26aulast%3DCunningham%26aufirst%3DT.%2BJ.%26aulast%3DYu%26aufirst%3DM.%2BS.%26aulast%3DMcKeithan%26aufirst%3DW.%2BL.%26aulast%3DSpiering%26aufirst%3DS.%26aulast%3DCarrette%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DC.%2BT.%26aulast%3DBushway%26aufirst%3DP.%2BJ.%26aulast%3DTierney%26aufirst%3DM.%26aulast%3DAlbini%26aufirst%3DS.%26aulast%3DGiacca%26aufirst%3DM.%26aulast%3DMano%26aufirst%3DM.%26aulast%3DPuri%26aufirst%3DP.%2BL.%26aulast%3DSacco%26aufirst%3DA.%26aulast%3DRuiz-Lozano%26aufirst%3DP.%26aulast%3DRiou%26aufirst%3DJ.%2BF.%26aulast%3DUmbhauer%26aufirst%3DM.%26aulast%3DDuester%26aufirst%3DG.%26aulast%3DMercola%26aufirst%3DM.%26aulast%3DColas%26aufirst%3DA.%2BR.%26atitle%3DId%2520genes%2520are%2520essential%2520for%2520early%2520heart%2520formation%26jtitle%3DGenes%2520Dev.%26date%3D2017%26volume%3D31%26spage%3D1325%26epage%3D1338%26doi%3D10.1101%2Fgad.300400.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E. W.</span></span> <span> </span><span class="NLM_article-title">Small molecule fluorescent voltage indicators for studying membrane potential</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2016.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.cbpa.2016.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=27318561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWlt7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2016&pages=74-80&author=E.+W.+Miller&title=Small+molecule+fluorescent+voltage+indicators+for+studying+membrane+potential&doi=10.1016%2Fj.cbpa.2016.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule fluorescent voltage indicators for studying membrane potential</span></div><div class="casAuthors">Miller, Evan W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74-80</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Voltage imaging has the potential to unravel the contributions that rapid changes in membrane voltage make to cellular physiol., esp. in the context of neuroscience.  In particular, small mol. fluorophores are esp. attractive because they can, in theory, provide fast and sensitive measurements of membrane potential dynamics.  A no. of classes of small mol. voltage indicators will be discussed, including dyes with improved two-photon voltage sensing, near IR optical profiles for use in in vivo applications, and newly developed electron-transfer based indicators, or VoltageFluors, that can be tuned across a range of wavelengths to enable all-optical voltage manipulation and measurement.  Limitations and a 'wish-list' for voltage indicators will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5rInIZDIpAbVg90H21EOLACvtfcHk0lhRRRnWp14ucg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWlt7fJ&md5=19c7b115efe8704ca01d70edc78b64a7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2016.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2016.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DE.%2BW.%26atitle%3DSmall%2520molecule%2520fluorescent%2520voltage%2520indicators%2520for%2520studying%2520membrane%2520potential%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D33%26spage%3D74%26epage%3D80%26doi%3D10.1016%2Fj.cbpa.2016.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cerignoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingermanson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehalot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savchenko, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonough, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercola, M.</span></span> <span> </span><span class="NLM_article-title">High throughput measurement of Ca<sup>2+</sup> dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry</span>. <i>J. Pharmacol. Toxicol. Methods</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">256</span>, <span class="refDoi"> DOI: 10.1016/j.vascn.2012.08.167</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1016%2Fj.vascn.2012.08.167" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=22926323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2rsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2012&pages=246-256&author=F.+Cerignoliauthor=D.+Charlotauthor=R.+Whittakerauthor=R.+Ingermansonauthor=P.+Gehalotauthor=A.+Savchenkoauthor=D.+J.+Gallacherauthor=R.+Towartauthor=J.+H.+Priceauthor=P.+M.+McDonoughauthor=M.+Mercola&title=High+throughput+measurement+of+Ca2%2B+dynamics+for+drug+risk+assessment+in+human+stem+cell-derived+cardiomyocytes+by+kinetic+image+cytometry&doi=10.1016%2Fj.vascn.2012.08.167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput measurement of Ca2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry</span></div><div class="casAuthors">Cerignoli, Fabio; Charlot, David; Whittaker, Ross; Ingermanson, Randy; Gehalot, Piyush; Savchenko, Alex; Gallacher, David J.; Towart, Rob; Price, Jeffrey H.; McDonough, Patrick M.; Mercola, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-256</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Current methods to measure physiol. properties of cardiomyocytes and predict fatal arrhythmias that can cause sudden death, such as Torsade de Pointes, lack either the automation and throughput needed for early-stage drug discovery and/or have poor predictive value.  To increase throughput and predictive power of in vitro assays, we developed kinetic imaging cytometry (KIC) for automated cell-by-cell analyses via intracellular fluorescence Ca2+ indicators.  The KIC instrument simultaneously records and analyzes intracellular calcium concn. [Ca2+]i at 30-ms resoln. from hundreds of individual cells/well of 96-well plates in seconds, providing kinetic details not previously possible with well averaging technologies such as plate readers.  Analyses of human embryonic stem cell and induced pluripotent stem cell-derived cardiomyocytes revealed effects of known cardiotoxic and arrhythmogenic drugs on kinetic parameters of Ca2+ dynamics, suggesting that KIC will aid in the assessment of cardiotoxic risk and in the elucidation of pathogenic mechanisms of heart disease assocd. with drugs treatment and/or genetic background.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT-tv2e7NlGrVg90H21EOLACvtfcHk0liKz_vFZrtquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2rsrbP&md5=ce55217aa45873af8fb192c86f04c9c5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2012.08.167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2012.08.167%26sid%3Dliteratum%253Aachs%26aulast%3DCerignoli%26aufirst%3DF.%26aulast%3DCharlot%26aufirst%3DD.%26aulast%3DWhittaker%26aufirst%3DR.%26aulast%3DIngermanson%26aufirst%3DR.%26aulast%3DGehalot%26aufirst%3DP.%26aulast%3DSavchenko%26aufirst%3DA.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26aulast%3DTowart%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DJ.%2BH.%26aulast%3DMcDonough%26aufirst%3DP.%2BM.%26aulast%3DMercola%26aufirst%3DM.%26atitle%3DHigh%2520throughput%2520measurement%2520of%2520Ca2%252B%2520dynamics%2520for%2520drug%2520risk%2520assessment%2520in%2520human%2520stem%2520cell-derived%2520cardiomyocytes%2520by%2520kinetic%2520image%2520cytometry%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2012%26volume%3D66%26spage%3D246%26epage%3D256%26doi%3D10.1016%2Fj.vascn.2012.08.167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vega, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeiffer, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerignoli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towart, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallacher, D. J.</span></span> <span> </span><span class="NLM_article-title">High throughput measurement of Ca<sup>++</sup> dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometery: A cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">503</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfv201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1093%2Ftoxsci%2Fkfv201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=26358003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFagsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2015&pages=503-516&author=H.+R.+Luauthor=R.+Whittakerauthor=J.+H.+Priceauthor=R.+Vegaauthor=E.+R.+Pfeifferauthor=F.+Cerignoliauthor=R.+Towartauthor=D.+J.+Gallacher&title=High+throughput+measurement+of+Ca%2B%2B+dynamics+in+human+stem+cell-derived+cardiomyocytes+by+kinetic+image+cytometery%3A+A+cardiac+risk+assessment+characterization+using+a+large+panel+of+cardioactive+and+inactive+compounds&doi=10.1093%2Ftoxsci%2Fkfv201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput measurement of Ca++ dynamics in human stem cell-derived cardiomyocytes by kinetic image cytometry: a cardiac risk assessment characterization using a large panel of cardioactive and inactive compounds</span></div><div class="casAuthors">Lu, Hua Rong; Whittaker, Ross; Price, Jeffrey H.; Vega, Raquel; Pfeiffer, Emily R.; Cerignoli, Fabio; Towart, Rob; Gallacher, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">503-516</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are emerging as a powerful in vitro model for cardiac safety assessment which may allow for better identification of compds. with poor arrhythmogenic liability profiles early in the drug discovery process.  Here, we describe our examn. of the Kinetic Image Cytometer (KIC) system's ability to predict adverse compd. effects using hiPS-CMs and a library of 53 compds., the majority of which are known to be cardioactive compds., and several neg. controls.  The KIC provides a high throughput method for analyzing intracellular calcium transients.  In the cardiomyocyte, intracellular calcium transients integrate the electrochem. signals of the action potential (AP) with the mol. signaling pathways regulating contraction.  Drug-induced alterations in the shape and duration of AP result in changes to the shape and duration of the intracellular calcium transient.  By examg. calcium transient dynamics in hiPS-CMs, KIC can be used as a phenotypic screen to assess compd. effects across multiple ion channel types (MITs), detecting MITs, calcium handling and signaling effects.  The results of this blinded study indicate that using hiPS-CMs, KIC is able to accurately detect drug-induced changes in Ca2+ transient dynamics (ie, duration and beat rate) and therefore, may be useful in predicting drug-induced arrhythmogenic liabilities in early de-risking within the drug discovery phase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriSPtVMgTMM7Vg90H21EOLACvtfcHk0liKz_vFZrtquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFagsLs%253D&md5=1505649f8fd0b8fae8d14a3a1a68db58</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfv201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfv201%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%2BR.%26aulast%3DWhittaker%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DJ.%2BH.%26aulast%3DVega%26aufirst%3DR.%26aulast%3DPfeiffer%26aufirst%3DE.%2BR.%26aulast%3DCerignoli%26aufirst%3DF.%26aulast%3DTowart%26aufirst%3DR.%26aulast%3DGallacher%26aufirst%3DD.%2BJ.%26atitle%3DHigh%2520throughput%2520measurement%2520of%2520Ca%252B%252B%2520dynamics%2520in%2520human%2520stem%2520cell-derived%2520cardiomyocytes%2520by%2520kinetic%2520image%2520cytometery%253A%2520A%2520cardiac%2520risk%2520assessment%2520characterization%2520using%2520a%2520large%2520panel%2520of%2520cardioactive%2520and%2520inactive%2520compounds%26jtitle%3DToxicol.%2520Sci.%26date%3D2015%26volume%3D148%26spage%3D503%26epage%3D516%26doi%3D10.1093%2Ftoxsci%2Fkfv201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fertig, N.</span></span> <span> </span><span class="NLM_article-title">HTS techniques for patch clamp-based ion channel screening - advances and economy</span>. <i>Expert. Opin. Drug. Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1517/17460441.2012.682056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1517%2F17460441.2012.682056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=22507077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=1%3ACAS%3A528%3ADC%252BC38Xns1Srt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=515-524&author=C.+Farreauthor=N.+Fertig&title=HTS+techniques+for+patch+clamp-based+ion+channel+screening+-+advances+and+economy&doi=10.1517%2F17460441.2012.682056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">HTS techniques for patch clamp-based ion channel screening - advances and economy</span></div><div class="casAuthors">Farre, Cecilia; Fertig, Niels</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">515-524</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Ten years ago, the first publication appeared showing patch clamp recordings performed on a planar glass chip instead of using a conventional patch clamp pipet.  "Going planar" proved to revolutionize ion channel drug screening as we know it, by allowing high quality measurements of ion channels and their effectors at a higher throughput and at the same time de-skilling the highly laborious technique.  Over the years, platforms evolved in response to user requirements regarding exptl. features, data handling plus storage, and suitable target diversity.Areas covered: This article gives a snapshot image of patch clamp-based ion channel screening with focus on platforms developed to meet requirements of high-throughput screening environments.  The com. available platforms are described, along with their benefits and drawbacks in ion channel drug screening.Expert opinion: Automated patch clamp (APC) platforms allow faster investigation of a larger no. of ion channel active compds. or cell clones than previously possible.  Since patch clamp is the only method allowing direct, real-time measurements of ion channel activity, APC holds the promise of picking up high quality leads, where they otherwise would have been overseen using indirect methods.  In addn., drug candidate safety profiling can be performed earlier in the drug discovery process, avoiding late-phase compd. withdrawal due to safety liability issues, which is highly costly and inefficient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tSCyX217D7Vg90H21EOLACvtfcHk0lgFc-vDI4f-ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xns1Srt7k%253D&md5=f4b59fbeba561efe68afe4b0c78fcdef</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1517%2F17460441.2012.682056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2012.682056%26sid%3Dliteratum%253Aachs%26aulast%3DFarre%26aufirst%3DC.%26aulast%3DFertig%26aufirst%3DN.%26atitle%3DHTS%2520techniques%2520for%2520patch%2520clamp-based%2520ion%2520channel%2520screening%2520-%2520advances%2520and%2520economy%26jtitle%3DExpert.%2520Opin.%2520Drug.%2520Discovery%26date%3D2012%26volume%3D7%26spage%3D515%26epage%3D524%26doi%3D10.1517%2F17460441.2012.682056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bankston, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spyres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silver, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kass, R. S.</span></span> <span> </span><span class="NLM_article-title">A novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic response</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">e1258</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0001258</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=10.1371%2Fjournal.pone.0001258" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;key=18060054" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&author=J.+R.+Bankstonauthor=M.+Yueauthor=W.+Chungauthor=M.+Spyresauthor=R.+H.+Passauthor=E.+Silverauthor=K.+J.+Sampsonauthor=R.+S.+Kass&title=A+novel+and+lethal+de+novo+LQT-3+mutation+in+a+newborn+with+distinct+molecular+pharmacology+and+therapeutic+response&doi=10.1371%2Fjournal.pone.0001258"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0001258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0001258%26sid%3Dliteratum%253Aachs%26aulast%3DBankston%26aufirst%3DJ.%2BR.%26aulast%3DYue%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DW.%26aulast%3DSpyres%26aufirst%3DM.%26aulast%3DPass%26aufirst%3DR.%2BH.%26aulast%3DSilver%26aufirst%3DE.%26aulast%3DSampson%26aufirst%3DK.%2BJ.%26aulast%3DKass%26aufirst%3DR.%2BS.%26atitle%3DA%2520novel%2520and%2520lethal%2520de%2520novo%2520LQT-3%2520mutation%2520in%2520a%2520newborn%2520with%2520distinct%2520molecular%2520pharmacology%2520and%2520therapeutic%2520response%26jtitle%3DPLoS%2520One%26date%3D2007%26volume%3D2%26doi%3D10.1371%2Fjournal.pone.0001258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i129"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01545">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_40085"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01545?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01545</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_001.csv">CSV</a>)</p></li><li><p class="inline">HPLC Methods and traces (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_001.csv">jm0c01545_si_001.csv (2.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01545/suppl_file/jm0c01545_si_002.pdf">jm0c01545_si_002.pdf (2.24 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01545&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-9%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01545" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01545" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679970fed85122c0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
